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Abstract 
Addressing the harms related to youth substance use: Treatment of 
individuals and population focused legislative responses. 
 
Substance use, and substance use disorders (SUD), are major contributors to global burden 
of disease among youth. They constitute an important risk factor for other disorders, 
including mental disorders. This thesis seeks to examine methods to reduce the harm 
associated with youth substance use, looking at the impact of treatment on the individual 
adolescent with a SUD and at legislative measures operating at the population level. While 
treatment models for SUD have become more liberal and harm reduction orientated in 
recent decades, legislation remains conservative and prohibitionist. The archetypal harm 
reduction treatment is opiate substitution treatment (OST) used with heroin dependence. 
The evidence base for OST in adolescents is sparse. Outcome of OST was examined. It 
emerged that OST delivers early reductions in heroin use, which continue to improve 
significantly from month three to month twelve of treatment. Evidence of improved 
psychological wellbeing is also demonstrated by adolescents on OST. In order to explore the 
impact of conservative legislative measures on harm related to substance use, a quasi-
experimental approach was undertaken to explore changes which occurred in Ireland 
before, during and after the arrival of a vast network of head shops selling new psychoactive 
substances (NPS). Evidence is presented indicating that the expansion of head shops 
coincided with increased NPS addiction episodes among both adolescents and young adults. 
There was also evidence of increased drug related psychiatric admissions. All of these harms 
began to diminish within months of the closure of the head shops. Overall, these findings 
lend support to the position of providing tolerant and responsive treatment which does not 
demand abstinence for the small subset of youth who develop a SUD, while simultaneously 
maintaining an intolerant and conservative approach to prevention of substance use at the 
wider population level.  
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Chapter 1 
Thesis Overview & Structure 
1.1 Introduction 
Substance use by young people is a cause of concern for societies and for health 
professionals across the world.(1) Approximately 10% of young people who use any specific 
substance will become dependent upon it, i.e. develop a substance use disorder (SUD).(2-4)  
While dependence clearly causes harm, harms can also arise in young people who are not 
using a substance dependently. These other harms are frequently related to acute 
intoxication and can also include the adverse impact which substance use can exert upon 
mental health.(5, 6) There appears to be a complex and reciprocal relationship between 
substance use and mental health problems.(7, 8) Taken together, mental disorders and 
SUDs account for 45% of all years lost to disability globally among young people aged 10 to 
24 years.(9) 
The societal response to drug related harm is multifaceted.(6, 10, 11) Key components 
include the provision of treatment to individuals with substance use disorders and also 
broader population measures including legislation which prohibits use of most drugs.(5, 6, 
11) 
Treatment approaches have changed substantially in the past 40 years, moving away from 
abstinence based treatments and towards more liberal and tolerant harm reduction based 
treatments(12-16). Although this change is now generally accepted in most western 
countries for adults, there is some ongoing uncertainty about the appropriateness of harm 
reduction type treatments for adolescents.(11, 17, 18)  
In the past decade, there has been increased discussion about legislative responses to drug 
use and there have been increasing calls for these to also move in a more tolerant 
direction.(10, 19) The ‘global drug prohibition regime’ of the past 50 years has been widely 
characterised as ineffective and possibly even harmful in itself.(20, 21) 
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In the past 15 years, Ireland has moved towards provision of harm reduction treatments to 
youth, perhaps moving further and faster down this route than many other countries, while 
simultaneously retaining the old ‘prohibition-styled’ approach to preventing drug use.(22) 
 
1.2 Aims & Objectives 
In this article-based PhD, I sought to gather evidence to build the case for and against this 
current position on drug related harm among youth in Ireland, which seems somewhat 
contradictory in simultaneously containing both quite liberal and quite conservative 
components.  
More specifically, I sought to examine outcome for adolescents who receive harm reduction 
styled treatment for substance use disorders, and in particular examining the most 
controversial harm reduction treatment in the adolescent age range, this being opiate 
substitution treatment for heroin dependent adolescents.(17, 18) Secondly, I sought to 
examine the impact of prohibition styled legislation targeted at new psychoactive 
substances, examining three different types of harm. This strategy has been described by 
Donald Campbell as using a quasiexperimental approach to policy evaluation by using 
‘multiple measures of independent imperfection’, and discussed more recently by Wayne 
Hall in the evaluation of alcohol policy.(23, 24) 
 
1.3 Specific Research Outputs 
In order to examine strategies which reduce harms related to youth substance use, at the 
level of the individual and across the populations, six studies were conducted. These were:- 
1/ An examination of the treatment outcome for adolescents with alcohol and cannabis use 
disorders. This study describes the profile of Irish adolescents who attend addiction 
treatment, reports on rates of polysubstance use and examines motivation amongst this 
patient group. As harm reduction interventions have come to the fore, there has been a 
move away from abstinence as a sole acceptable outcome. This study utilises a somewhat 
novel approach to examine outcomes which fall short of abstinence, in seeking to determine 
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what proportion of patients with alcohol and cannabis use disorders achieve a 'reliably 
reduction’ in their substance use. 
2/ The archetypal harm reduction treatment is opiate substitution treatment (OST) for 
heroin dependence, which utilises agonist medications such as methadone and 
buprenorphine. In view of the great paucity of studies of OST in the adolescent age range, 
this study examines the reductions in heroin use during the first year of OST. Given the 
frequency of polydrug use, the study seeks to determine if OST also delivers reductions in 
use of other substances. Treatment retention, and its correlates, is also examined. 
3/ Taking a broader view of OST and harms related to heroin use disorders, this third study 
examines the impact of OST upon psychological wellbeing of heroin dependent adolescents 
during treatment. 
 4/ Having explored the impact of treatment on individual adolescents with substance use 
disorders in the preceding studies, this fourth study seeks to determine if national legislative 
measures influence the pattern of adolescent substance use disorders. The study examines 
changes in use of new psychoactive substances (NPS) among adolescents attending the 
treatment service examined in the first study above, following a conservative and 
prohibition-styled legislative response to the arrival of head shops in Ireland. 
 5/ This study extends the theme of the previous study, by examining whether or not there 
is evidence of changes in the rate of addiction presentations related to NPS in young adults 
following the arrival and departure of the head shops. It uses evidence from the national 
drug treatment reporting system. 
6/ Taking a broader view again of harms related to NPS and returning to the theme of 
mental health, this final study examines all drug related psychiatric admissions in Ireland 
during this head shop era. It seeks to determine if there was evidence of increased 
psychiatric presentations while the head shops were at their most active and whether this 
harm declined following their closure. 
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Table 1.1. Overview of research outputs from thesis 
No. Paper title Journal Paper 
Type 
Status 
1 Outcome for adolescents abusing alcohol and 
cannabis following outpatient treatment: how 
many 'reliably improve'?  
 
Irish Medical 
Journal 
Research 
paper 
Published 
2 Opioid substitution treatment and heroin 
dependent adolescents: Reductions in heroin use 
and treatment retention over twelve months 
 
BMC 
Paediatrics 
Research 
paper 
Accepted 
for 
publication 
3 Changes in psychological well-being among 
heroin-dependent adolescents during 
psychologically supported opiate substitution 
treatment. 
 
Early 
Intervention 
in Psychiatry 
Research 
paper 
Published 
4 "So prohibition can work?" Changes in use of 
novel psychoactive substances among 
adolescents attending a drug and alcohol 
treatment service following a legislative ban. 
 
International 
Journal of 
Drug Policy 
Short 
report 
Published 
5 Decline in new psychoactive substance use 
disorders following legislation targeting 
headshops: evidence from national addiction 
treatment data.  
 
Drug & 
Alcohol 
Review 
Research 
paper 
Published 
6 Legislation targeting head shops selling new 
psychoactive substances and changes in drug 
related psychiatric admissions: A national 
database study 
 
BMC 
Psychiatry 
Research 
paper 
Under 
review 
7 New psychoactive substances in Ireland following 
the Criminal Justice (Psychoactive Substances) Act 
– why all the pessimism? 
 
Addiction Research 
Letter 
Published 
 
1.4 Thesis format – chapters 
Following this brief overview, Chapter 2 will describe the background literature on 
substance use among youth and on the treatment and legislative strategies which are 
employed to reduce harms. Specifically, it will examine in more detail OST among 
adolescents and the international experience and evidence regarding legislative responses 
to the challenges posed by new psychoactive substances. 
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As each research paper had to be written as a ‘stand alone’ contribution to the scientific 
literature as a published article, some of the methodology sections are quite narrow in 
focus. In Chapter 3, I have sought to address this by discussing in more detail some of the 
methodological challenges encountered during the PhD process and provide more context 
to explain the rationale for use of the chosen methodologies. 
Chapters 4 to 9 each contain individual research papers. Each chapter starts with a brief 
introduction which seeks to put that paper into context for the overall thesis. The final 
published version of two papers involved a shortened format (papers 1 and 4 from the list 
above). A more comprehensive and detailed version of each of these papers is included in 
the chapters, with content modified based upon the referees’ comments regarding the 
submissions. There were limits on number of tables and figures for some journals which 
resulted in the use of on-line supplemental material linked to those papers. For ease of 
reading this thesis, that supplemental material has either been incorporated into the body 
of the chapter or added as an appendix to the chapter. The research letter published in 
Addiction forms the basis of Chapter 10, this summarising some of the key findings from the 
three studies examining temporal changes in NPS related harms.  
To assist presentation of the published empiric research papers, a consistent formatting has 
been used across all chapters. Chapter Z is divided into the following sections:- 
Z.1 = Introduction of context of this paper within overall thesis 
Z.2 = Abstract 
Z.3 = Introduction 
Z.4 = Methods 
Z.5 = Results 
Z.6 = Discussion 
Z.7 = Author Contributions. 
 
For some studies, there was input and support provided by individuals, especially in the area 
of statistical methodology, who were not co-authors of the published research paper. The 
contribution of those individuals is described in Appendix 1. 
Chapter 11 presents a synthesis of the key research findings from the individual studies and 
draws together the major themes and conclusions. 
As journal specifications differ regarding referencing, the references in Chapters 4-10, which 
are taken from published papers, varies from one chapter to the next, consistent with the 
20 
 
required journal style. A bibliography is provided for references used in the remaining 
chapters (i.e. Chapters 1 to 3 and Chapter 11). 
 
1.5 Terminology 
1.5.1 “Youth” 
This thesis is focused upon youth. There is no universally agreed definition of youth. While 
lamenting the challenges posed by adolescent behaviours, Shakespeare identified the years 
between 10 and 23 as constituting “youth” in A Winter’s Tale. Modern neuroimaging studies 
have confirmed that brain development continues until the mid 20s.(6) Health reviews 
focused upon youth tend to use the years 10 to 24 years, especially those addressing mental 
health and substance use.(9, 25) Although substance use tends to commence during the 
teenage years, morbidity associated with drug use peaks between the ages of 20 and 34 
years.(25, 26) 
The treatment studies in this thesis are focused upon adolescents aged 18 years and under, 
this age cut-off being typical of adolescent addiction treatment services in Ireland and 
elsewhere. It is among this younger age group that treatment research is most sparse. The 
studies addressing the impact of policy upon harms related to substance use include a 
broader age span, which extends as far as 34 years.  
 
1.5.2 Language used to describe drug use and associated problems 
There are very many divisive issues in the sphere of drug policy. Language is certainly one of 
those issues. Many journals and professional bodies have strong policy statements on the 
appropriate use of language to describe the act of drug use, the people who use drugs and 
the problems which can arise from such use.(27, 28) Terms such as ‘alcoholic’ are now 
generally avoided. The word ‘abuse’ in the diagnostic term substance abuse is criticised by 
many as potentially stigmatising. Even the words ‘dependence’ and ‘addiction’ provoke 
some criticism. 
In this thesis, many words and expressions are used to describe the act of drug use and the 
people who engage in that activity. While efforts have been made to reduce use of 
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potentially stigmatising language, some of the terminology used may still fall short of the 
ideal standard. For example, the term ‘substance abuse’ is used where studies quoting this 
DSM-IV diagnostic category are reported.   
Apart from issues of stigma, the terms used to describe problems associated with drug use 
vary from the USA to Europe and have also changed over time. The biggest change in recent 
years has been the creation of a single diagnosis of substance use disorder in DSM V, this 
replacing the previous categorization of Substance Dependence and Substance Abuse.(29, 
30) For the time being, ICD-10 retains two illness categories, these being Dependence 
Syndrome and Harmful Use. Some of these expressions are used interchangeably during the 
course of this thesis. Equivalent terms are outlined in table 1.2 below. 
Table 1.2 Terms used to describe problematic substance use in this thesis 
DSM IV DSM V ICD 10 Other equivalent and 
colloquial terms 
Substance 
Dependence 
Substance use disorder - 
severe 
Dependence 
Syndrome 
Addiction 
Substance 
Abuse 
Substance use disorder – 
Mild to moderate 
Harmful Use  
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Chapter 2 
Background Literature 
2.1 Overview of chapter 
This chapter aims to put the overall thesis into context. It will briefly summarise potential 
harms which can arise for youth who use drugs. It will examine temporal trends in drug use 
internationally and nationally. It will characterise the potential progression to substance 
dependence, this dependence being a key focus of many of the studies in this thesis. It will 
examine some key approaches which societies employ to influence that potential journey. 
Specifically, it will introduce treatment responses to the subset of individual adolescents 
who progress to develop substance use disorders, and examine how the principles 
underpinning treatment have altered in recent decades to become more liberal and harm 
reduction orientated.    In contrast, it will describe how legislative responses have remained 
largely unchanged and conservative, in spite of growing calls for their review. Finally, it will 
provide a detailed examination of the literature on (1) use of opiate substitution treatment 
(OST) in adolescents, and (2) impact of legislative responses upon new psychoactive 
substances (NPS) use and NPS related harms. 
 
2.2 Potential harms which can arise from youth substance use 
2.2.1 Range of Harms 
It is not the use of substances in itself that is the primary concern for health professionals. It 
is the potential harms which may arise from their use.(5) These possible harms include:- 
 Dependence, harmful use (or substance use disorders)(6) 
 Problems related to acute intoxication(10) 
o Fatal overdose 
o Non-fatal accidental overdose 
o Medical event (e.g. seizure, cardiac arrhythmia) 
o Acute psychiatric disturbance (e.g. paranoia, acute anxiety, deliberate self 
harm, suicide) 
23 
 
o Injury arising from impaired functioning (e.g. fall due to intoxication 
precipitated ataxia) 
o Risky behaviour (e.g. unplanned & unsafe sex, driving while intoxicated) 
 Problems related to cumulative consumption over time 
o Carcinogenic effects (e.g. alcohol & oropharyngeal cancer, tobacco & lung 
cancer) 
o Potential neurotoxic effects (e.g. alcohol and dementia(31), cannabis and 
psychosis(32)) 
o Coronary artery disease (e.g. tobacco, methamphetamine(33)) 
o Deteriorating mental health – development of dual diagnosis.(8, 34) 
In addition to these potential health risks and harms, there are also many negative social 
impacts which can arise secondary to substance use. These include issues such as 
intoxication fuelled anti-social behaviour and violence, acquisitive crime to fund substance 
use, negative impact on relationships and impaired academic performance.(5, 6) The fact 
that young people can end up with criminal charges arising from their drug use is 
increasingly recognised as a drug related harm for those individuals.(4, 10) 
 
2.2.2 Quantifying the harms 
The Global Burden of Disease (GBD) project has highlighted the vast extent of the morbidity 
related to substance use. GBD examines this in two ways. Firstly, it looks at the contribution 
made by substance use as a risk factor for other illnesses and disorders. Secondly, it 
measures disability arising from substance use disorders themselves. It has emerged that 
substance use constitutes the biggest single risk factor for morbidity globally, as measured 
in disability adjusted life years (DALYs), for 15 to 24 year-olds.(9) Neuropsychiatric disorders, 
which includes both mental and substance use disorders, account for 45% of all years lost to 
disability among 10-24 year-olds.(9) The contributions of various specific neuropsychiatric 
disorders to DALYs are provided in Figure 2.1.(26) It can be seen that drug use disorders 
emerge as a major contributor to disability in the late teens, being second only to 
depression as an issue during the 20s. Degenhardt et al examined the relative contribution 
of different specific substance use disorders to the overall morbidity caused by SUDs in 
another GBD study. In the 15 to 24 year old range, it emerges that opioid and cannabis use 
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disorders are the biggest specific contributors to DALYs, as shown in Figure 2.2.(35) The 
treatment studies in this thesis will focus upon heroin and cannabis use disorders. 
 
Figure 2.1 Disability adjusted life years (DALYs) for each mental and substance use disorder 
in 2010, by age. (Reproduced with permission from Whiteford et al 2013:382;1575-86)(26) 
 
 
Figure 2.2 Disability adjusted life years (DALYs) attributable to each type of drug 
dependence by age in 2010. (Reproduced with permission from Degenhardt et al 
2013:382;1564-74)(35) 
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2.3 Patterns of substance use among Youth  
Epidemiological data relevant to youth is considered in the sections below. Among youth, 
two age groups are considered separately, these being adolescents (aged under 18 years) 
and young adults (aged over 18 years). 
 
2.3.1 Temporal and geographic variations among adolescents 
Patterns of substance use by adolescents vary greatly from one country to another and over 
time within individual countries. The USA has been monitoring this issue for a longer period 
than other countries. They have been measuring drug use by adolescents since 1975 in the 
annual Monitoring the Future (MTF) survey.(36, 37) Over the 40 years of this study, it was in 
1979 that drug use hit its peak, with 54% of 12th grade (about 17 years of age) students 
reporting use of at least one illicit substance in the previous year (see Figure 2.3). This fell to 
27% in 1992. By the late 1990s it had increased to 40% once again and it has been relatively 
stable (36% - 42%) at this level for the past 20 years.  
 
Figure 2.3. Use of any illicit drug in the past year. 12th grade (circa 17 years old) students in 
USA. Monitoring the Future survey, 1975 to 2017 
 
 
26 
 
Cannabis has been the most commonly used illicit substance, it being used by the vast 
majority of students who reported use of any illicit substance. The temporal pattern of use 
of substances other than cannabis, such as cocaine, reveals greater fluctuations in use from 
peak to trough (13% in 1985 to 2% in 2016), as shown in Figure 2.4. 
 
Figure 2.4. Use of Cocaine in the past year. 12th grade (age circa 17 years) students in USA. 
Monitoring the Future survey, 1975 to 2017 
 
 
Across Europe, the European School Survey Project on Alcohol and Other Drugs (ESPAD) survey 
has been conducted in schools every four years since 1995, students being interviewed 
around the time of their 16th birthday.(1, 38, 39) Lifetime use of any illicit drug increased 
overall from 1995 to 2003, from 12% to 20%. Since then it has fallen slightly for boys from 
23% to 20% in 2015. It has remained relatively stable for girls over the past 12 years at 15% 
to 17%. Like USA, cannabis is the most widely used illicit substance. Across the 20 year 
period, lifetime use of illicit drugs apart from cannabis was at its lowest in 1995, peaked in 
2007 and has fallen marginally since then (see Figure 2.5) 
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Figure 2.5. ESPAD surveys of 16 year olds. Lifetime use of an illicit drug other than cannabis, 
by gender (%) 
 
 
Past month cannabis use across Europe increased substantially from 1995 to 2003 (see 
Figure 2.6). It has remained quite stable since that time, being about 6% for girls and 8-9% 
for boys. While gender differences have tended to narrow over past decades, most 
international studies also demonstrate a higher prevalence of drug use among males. 
 
Figure 2.6. ESPAD surveys of 16 year olds. Cannabis use in the past 30 days, by gender (%) 
 
 
This pattern of relative stability in use across Europe as a whole conceals substantial 
fluctuations within individual countries. Analysis by country also reveals movement in 
28 
 
opposite directions (see Figure 2.7).(39) In Ireland, past month cannabis use fell from 19% to 
7% from 1995 to 2011, before then climbing again to 10% in 2015. In contrast, Portugal has 
demonstrated a pattern of increased use, albeit starting from a relatively low base. Iceland 
also started at a low base in 1995, avoided any increase over the following decades and 
then actually declined to just 2% in 2015. 
 
Figure 2.7. ESPAD surveys of 16 year-olds. Past month cannabis use in four different 
countries (%) 
 
        Footnote to figure 2.7. Netherlands did not participate in ESPAD in 2011. 
 
 
2.3.2 Temporal trends in substance use by young adults in Ireland. 
Patterns of use among adolescents typically mirror changes in use among young adults 
within countries and over time. In Ireland, the National Advisory Committee on Drugs 
(NACD) has been conducting a survey of substance use in the general population every four 
years since 2002/3.(40, 41) Figure 2.8 shows the rate of past year use of a range of 
substances by young adults aged 15 to 34 years since that first survey. Over the twelve year 
period the proportion reporting use of at least one illicit drug has tended to increase, with 
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cannabis being a component of that substance use in 80-90% of cases, mirroring trends seen 
elsewhere. 
In the 2010/11 survey, questions were asked for the first time about a class of drugs known 
as New Psychoactive Substances (NPS). NPS include a range of drugs such as synthetic 
cannabinoids, cathinones, piperazines and phenethylamines. They were designed to mimic 
the effects of traditional drugs such as cannabis, MDMA and cocaine. They were becoming 
an increasing source of national and international concern around 2009-2010 and 
consequently a question on their use was added to the survey in 2010/11. This revealed that 
NPS were the second most popular category of drug use, after cannabis, at that time. The 
2015/16 survey indicates a substantial decline in NPS use. 
 
Figure 2.8. Past year use of substances in Ireland by young adults, aged 15 to 34 years 
 
2.4 Progression of substance use 
2.4.1 Journey into, through and out of substance use 
Experimentation with substances typically commences in adolescence, and earlier age of 
onset tends to predict more rapid and more frequent progression to development of a 
substance use disorder.(25, 42) Most adults who develop substance dependence 
commenced their substance use as adolescents.(25, 43) However, many people who try a 
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substance do not persist with use, quickly becoming an ex-user.(42) Of those who do 
persist, some opt to use episodically and opportunistically.(44) This group of infrequent 
users face some risks associated with acute intoxication, as outlined in section 2.2. Other 
people may progress to more regular use, and increased frequency of use typically brings 
with it increased risk of harms.(45) 
Across any given population, this potential progression of substance use can be presented 
diagrammatically as in Figure 2.9.(42) This presents the various categories of individuals 
according to their use profile. When followed up over time, some people move in a clock-
wise direction towards patterns of increasing use, while others reduce, or potentially cease, 
their use.(42, 46) 
 
Figure 2.9. Potential journey through stages of drug use and points of health service and public 
policy intervention 
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Individuals can make positive changes to their own substance use without any treatment or 
formal government intervention. For example, they may even move from a dependent 
pattern of use to abstinence, this being referred to as natural recovery.(46)  This was 
highlighted in the study of Vietnam Veterans with histories of heroin dependence while at 
war who reverted to abstinence upon return to USA and also in follow up studies of adults 
with severe alcohol dependence.(47-50)  Also it has been observed that some dependent 
users move back to regular but non-dependent use, and they may make this transition both 
with or without with assistance of a treatment intervention.(46, 51) 
Others may revert from a pattern of regular use to abstinence or to very infrequent use.(46) 
In a survey of young adults aged 15-34 years in Ireland, it emerged that 74% of those who 
had used cannabis regularly in the past reported that they had ceased use at the time of 
interview.(52) The reasons for ceasing use were diverse but the five most frequently cited 
reasons were:- “Did not want to take anymore” (28%),  “Health Concerns” (18.4%), “No 
longer part of social life” (16.1%),  “Impact on Job/Friends/Family” (8.0%) and “Persuaded 
by friends / family” (7.6%). 
 
A Canadian study of adults who had recovered from a cannabis use disorder (CUD) reported 
quite similar findings.(46) They found that the three main reasons given by people for 
addressing their CUD were self-incompatibility (i.e. level of use had become incompatible 
with lifestyle, values or goals), social incompatibility (i.e. incompatible with family, friends or 
society) and mental health concerns. 
 
2.4.2 Societal and health service attempts to influence the substance use journey.  
This diagram (Figure 2.9) also seeks to depict the points at which society or the health 
service strives to intervene in this potential journey towards escalating use. These 
interventions are delivered with the intention of reducing the harms associated with drug 
use.(10, 11) 
Primary prevention aims to prevent any use of the substance.(53) Legislative bans, or 
prohibition, seek to achieve this goal by presenting a major obstacle to easy drug assess and 
providing a disincentive to use. This disincentive is of course the possibility of a criminal 
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conviction, a fine or some other punishment, possibly even imprisonment. A recent review 
concluded that there was evidence pointing towards the effectiveness of such interventions 
in reducing harm for adolescents.(11) The possible impact of a drug’s legal status upon 
decision making by users will be discussed further in section 2.6.2.2. 
Other primary prevention initiatives include universal school based education such as the 
Social Personal & Health Education (SPHE) program in Irish Secondary schools.(11) 
Secondary prevention seeks to curtail progression to more problematic substance use 
patterns where experimentation has already occurred. Such approaches are sometimes 
called indicated prevention, and may be targeted at specific high risk groups of youth.(53, 
54) 
In recent decades there has been an increased emphasis upon brief interventions with 
people who are engaging in substance use.(55, 56) Health professionals in many settings are 
encouraged to ask service users about substance use and to engage in a conversation about 
that use where it is reported.(57) The goal of these conversations is to nudge behaviour in a 
healthier direction, and to advise people of their treatment options if a treatment need has 
been identified. Such approaches have become an increasing component of health service 
delivery internationally. They have also been used in Ireland over the past 20 years in 
selective settings with specific patient groups.(58) Very recently, the Making Every Contact 
Count framework has been established in Ireland to generalise and increase the provision of 
brief interventions in all healthcare settings.(59)  
Treatment interventions are typically confined to people with substance dependence or 
substance abuse. Prior to the 1980s, almost all treatment approaches had a sole goal of 
abstinence. In other words, the treatment goal was to support the patient in becoming an 
ex-user and remaining as an ex-user. Since the 1980’s there has been a substantial increase 
in so called harm reduction treatment approaches.(60) These are not abstinence focused, 
and ongoing but reduced use both during and after treatment is seen as an acceptable 
outcome.(51, 60) 
 
2.4.3 Characteristics of Irish youth based upon their substance use status 
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General population surveys, or surveys of specific age ranges within a population, can 
provide a snapshot of the population profile with regard to use of any particular drug. 
Surveys (such as Monitoring the Future [MTF] & ESPAD discussed earlier in section 2.3) 
typically report lifetime use, past year use and past month use.(37, 39) It is also possible to 
make estimates of the proportion of substance users who meet criteria for a diagnosis of 
substance abuse and for substance dependence using survey data from Ireland and 
elsewhere. 
For the purposes of considering the situation in Ireland regarding substance use across the 
youth population in recent years, the following definitions are used to describe the 
characteristics of each distinct group in Figure 2.9. Every member of a population can be 
placed into one of these mutually exclusive categories for every individual substance (e.g. 
cigarettes, alcohol, LSD, heroin) at any given point in time. 
 
“Never users” of substance X are those people who report never having used 
substance X at any point in their lives. 
[Never users] = [Total population] - [Lifetime users]  
 
“Ex-users” of substance X are people who report some lifetime use of X but no use in 
the past year. 
[Ex-users] = [Lifetime users] – [Past year users] 
 
“Infrequent users” of substance X are people who report some use of X in the past 
year but no use in the past month. 
[Infrequent users] = [Past year users] – [Past month users] 
 
“Dependent users” are estimated from the known or estimated fraction of past year 
users who meet criteria for dependence. 
[Dependent users] = [proportion of past year users who meet dependence criteria] * 
[Past year users] 
 
“Substance abusers” are estimated from the known or estimated fraction of past year 
users who meet criteria for Substance abuse, but not dependence. 
[Substance abusers] = [proportion of past year users who meet substance abuse 
criteria] * [Past year users] 
 
34 
 
In order to ensure the groups are mutually exclusive, then “Regular users” of 
substance X are those who have used in the past month, but do not meet criteria for a 
diagnosis of Dependence upon or abuse of substance X.  
[Regular users] = [Past month users] – {[Dependent users] + [Substance abuse]} 
 
Figures 2.10 to 2.13 present some Irish data making use of this approach to considering 
substance use across the population. Figure 2.10 outlines alcohol use from the ESPAD 
survey results of 2011, most Irish adolescents having consumed alcohol at least once by the 
time they reach 16 years.(38)  
 
Figure 2.10. Profile of exposure to alcohol among 16-year-olds in Ireland in 2011 
 
Footnote to Figure 2.10. ESPAD 2011, alcohol use in Ireland, Lifetime use = 81%, Past year use = 73%, Past month use = 
50%.(38) The My World Survey included 786 4
th
 Year students and was published in 2012.(61) The AUDIT was administered 
and this found that 3% had a score suggestive of dependence and 2% had a score suggestive of “hazardous drinking” which 
equates to abuse of alcohol.  These are probably underestimates as the My World survey team used adult cut-offs when 
interpreting AUDIT score results, while the consensus is that cut-off scores need to be reduced for adolescents. 
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Cannabis is the most widely used illicit drug. Data on use is provided in the aforementioned 
NACDA General Population survey.(52) Figure 2.11 indicates the profile of cannabis use 
among people aged 15 to 34 years in 2010/11. The population estimates of dependence and 
abuse are derived from the Munich Composite International Diagnostic Interview (M-CIDI), a 
19 item instrument reflecting the four cannabis abuse and seven cannabis dependence 
criteria, which used administered in that survey.  
 
Figure 2.11 Profile of exposure to cannabis among young adults in Ireland in 2010/11, 
proportions 
 
Footnote to figure 2.11.  Data obtained from  NACDA General Population survey 2010/11, cannabis use by 15-34yo.(61) 
Lifetime use = 33.4%, Past year use = 10.3%, Past month use = 4.7%, Cannabis Abuse 2.7% and cannabis dependence 1.1%. 
The proportions above assume that (a) all meeting these criteria for a current diagnosis had used in the past month and (b) 
all people meeting criteria for dependence also meet criteria for substance abuse. 
 
According to the CSO website there were 1,208,633 people in Ireland aged 18 to 34 years in 
2011. Figure 2.12 uses the prevalence estimates in Figure 2.11 to provide estimates of the 
number of people in each category in 2011. This indicates that 32,600 people aged 18-34 
years met criteria for either cannabis abuse or cannabis dependence. People with such 
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diagnoses may choose to seek addiction treatment, especially those who are 
dependent.(46) 
 
 
Figure 2.12 Profile of exposure to cannabis among young adults in Ireland in 2010/11, 
numbers (k=1000) 
 
Footnote to figure 2.12.  While the NACDA survey reports on people aged 15-34 years, the population estimates above 
relate to those aged 18-34 years only, and assumes that proportions are similar in this slightly smaller and slightly older 
group. The numbers above also assume that (a) all meeting these criteria for a current diagnosis had used in the past 
month and (b) all people meeting criteria for abuse also meet criteria for dependence. 
 
The National Drug Treatment Reporting System (NDTRS) gathers data on all addiction 
treatment episodes in Ireland. A summary of this information can be accessed on line at 
www.drugsandalcohol.ie/tables/ . This dataset indicates that there were 1155 treatment 
episodes involving adults aged 18-34 years in 2011 where the primary substance problem 
related to cannabis use. There was a further 1994 treatment episodes where cannabis was a 
secondary problem (personal communication from Anne Marie Carew who works with the 
NDTRS in the Health Research Board [HRB] in Dec 2017). This yields a total of 3149 cannabis 
related treatment episodes in 2011 in this age range. This number equates to 9.7% of the 
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number of people with cannabis abuse / dependence noted above. An unknown number of 
people will have had more than one treatment episode during the year. It is certainly the 
case that the vast majority, over 90%, of young adults with cannabis abuse/dependence did 
not access treatment. The ‘rule of thumb’ for drug and alcohol use disorders states that 
about 10-12% of people will access treatment in any given year.(62)  The data presented 
above for cannabis indicates that treatment attendance in Ireland is close to this 
international norm. This has relevance for this thesis, as many of the studies (Chapters 4 to 
8) make use of data arising from that subset of youth who attend addiction treatment. 
Figure 2.13 indicates the profile of cannabis use in 2011 among adolescents aged 16 years of 
age based upon the ESPAD survey.(38) In spite of their younger age relative to the young 
adults in Figure 2.11, the proportions in the categories of ‘regular use’, ‘cannabis abuse’ and 
‘dependence’ are very similar. For the older group, the proportion of ‘never users’ is lower 
and the proportion of ‘ex-users’ is higher, these differences being a function of the 
increased opportunity for experimental use over increased years of life.  
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Figure 2.13. Profile of exposure to cannabis among 16-year-olds in Ireland in 2011, based 
upon ESPAD 
 
Footnote to Figure 2.13. ESPAD 2011, cannabis use in Ireland, Lifetime use = 18%, Past year use = 14%, Past month use = 
7%(62). (Data on dependence and abuse is not available for adolescents in Ireland. To estimate prevalence of abuse / 
dependence, we have used the 2010/11 General population survey which found that 20.1% of past year users aged 15-
34yo met criteria for cannabis abuse and 9.8% of past year users met criteria for dependence.(52) The estimates above 
assume that (a) all meeting these criteria for a current diagnosis had used in the past month and (b) all people meeting 
criteria for abuse also meet criteria for dependence.  
 
2.5 Drug Policy 
2.5.1 Regulatory framework and treatment 
Within this over-arching conceptual framework for considering substance use (Figure 2.9), 
there are dozens of areas worthy of more detailed exploration. This thesis will focus on two 
key areas. Firstly, there is the issue of treating young people who have reached the most 
harmful patterns of use, i.e. dependence and substance abuse. Secondly, the relationship 
between the wider regulatory / legislative context and the likelihood that young people 
develop dependence and serious mental health harms will be explored.  
Ultimately, both treatment and legislation share the same goal of reducing the number of 
people who are dependent and the number experiencing serious harm, albeit operating at 
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different areas of the potential journey through substance use (see Figure 2.9).(11) The 
latter aspires to reduce the numbers who move in a clockwise direction and who progress to 
problematic and dependent use while the former seeks to divert people away from 
dependence once there. 
 
2.5.2 Emergence of dissonance in drug policy  
During the 1960s through to the early 1980s, there was a very clear and coherent message 
from Western societies, as articulated through drug policy, on issues pertaining to use of 
psychoactive substances. With the notable exceptions of alcohol and tobacco, the messages 
were consonant and uniformly very conservative. Firstly, the ‘prevention’ message to 
citizens was that you should not use drugs at all and you would be punished if you opted to 
do so. The foundation of this so called ‘global drug prohibition regime’ was the 1961 United 
Nations Single Convention on Narcotic Drugs (and amended by the 1972 Protocol).(10, 63) 
This international position was supplemented by national laws, such as the Misuse of Drugs 
Act in Ireland in 1977, which dictated that drug use was viewed as a criminal act and would 
bring with it a criminal sanction.  
Citizens who opted to use drugs and who developed an addiction to illegal drugs were 
directed towards treatment programs which reflected the same style of intolerant message, 
this being that all drug use must completely cease.(64, 65) Abstinence was the only goal 
worthy of consideration for the person with an addiction and for the addiction treatment 
provider. 
From the 1980s onwards, there has been a growing discrepancy between the treatment 
message and the prevention or prohibition message (see Figure 2.14). Treatment 
approaches built on harm reduction principles had begun to emerge in the 1970s.(15, 51) 
The archetypal harm reduction treatment was the provision of methadone, a long-acting 
opioid agonist, to people who were heroin dependent.(66) While such treatment 
approaches initially remained relatively marginalised and widely criticised within the wider 
world of addiction treatment, they gained a great deal of traction in the mid-1980s with the 
advent of HIV/AIDS.(65) Evidence mounted that delivery of methadone treatment to heroin 
dependent adults resulted in reduced heroin use, reduced unsafe injecting, reduced 
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mortality and reduced criminality.(14, 67) While such treatment remains somewhat divisive, 
it has certainly become a mainstream approach to treatment of heroin dependence in a 
wide number of western countries including US, UK, Australia, Ireland and the rest of 
Europe.(12)  It is now also being used in quite different cultural contexts, such as China.(68) 
However, some countries remain steadfastly opposed to use of methadone or 
buprenorphine, such as Russia.(69) Many other countries globally  remain very wary of OST, 
such as those in Latin America and Asia.(70) While it has been the mainstay of treatment in 
most western countries, it also continues to experience episodic criticism in those 
locations.(71, 72) 
As mentioned earlier, research also began to emerge in the 1970s that some people with 
severe addiction problems could cease use themselves, or could even revert to non-
problematic patterns of use, without treatment.(48) Treatments emerged which viewed 
‘controlled use’ as a very acceptable treatment outcome. Their arrival provoked highly 
divisive debate.(15) Nevertheless, treatment approaches with goals other than abstinence 
have continued to gain a much more substantial foothold in the world of addiction 
treatment (e.g. motivational interviewing, Community Reinforcement Approach, CBT).(51, 
60, 73)  
In recent years the very concept of addiction or dependence has been challenged. In the 
latest revision of the diagnostic guidelines by the American Psychiatric Association, DSM V, 
major changes were made to substance related diagnoses.(30) It was determined that there 
was insufficient evidence of any clear aetiological or clinical difference between substance 
abuse and substance dependence. The terms were consequently abandoned. The expression 
‘Substance Use Disorder’ is now used to capture the full spectrum of problems, which are 
simply ranked as mild, moderate or severe. This change constitutes a further challenge to 
the older abstinence based treatment models, such as the 12-step approach used in 
Narcotics Anonymous, Alcoholics Anonymous or those used in therapeutic communities.(74) 
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Figure 2.14. Substance use – divergence of treatment and legislative paradigms 
         
   1970-1985  1986-2018  2020+  
   The era of Intolerance 
A Consonance of 
paradigms 
 The era of Ambivalence 
Dissonance of paradigms 
 The era of Tolerance? 
A new consonance of 
paradigms? 
 
         
  
Treatment 
  
Abstinence orientated 
treatments dominate. 
  
Harm reduction 
approaches become the 
dominant paradigm 
 Should we continue 
with harm reduction 
treatment 
approaches for 
adolescents? 
 
         
  
Legislation 
  
Prohibition styled 
legislation 
  
Prohibition styled 
legislation persists, but 
growing international 
debate on utility of same 
 Should we move 
towards a more 
liberal drug policy, 
perhaps regulating 
sale and use? 
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2.5.3 Treatment in Ireland 
In the midst of a huge increase in cases of heroin dependence in Dublin in the mid-1990s, a 
major policy shift occurred in Ireland, whereby the treatment of choice moved away from 
abstinence-based treatments. The standard first line treatment of heroin dependence had 
been the provision of a brief outpatient detox.(22) This then switched towards longer term 
maintenance treatment with methadone. The Methadone Protocol provided the template 
for treatment.(22) This new focus on harm reduction was further consolidated at the end of 
that decade by the first National Drugs Strategy 2000-2008. The four pillars of this strategy 
were Treatment, Prevention, Research and Supply Reduction. Although called a National 
Drugs Strategy, the vast bulk of the actions and resources within the Strategy were directed 
very clearly at heroin dependence and largely focused upon Dublin, where the heroin 
problem was most evident. The treatment arm prioritised expansion of methadone 
treatment programmes. 
In 2006, the Department of Health & Children (DoHC) convened a working group to examine 
provision of addiction treatment services for adolescents under the age of 18 years with 
serious drug problems.(75) This group recommended a four tier model of treatment quite 
similar to that being developed in the UK.(76) The principle deficiency identified in the 
treatment service provision for adolescents at that time was the absence of a network of 
services operating at Tier three, these being outpatient specialist multidisciplinary 
adolescent addiction treatment services. While the working group was not prescriptive 
about the treatment approach, they did recommend treatments such as motivational 
interviewing and CBT, treatments which are not insistent upon abstinence as the sole 
acceptable goal.(11, 60) The Youth Drug & Alcohol (YoDA) service was developed as a result 
of pilot funding arising from this DoHC report. YoDA is the setting for two of the studies in 
this thesis (Chapters 4 & 7).  
That DoHC report did note some ambivalence about harm reduction based treatments, 
especially the use of methadone.(75) The report states:- 
“Different views have been expressed concerning harm reduction approaches as 
they apply to young people presenting with problem drug misuse. In particular, the 
role of methadone in the treatment of young persons gave rise to differing views. 
The Group felt that substitution treatment should only be prescribed to young 
43 
 
persons within a specialist context and should be considered as only a short term 
solution.” 
The group and the report did not specify what constitutes “short term” however. The 
general view regarding use of substitution treatment among adults who are heroin 
dependent is that treatment should be long term. There is a consensus that imposing a 
predetermined time limit on treatment is associated with greater treatment drop out and 
greater harm for adult patients.(77, 78) The UK guidelines on use of psychopharmacology in 
adolescent addiction state:- 
“Some [adolescents] will have severe dependence, a well established history of 
misuse and/or previous treatment and multiple difficulties including mental health 
problems, and will be at high risk of future overdose. These and other factors such 
as the age of the young person may indicate that they may be more suitable for 
maintenance.”(79) 
Many countries remain more wary than Ireland of the longer term use of medications such 
as methadone in the treatment of heroin dependent adolescents. In USA, clinics must 
obtain a special federal waiver to prescribe methadone to under 18s and even then they can 
only do so when the adolescent has had two failed treatment efforts to cease heroin use 
without medication.(17, 18) So although harm reduction based treatments have become 
the norm for adults, there is some ongoing ambivalence about their appropriateness in the 
treatment of addiction in adolescents, both nationally and internationally.  
 
2.5.4 Drug related legislation in Ireland 
While the treatment landscape is very different to a generation ago, the legislative approach 
to drug use has remained largely unchanged in most countries, including Ireland. Most 
fundamentally, drug use remains a criminal offence, as is possession, sale, supply and 
manufacture of drugs listed in the Misuse of Drugs Act.  There is an apparent dissonance 
between a newer liberal and relatively tolerant approach to the treatment of individuals 
with substance use disorders and this older prohibition-styled punitive legislative framework 
to drug use in the general population.  This dissonance is certainly still evident in Ireland as 
it is in most Western countries at this time. This has contributed in increased debate globally 
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about liberalising the legislative response to tackling drug use and related harms.(4, 10, 19, 
80) The success of harm reduction based treatments and the failings of abstinence based 
treatment approaches have featured among the arguments for change. A small but growing 
number of countries have taken tentative steps down this path.(19)  
 
2.5.5 Resolving the ambivalence – a new consonance with tolerant treatment and 
legislation? 
The Netherlands initially decriminalised cannabis possession in the 1970s.(19) Some 
municipalities subsequently proceeded to tolerate small scale sale and distribution of 
cannabis via regulation of ‘coffee shops’. There is some evidence though that alterations in 
the number of coffee shops correlated with changes in prevalence of cannabis use, increase 
in shop numbers being associated with increased use.(81) Although legal at the front door, 
the delivery of cannabis to the back door has remained illegal.(19, 81) Use of other drugs, 
such as cocaine and heroin, has remained a criminal offence.  
Portugal opted to remove the automatic criminal sanction for people caught using any drug, 
from cannabis to heroin, in 2001. While criminal penalties may arise, the default 
consequence is a civil sanction which may include a mandatory referral to a so-called 
‘dissuasion commission’. Therefore, while Portugal decriminalised drug use, they did not 
depenalise use.(4)   
A number of states in USA have recently decided to depenalise use and to also regulate sale 
and supply of cannabis, much in the same manner in which sale and supply of alcohol is 
regulated.(19) Canada appears to be on the cusp of making similar changes.(19) Uruguay 
has also opted to pursue a regulated cannabis market, albeit with many more controls in 
place compared to states such as Colorado in USA.(19) 
New Zealand also passed legislation which acknowledged the possibility that psychoactive 
drugs could be manufactured, sold and used legally for commercial and leisure purposes. 
However, the important caveat in that apparently liberal legislation was the requirement 
placed upon the producer of the drug to first demonstrate the relative safety of their 
product. In reality, this requirement has resulted in the new law functioning as de facto 
prohibition.(82, 83)  
45 
 
In tandem with the increase in the number of countries which are experimenting with less 
conservative approaches to drug policy, a vast array of lobbying and advocacy groups and 
organizations have emerged to build support for liberalization of drugs policy. The term 
‘harm reduction’ has moved outside the narrow treatment arena and into discussions on 
issues such as prevention and wider drug policy.(84) It is frequently cited as a reason for 
supporting more liberal policies, the argument being made that criminalising users is 
causing harm to them and to society, and is fuelling further criminal and antisocial 
activity.(85)  
In 2016, the Johns Hopkins–Lancet Commission on Drug Policy and Health published a 
review of evidence on drug policy internationally.(4) Like many of the groups and 
organizations which advocate for liberalization of drugs policy, this commission was also 
funded by the Open Society Foundation. This concluded that current policy was failing 
society and stated that the world should “move gradually toward regulated drug markets.” 
Commenting on the report, a Lancet editorial stated:- 
 “drug policies intended to protect people, but based on prohibition and 
criminalisation, have had detrimental effects on public health in multiple ways”.(21) 
The view is espoused that moving away from the criminalization of drug use, and towards 
the regulation of use, will result in less net harm across society.(4, 80) Given the fact that 
the move away from conservative abstinence based treatment towards harm reduction 
treatments has been generally well received by clinicians and policy makers in the drugs 
field, it appears that very many experts in these fields are now favourably disposed to a 
more liberal policy on the legislative and regulatory fronts.(4, 86)  
 
2.6 Two specific areas of ongoing controversy 
2.6.1 Opiate Substitution treatment for adolescents with heroin dependence 
As suggested earlier in this chapter, one area of controversy relates to use of longer-term 
opioid substitution medications such as methadone in the treatment of adolescents who are 
heroin dependent.(17, 18, 75) To explore this issue, the literature was reviewed to identify 
studies reporting outcome for opioid dependent adolescents who were provided with 
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opioid substitution treatment (OST) for three months or more. The outcomes of interest 
were (1) reductions in use of non-prescribed opioids, (2) retention in treatment and (3) 
changes in mental health or psychological well-being.  
To conduct the electronic search, three biomedical electronic reference libraries, PubMed, 
Cochrane library and PsychINFO were searched using search terms that described opioid or 
heroin dependence and treatment. The search terms included a number of key words and 
combinations of key words (see table 2.1). 
The searching was limited to articles published in English. The search was not limited to 
empirical research. A review of relevant clinical and professional material was also 
conducted. This included examination of professional documents, national reports on 
adolescent addiction treatment and relevant web based resources such as the National 
Treatment Agency in the UK and National Institute of Drug Abuse (NIDA) in USA. Articles and 
materials retrieved during the search were examined and included if appropriate. A manual 
search of the literature was also conducted. This included a reference search of the relevant 
articles identified through the electronic search.  
 
Table 2.1 Literature search key words on use of OST for heroin dependent adolescents 
Keywords Combination with keywords 
  
Heroin Dependence Adolescent 
Heroin Addiction Teenager 
Heroin Use Disorder Youth 
Heroin abuse Substitution treatment 
Opioid Dependence Maintenance treatment 
Opioid Addiction Medication Assisted treatment 
Opioid Use Disorder Outcome 
Adolescent Treatment 
Teenager Depression 
 Anxiety 
 Anger 
 Mental Health 
 Retention 
 Adherence 
  
 
The resulting studies are summarised in Table 2.2 below. Most of the studies were 
conducted in USA. Sample sizes have tended to be very small relative to adult studies of 
OST. The two largest studies were conducted in the 1970s. While older studies focused upon 
47 
 
methadone as the treatment intervention, most studies in the past 15 years have examined 
treatment outcome with buprenorphine based treatments. Some of the included studies 
comprise primarily young adults, aged over 18 years, and fail to give specific outcome 
information on the few included adolescents aged under 18 years. Many of the studies 
provide information on treatment drop out. Few of the studies provide specific information 
on ongoing use of heroin or other drugs during treatment.  
None of the studies provides information of changes in mental health symptoms during the 
course of OST. One study was identified which reported changes in mental health symptoms 
during the buprenorphine treatment of 18 adolescents.(87) However, this study examined 
changes in symptoms after a period of just four weeks and the treatment provided was a 
detoxification, rather than a longer term substitution treatment. They found significant 
improvements in internalizing symptoms. While the change in overall externalizing 
symptoms approached significance, there was no significant improvement in aggression and 
rule-breaking. 
In addition to the table, there is a summary below of the key findings and some key 
methodological considerations for each of the studies. 
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Table 2.2. Summary of outcome studies examining opioid substitution treatment in adolescents 
Author (Study) Country Year Number 
<18 years 
(% of study 
sample) 
Duration of 
treatment 
Medication 
Utilised 
Outcome Information Reported? 
Treatment Retention Changes in drug Use 
while on treatment 
Changes in 
mental health 
Millman, Khuri & 
Nyswander(88)  
USA 1978 153  
(100%) 
One year Methadone Yes. 
22% drop out, most in first 
few months. 
Not reported Not reported 
Sells & Simpson (Drug 
Abuse Reporting 
Program [DARP])(89, 
90) 
USA 1979 127  
(100%) 
One year Methadone Yes. 
63% drop out at 12/12 & 
28% drop out at 4/12. 
Yes. 
Reduced heroin use, but 
no specific information. 
Not reported. 
Crome (91) UK 2000 48  
(100%) 
unclear Methadone Yes, but vague timeline. 
“80% retention” 
Very vague.  
37% had a “good 
outcome”. 
Not reported 
Bell & Mutch(92) Australia 2006 45  
(100%) 
One year Methadone & 
Buprenorphine 
Yes. 
25% drop from Bup by day 
5 and from Methadone by 
day 76. 
Not reported Not reported 
Kellogg (93) USA 2006 155 aged 
15-23 years 
(??) 
One year Methadone Yes. 
48% retention at one year. 
Yes, but ambiguous. 
Reduced heroin use 
reported. 
Not reported 
Subramaniam (NIDA 
Multisite 
Buprenorphine 
Treatment Trial)(94-96) 
USA 2011 12  
(16%) 
12 weeks Buprenorphine Yes. 
72% retention at 3 months 
from overall group, aged 
15-21 yrs - no age specific 
data provided. 
Yes. 
77% opiate negative at 
week 10.  
Not reported 
Matson(97) USA 2014 28  
(27%) 
One year Buprenorphine Yes.  
25% drop out day two. 50% 
drop out by day 60  
Not reported Not reported 
Mutlu (98) Turkey 2016 112  
(100%) 
One year Buprenorphine Yes. 
30% drop out within one 
month. 
Yes. 
10% abstinent at one 
year. 
Not reported 
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A recent Cochrane review found that there are no clinical trials examining outcome of OST 
beyond three months in people aged under 18 years old.(99) There were only two clinical 
trials of less than three months and one of these, the NIDA Multisite Buprenorphine 
Treatment Trial is included in the summary above as it provides outcome information up to 
12 weeks.(96) This NIDA study has generated many publications.(94-96) 
There are a small number of ‘open label’ longer term studies. Two of the largest studies 
providing longer term outcome information on methadone treatment of heroin dependence 
in adolescents were conducted in United States in the 1970s. The DARP study reported 
outcome on 5400 young people under the age of 20 years who received a range of different 
treatments and presented with a variety of substance use disorders.(89) There were only 
127 under 18s on methadone treatment (MT) in DARP. Among that subset, 63% dropped 
out within one year, with 28% dropping out within 120 days, these rates of unplanned exits 
being higher than those seen in the young adults on MT in DARP. It was reported that heroin 
use declined progressively over the year, although specific data is not provided. At follow-
up, alcohol and cannabis problems had escalated from baseline levels. Millman, Khuri & 
Nyswander reported outcome from their MT program for 153 heroin-dependent 
adolescents in New York in the 1970s.(88) The methadone dose was limited to 20mgs, a 
dose which would be seen to be sub-therapeutic my modern standards.(100) The treatment 
goal was cessation of heroin use and detoxification from MT. Just 22% of people dropped 
out, most of whom did so during the first three months. No information is provided on 
cessation of heroin use among those who remained on MT.  
More recently, Crome et al reported on the outcome of the first 48 patients with severe 
heroin dependence who were prescribed methadone at a youth treatment service in 
England.(91) It was reported that 80% were retained in treatment and that 37% had a 
“good” outcome but the criteria utilised to determine outcome were subjective and 
somewhat unclear.  
An Australian study examined treatment adherence in a cohort of 45 teenagers on OST.(92) 
They found significantly better retention among those treated with methadone compared 
to buprenorphine, with 25% exiting MT by day 76 and 25% exiting buprenorphine treatment 
(BT) by day 5. No data were reported on rates of cessation of heroin use.  
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Matson et al reported outcome of a cohort of youth treated with buprenorphine/naloxone, 
among whom 28 were aged under 18 years.(97) This outpatient treatment program had a 
very high expectation that patients would cease heroin use and ongoing use during 
treatment could result in discharge. Only 50% of the under eighteen group remained in 
treatment for over 60 days. Among the overall group, retention was better in females, and 
in those who ceased heroin and cannabis use. Abstinence rates during treatment were not 
reported.  
Mutlu et al reported the one year outcome of 112 heroin dependent adolescents who 
received outpatient buprenorphine/naloxone, following a two month inpatient admission 
for induction and stabilisation.(98) At 30 days, 70% were still in treatment and this dropped 
to 16% at one year. This study also examined the time to relapse to heroin use following 
inpatient admission and 63% had relapsed within 60 days, while only 10% remained 
abstinent for one year of outpatient BT. The mean buprenorphine dose was just 4mgs and 
this is low in comparison to advised maintenance doses.(101) It emerged that higher dose 
was associated with better retention and longer abstinence. Among the examined baseline 
characteristics, those who had a comorbid psychiatric disorder demonstrated better 
retention, but there were no predictors of abstinence.  
The NIDA multisite buprenorphine/naloxone treatment trial mentioned earlier examined 
treatment of youth who were provided with an extended detoxification treatment and 
included 12 under eighteens(96). This clinical trial excluded patients with evidence of 
benzodiazepine or methadone use at baseline. Patients were provided BT for 9 weeks, 
followed by a 3 week dose taper. By week 10, 25% had dropped out of BT. Polydrug use was 
associated with increased risk of dropout.(95) At week eight, 23% of those retained on BT 
provided an opiate positive urine drug screen.(96) Abstinence from heroin at 12 weeks was 
associated with greater baseline medical and psychiatric problems, a history of recent 
injecting and evidence of early cessation of heroin use during BT.(94)  
Kellogg et al reported one year outcome of a slightly older group of 15-23 year olds, with 
unknown proportion of under 18s.(93) They were treated with methadone, mean dose of 
100mgs. Retention was 48% at twelve months, and half of the drop outs occurred in the first 
four months. Greater heroin and cocaine use during treatment was associated with drop 
out. Higher heroin use during treatment was associated with larger methadone doses. 
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Among the 48% who persisted with treatment for the full year, there was no evidence of 
heroin use in about half of the twelve individual months. There was a significant decline in 
heroin use over that year, but no significant changes in use of cocaine or benzodiazepines. 
An overview of these studies, suggests 25% of patients drop out after about 2-3 months and 
12 month retention on OST is 20-50%. Rates of retention appear better in MT than with BT. 
Although there is substantial heterogeneity in how studies define drop out, it seems more 
likely to occur in those with greater ongoing use of heroin and other drugs, especially 
cocaine. One of the explicit purposes of OST is to facilitate the patient to reduce, and ideally 
cease, their heroin use. Unfortunately, this current body of research does not make it clear 
what proportion of adolescents on OST cease heroin use during treatment. While providing 
no specific information on levels of use during treatment, the Kellogg et al and DARP studies 
suggest heroin abstinence does increase with longer treatment.(89, 93) As mentioned 
earlier, mental health outcomes on OST are not reported in any study. These gaps in the 
literature make it more difficult for adolescent patients, their parents, referrers, treatment 
providers to make informed decisions regarding this treatment. The limitations in 
information may also add to the reluctance of policy makers to support delivery of OST in 
this age range, especially longer term OST treatment.(17, 75)  
This thesis seeks to address some of these gaps and uncertainties in the literature by 
addressing a number of questions: 
 What proportion of adolescents on OST cease heroin use during treatment? 
 Does abstinence from heroin simply plateau after three months or does it continue 
to improve for those who persist with treatment? 
 Does the mental health of adolescents on OST improve, remain static or deteriorate? 
 Are there patient or treatment characteristics which are associated with better 
adherence to OST and to better outcome during OST? 
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2.6.2 New Psychoactive Substances – a new test for old prohibition styled legislation  
2.6.2.1 Arrival of New Psychoactive Substances in Ireland 
A second area of controversy relates to the legislation surrounding drug use. There is an 
emerging consensus that criminalising drug users and the drug market place is not just 
ineffective in reducing harm for society and for individuals, it is actually adding to harms.(4, 
102) It is argued that international drug policy should move towards regulating sale and 
supply of drugs.(80, 102)  
New psychoactive substances (NPS) arrived on the scene worldwide in dramatic fashion in 
the past decade.(103) These are drugs which are designed to mimic the effects of older 
‘traditional’ illegal drugs such as cannabis, ecstasy, amphetamines and cocaine. They are 
generally synthetic. Due to the fact that they were not named in specific drugs legislation 
internationally, they began to be used and sold in a relatively open and commercial manner 
in many jurisdictions.(104) These new market places for drugs were completely 
unregulated.  
For reasons that are unclear, use of NPS became particularly popular among youth in Ireland 
around 2010. A telephone survey of youth across Europe revealed that young people in 
Ireland reported the highest rate of lifetime use of NPS.(105) As indicated in Figure 2.8 
earlier in this chapter, the NACD general population survey of drug use in 2010/11 reported 
that NPS as a group were second only to cannabis in popularity among young adults in 
Ireland.(40) Qualitative research conducted in Ireland indicated that most NPS users at this 
time had a history of use of other drugs, most notably cannabis, ecstasy and cocaine.(104) 
This growth in use of NPS in Ireland coincided with a large increase in the number of head 
shops selling NPS. There may have been a reciprocal relationship between numbers of head 
shops and use of NPS, demand driving the supply and supply possibly driving the demand.  
There was widespread public concern regarding head shops. There were mass protests by 
communities across Ireland regarding their presence in their towns. There was intense 
debate within the media (See Figure 2.14 and 2.15) and among politicians regarding the 
appropriate response to this new challenge to Ireland’s drug policy regime (see Figure 2.16).  
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Figure 2.14. Number of mentions of “head shop” in Irish newspapers per month 
 
Footnote to Figure 2.14. The graph depicts the number of mentions of the word/expression "headshop" or 
"headshops" or "head shop" or "head shops" in Irish Times newspaper, Irish Independent Newspaper and 
regional newspapers affiliated with the Independent Newspaper over the period Jan 2009 to December 2013. 
The data was obtained from Newspaper websites on 27
th
 April 2016. 
 
 
 
Figure 2.15. Head shops and NPS in the news: Newspaper headlines from 2010. 
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Figure 2.16. Number of mentions of the expression “head shop” in Dail Debates per quarter 
 
Footnote to Figure 2.16. The graph depicts the number of mentions of “head shop” in Dail debates via a 
search of 
http://oireachtasdebates.oireachtas.ie/debates%20authoring/debateswebpack.nsf/fulltextsearch?readfo
rm  . The figure presents the number of mentions per quarter from 1
st
 quarter of 2008 to last quarter of 
2013. Data was obtained from the Oireachtas website on 29
th
 April 2016 
 
 
There were about 20 head shops open across Ireland for a number of years prior to 2009. 
Figures 2.14 to 2.16 confirm that there was little or no political, public or media interest in 
these head shops in Ireland prior to very late in 2009. Up until then, they generally just sold 
drug related memorabilia such as t-shirts and some paraphernalia for drug use. There was 
occasional concern regarding their sale of a small number of psychoactive substances such 
as Pscylocibin found in ‘magic mushrooms’. In 2008, the Garda National Drug Unit (GNDU) 
conducted an investigation of all head shops in Ireland as part of Operation Flourine 
(personal communication, GNDU). This was initiated due to concerns that they were selling 
natural plant products containing hallucinogenic substances such as Lysergamide, 
Pscylocibin & Mescaline. Concern increased once again in late 2009/early 2010 in tandem 
with the public protests, media coverage and political interest in NPS. Operation Kingfisher 
was commenced around this time and continued over the following 18 months (personal 
communication, GNDU). These Garda operations provide relatively detailed information on 
the number of headshops in Ireland over the period 2008 to 2011. This information is 
presented in Figure 2.16. 
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Figure 2.17. Number of head shops in Ireland, 2008 to 2011. 
 
 
By May 2010, the number of head shops had increased to 102. Test purchasing of products 
obtained from headshops in 2010 confirmed a wide range of NPS were being sold 
commercially and legally.(106) There was a period of brief but intense debate as reflected in 
Figures 2.14 - 2.16. In the first instance, the Irish Government opted for the default strategy 
of simply adding over 100 NPS to the pre-existing Misuse of Drugs Act, thereby making it a 
criminal offence to use, possess, sell or distribute the specified NPS. This made these 
specific NPS illegal in exactly the same manner as ‘traditional’ drugs such as cannabis and 
cocaine.  
About half of the entrepreneurs who had set up head shops in the preceding months then 
decided to immediately cease trading, their shops closing. The remaining shops simply 
opted to cease selling the recently banned NPS and commenced selling NPS which were not 
yet banned.(106) This provoked further debate during the summer of 2010. With minimal 
consultation and little warning (and in dramatic contrast to recently enacted similar 
legislation in the UK), the Irish Government opted to proceed with entirely novel and 
untested legislation. The Criminal Justice (Psychoactive Substances) Act was passed and 
enacted in late August 2010. This stated that ‘a person who sells a psychoactive substance 
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knowing or being reckless as to whether that substance is being acquired or supplied for 
human consumption shall be guilty of an offence’. 
In contrast to the Misuse of Drugs Act, this new legislation did not criminalise or prohibit use 
by individuals. Instead, it simply targeted the vendors. There was scepticism among legal 
experts and policy makers regarding this Act. There was a view that it would be difficult to 
prove in court and highly problematic to prosecute cases.(107, 108) However, it achieved its 
goal in that the remaining head shop owners opted not to test out its legal robustness and 
responded by either shutting their shops or by ceasing sale of NPS, reverting back to the 
type of business model which they had followed five years previously.(82) The GNDU 
continued to monitor their activities via Operation Kingfisher and compliance with 
legislation was observed to be good. There have been two successful prosecutions in the 
past seven years under the Criminal Justice (Psychoactive Substances) Act.(109)  
Most predicted that the decision to persist with prohibitionist styled policies of the past 
would cause problems associated with NPS to continue unabated and possibly even to get 
worse as NPS users turned to drug dealers.(110-112) Indeed, surveys of drug users 
conducted at that time generally indicated that people intended to continue using NPS and 
declared an intention to move to the black market and to the internet to source NPS.(105)  
There was general scorn among policy makers nationally and internationally for the 
approach adopted by the Irish Government. A national review of stakeholder views 
concluded that it constituted “a clear victory for traditional ‘war on drugs’ values”.(107) 
There was a view that harms related to NPS had been exaggerated and action was driven by 
a media generated “moral panic” as opposed to evidence (see Figure 2.14 and 2.15). The 
connection between media coverage of the NPS issue and legislative action has also been 
examined in other countries. Those reviews have reached a similar view and have also 
highlighted the tight correlation between increased media reporting, often perceived to be 
sensationalist, and government action.(112, 113)  
 
2.6.2.2 Motivations for use of NPS 
Is it plausible that legal status of a drug, and change in same, influences use? In order to 
explore the factors which influenced the decision by drug users to use NPS specifically, 
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Barratt, Cakic & Lenton conducted a survey of users of synthetic cannabinoids (SC) in 
Australia.(114) The three most common reasons for choosing SC were curiosity (50%), 
legality (39%) and availability (23%). Another recent Australian study indicates that many 
high school students interpret legal sale as an indication of safety and report increased 
willingness to use NPS in that scenario.(115) A survey of patients admitted to a psychiatric 
hospital in Australia found that over half had used NPS and the most common reasons given 
for use were legality and availability.(116) In New Zealand, Sheridan & Butler interviewed 
BZP users.(117) They viewed their legal sale as an indication of their safety and reported 
advantages related to the legal status such as better availability and the desire to avoid 
going to drug dealers. In the year that the prohibition of BZP was imposed, two of the three 
main reasons given for stopping BZP use were because it was ‘illegal’ and ‘didn’t know 
where to get it now it’s illegal’, 43% reporting the former and 23% the latter (118).  
An on line survey of drug users in Ireland was conducted in 2010 to explore use of NPS, 
most respondents having a history of use of drugs such as cannabis, ecstasy or cocaine.(104) 
The main sources of NPS were head shops (78%) and friends (66%). Sourcing NPS via the 
internet (16%) and from dealers (15%) was less common. Sixty-five per cent of respondents 
reported that there was a head shop within five kilometres of their home. Curiosity and 
availability were reportedly the main factors driving NPS use.(104)  
The influence of legal status on decisions to use other drugs, such as cannabis has been 
demonstrated in students, who report its illegal status as a reason for avoiding use in a 
Canadian study.(119) The importance of legal status of drugs was also demonstrated in the 
aforementioned follow-up studies of Vietnam veterans returning to USA.(47) Although 
many had used heroin in Vietnam where they had easy access to cheap high quality heroin, 
few used upon their return. The reasons for avoiding use in USA included its illegal status 
and worries regarding criminal charges and family disapproval.(47, 120, 121) Most of those 
who had used heroin in Vietnam agreed that it should remain illegal in USA.(121) 
These various studies provide some clues regarding the mechanisms via which prohibition 
styled legislation might influence both supply and demand for NPS. While legal, demand for 
NPS may increase as people confuse legality with safety. When made illegal, demand may 
fall as many people seem reluctant to migrate to drug dealers, some interpret illegality as 
implying greater health risk and some are put off simply by their illegal status. While legal 
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and sold commercially, supply and availability is obviously better than when made illegal, as 
high street shops compliment the always available black market. For regulated drugs such as 
alcohol, it is well established that increased access and availability lead to increased use and 
harms.(122) 
2.6.2.3 Literature review of studies examining change in use or harms after legislation 
Having identified this evidence that legal status of NPS may theoretically influence demand 
and supply, the international literature was explored. Research studies were sought which 
reported on some measure of NPS use or NPS related harm and provided data regarding 
same both before and after a legislative change. To conduct the electronic search, three 
biomedical electronic reference libraries, PubMed, Cochrane library and PsychINFO were 
searched using search terms that described NPS and legislation. The search terms included a 
number of key words and combinations of key words (see table 2.3). 
The searching was limited to articles published in English. The search was not limited to 
empirical research. A review of relevant clinical and professional material was also 
conducted. This included examination of professional documents, national and international 
reports on NPS and conference abstracts. Articles and materials retrieved during the search 
were examined and included if appropriate. A manual search of the literature was also 
conducted. This involved a reference search of the relevant articles identified through the 
electronic search. 
Table 2.3. Literature search key words on use of legislation to target NPS use and harms 
Keywords Combination with keywords 
  
New psychoactive substances Legislation 
Novel psychoactive substances Bans 
Mephedrone Prohibition 
Synthetic cannabinoids Prevention 
Legal Highs Harms 
Cathinones 
Head shop drugs 
 
  
  
 
Studies reporting on the impact of NPS focused legislation were identified and their 
characteristics and key findings are summarised in Table 2.4. 
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Table 2.4. Summary of studies examining changes in NPS use and harms following legislative changes targeting NPS. 
Author Year Country NPS type Study population 
or setting 
Use or harm 
examined 
                           Finding  
        
Ledberg (123) 2010 Sweden 8 Specific NPS Posts on web based 
discussion forums 
Mention of 
specific drugs 
in posts. 
For all eight substances the activity on the 
forum (measured as number of posts per day) 
showed a drastic decrease around the time of 
classification. 
 
McNamara et al 
(124) 
2010 Ireland Mainly cathinones Treatment attending 
Opiate dependent 
adults  
Use based on 
urine drug 
toxicology 
screens 
In the 10 weeks prior to scheduling of over 100 
NPS in May 2010, over 30% of samples were 
positive for NPS. This remained over 30% for 
the month after the ban, then dropped to zero 
from months two to three post ban. 
 
Wood, Green & 
Dargan (125) 
2013 UK Mephedrone Emergency 
Department (ED) 
Acute toxicity 
(poisoning) 
Cases of mephedrone toxicity peaked just prior 
to legal ban and fell over following 6-12 
months. 
 
Stogner et al 
(126) 
2012 USA Salvia divinorum Surveys of 
University students, 
pre and post a ban 
Use Past year use declined from 3% pre-ban to 0% 
post-ban. 
 
National Poisons 
Information 
Service (127) 
 
2012 UK Mephedrone Calls to Poison 
centres 
See Figure 6.4 on 
p37. 
Concerns re 
Acute toxicity 
(poisoning) 
Telephone enquires peaked in March 2010, 
month before ban. They fell by over 60% over 
the next three months, and remained at this 
lower level over following two years. 
 
Wilkins & 
Sweetsur (118) 
2013 New 
Zealand 
Benzylpiperazine (BZP) General population  Use Decline in past year use from 15% to 3%. No 
evidence of switch to use of other, not yet 
illegal NPS, use of these also falling. 
 
Sheridan et al, 
(128) 
2013 New 
Zealand 
BZP & other NPS Online survey of 
young adults (18-
30yo) 
Use of BZP & 
other NPS 
Use of BZP declined post ban. Use of still legal 
synthetic THC products also fell. Non-medical 
use of prescription drugs increased but use of 
stimulants was unchanged. 
 
Loeffler & Craig 
(129) 
2013 USA Mephedrone Calls to Poison 
centres 
Acute toxicity 
(poisoning) 
The number of calls per month fell by 89% 
over the 8 months after the legal ban. 
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Glue et al (130) 2015 New 
Zealand 
Synthetic Cannabinoids (SC) Patients presenting 
to an emergency 
psychiatric service 
SC related 
psychiatric 
presentations 
Comparing the three months before and after a 
legislative ban, there was a 52% reduction in 
patient presentations. 
 
Kriikku et al 
(131) 
2015 Finland 3, 4- 
methylenedioxypyrovalerone 
(MDPV) 
People caught 
driving under the 
influence of drugs 
(DUID) 2009-12 
Cases of DUID 
involving 
MDPV pre- 
and post ban. 
Number of DUID cases involving MDPV 
declined by 51% post ban in June 2010. 
 
Matsumoto et al 
(132) 
2016 Japan NPS Psychiatric 
inpatients and 
outpatients 
Drug related 
psychiatric 
disorders 
NPS related presentations increased in the 
period after NPS focused legislation. Other 
drug related disorders also increased during this 
period. 
 
Glue et al (133) 2016 New 
Zealand 
Synthetic Cannabinoids (SC) National Dataset of 
Patient 
presentations to 
general hospitals  
Patient 
presentations to 
related to SC 
use 
Steep declines in numbers of presentations 
occurred after each of three changes to 
legislation between 2011 and 2014. 
 
Mathai et al (134) 2016 USA Synthetic Cannabinoids (SC ED presentations 
related to SC use 
Referrals to 
hospital based 
addiction 
counsellor  
SC presentations increased by about 100% 
following a local city ordinance targeting wide 
class of SC.  
 
Cairns et al (135) 2017 Australia Synthetic Cannabinoids (SC) Calls to Poison 
centres 
Acute SC 
toxicity 
(concerns re 
poisoning) 
Federal bans of specific SC compounds had 
little impact. State-based legislation introduced 
in 2013 banning specific brand names of SC 
products was followed by a dramatic decrease 
in exposures, sustained for the two year follow-
up period 
 
Yeung et al (136) 2017 Scotland Ethylphenidate People who inject 
drugs 
Injection 
related S. 
pyogenes &/or 
S. aureus 
infections 
Rate of infection among PWID dropped from 
4.9 to 2.0/week (i.e. 59% decline), following 
ban of Ethylphenidate 
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New Zealand was one of the first countries to encounter problems related to a NPS and to 
implement a response. Use of Benzylpiperazine (BZP) became popular among young people 
around 2005 and this substance was not covered by the country’s existing legislation. 
Manufacturers promoted BZP tablets as legal and ‘safe’ alternatives to ecstasy and 
methamphetamine.(137) After a period of community and government tolerance of BZP 
use, there was further debate and BZP use was eventually prohibited in April 2008. This 
followed findings from a number of studies which indicated health risks. Past year 
prevalence of BZP among the general population fell from 15.3% in 2006 to 3.2% in 2009. 
(118) 
Summarising the various studies in Table 2.4, it appears that problems related to individual 
substances generally declined following the prohibition of that substance. In those studies 
which monitored events on a monthly basis, the observed declines tended to commence 
rapidly. While few studies looked for evidence of movement towards other drugs, those 
which did found little or no evidence of this. All studies revealed evidence of some ongoing 
use or harms following bans, albeit at reduced rates. Wood, Measham & Dargan reported 
substantial ongoing use of mephedrone among young people attending dance clubs after 
the ban of that drug, although they failed to measure rates of use prior to the ban.(138) 
They found that use increased when they repeated the survey 12 months later. Therefore, it 
seems certain that prohibition styled legislation does not eliminate all use or all harms.  
Many studies describe a pattern of multiple attempts by legislators to address these issues, 
with a series of new laws and regulations being introduced due to perceived deficiencies in 
the preceding legislative efforts.(133-135) The outcomes examined across the studies were 
quite diverse and included use in the general population, use by specific population 
subgroups, poisoning episodes and medical & psychiatric hospital attendances. It is striking 
that almost all of the studies reported some positive change, i.e. a reduction in harms 
and/or use. This may reflect a bias in submissions by researchers and/or a bias in journals 
towards reporting of positive rather than null findings.(139) 
There were two studies which reported negative findings, one from Japan and one from 
Texas in USA.(132, 134) The Japanese study examined NPS related treatment episodes at 
psychiatric services before and after legislative measures which targeted synthetic 
62 
 
cannabinoid (SC) and cathinone derivatives, banning partial modifications to the chemical 
structure of already banned drugs.(139) The authors reported an increase in NPS related 
episodes at psychiatric services in spite of these supply reduction initiatives. Psychiatric 
attendances related to use of other banned drugs also increased over the same period, 
suggesting a general increase in drug related presentations at this time. This complicates 
interpretation of the findings. The study by Mathai et al examined referrals to an addiction 
counsellor from an emergency department and an inpatient psychiatric unit in Houston, 
Texas and examined the period Nov 2013 to Feb 2015.(139) There had been a number of 
legislative measures taken to target SC prior to Nov 2013 which included federal and state 
legislation. There was further federal and state legislation later in 2015. A city ordinance 
targeting SC during the study period was followed by increased SC related referrals. The 
authors describe the legislative process as “an arms race”, with increasingly complex 
legislation being followed by diversification of SC subtypes being sold. 
In terms of limitations of the presented studies, many simply report a change in rates of 
events pre- and post-legislation and did not subject these changes to any statistical analysis. 
Most of the studies focus on legislation which targeted a single drug or drug class and do 
not examine the possibility that problems related to another NPS may have increased as the 
problems related to the targeted NPS declined. 
 
2.6.2.4 Rationale for studies focused upon Head shops and NPS in this thesis. 
The events of 2009 and 2010 in Ireland provide the opportunity for a natural experiment. 
The arrival of a vast network of head shops selling NPS constituted a period of legal and 
commercialised sale of drugs, albeit entirely unregulated. It constituted a particularly liberal 
version of a legal drug market and is akin to the ‘free market’ approach to drug policy 
described by Rogeberg et al.(80) It was quite short-lived being dealt a blow in May 2010 via 
the additions to the Misuse of Drugs Act and ultimately terminated abruptly in late August 
2010. Although quite brief in duration, these events provide the opportunity for ‘a natural 
experiment’ to examine some key questions of relevance not just for drug policy in Ireland, 
but also of international relevance.  
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1. Was there evidence of increased and significant harms related to NPS when access 
and availability increased via the expansion of the network of head shops? 
2. If harms were evident during this period, did they persist once the head shops were 
closed, did they diminish or could the problems even have escalated? 
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Chapter 3 
Methodological issues 
3.1 Measuring addiction treatment outcome 
3.1.1 What is meant by “outcome”? 
Many years ago, a senior political figure was doing a brief tour of the building in which I 
worked. As they passed quickly through our adolescent addiction service, I was asked one 
question: “What are your outcomes?” As I fumbled through an incoherent response, they 
moved on to the next person. This encounter has always troubled me. 
It is routine and common for people to ask about treatment outcomes in our health care 
system. Oncologists will quote the five year survival of the treatments they utilise. Infectious 
disease specialists will provide the response rate to their treatments. Even in mental health, 
psychiatrists and GPs will confidently state the response rate of depression to treatment 
with SSRI medications. Such information allows doctors, patients and health service 
managers and funders to make more informed decisions. While superficially attractive and 
clear, each of these apparently concrete measures conceals many uncertainties. Patients 
with cancer value quality of life as well as quantity of life. The clinical trials which provide 
much of the outcome data upon which we rely often exclude patients with comorbidities 
and those who demonstrate poor treatment adherence. Such patient attributes are very 
common in real world clinical settings. The definition of ‘cure’ used in clinical trials can seem 
quite arbitrary in many cases, perhaps being defined as a percentage decline in symptoms 
or symptoms falling below a cut-off point on a scale. 
For many chronic conditions, doctors will be familiar with the rule of thirds which often 
appears to apply to treatments. About one third of people do very well, one third make a 
partial recovery and one third obtain no meaningful benefit. 
When people outside the world of addiction treatment ask “what are your outcomes?”, it 
seems likely that they mean “how many of your patients stop using drugs?” or attain 
abstinence. However, that apparently more straight-forward question contains many 
uncertainties. Does it mean stop using their main drug or all drugs? Does it mean ceasing 
alcohol use too?  What about cigarette use? Over what time duration does “stop using” 
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apply? Does one month drug free count as abstinence? Does it mean life time 
abstinence?(140) 
What about outcomes beyond drug use? There has been a growth in focus on recovery in 
both the addiction and mental health fields in recent years. This movement emphasises the 
importance of psychosocial functioning, participation in community and general well-
being.(140) These treatment goals are viewed as at least as important as cessation of 
substance use. However, measurement of recovery is far from straight-forward and 
treatment providers seem to have very different perspectives to service users. (141) 
With these challenges and issues in mind, I wished to identify methods of examining aspects 
of treatment outcome among the adolescent patients attending two different treatment 
settings in Dublin. A finite number of patients and finite research resources imposed 
substantial limitations on the components of ‘outcome’ which could be examined. 
Pragmatism had to take priority over idealism. 
 
3.1.2 Outcome measures 
The first study examined a group of patients who commenced treatment at the Youth Drug 
& Alcohol (YoDA) service. Although all patients had a substance use disorder, they were 
quite heterogeneous. Polysubstance use was the norm and there were a wide range of 
substance combinations reported. This reflects real world clinical practice in adolescent 
addiction services internationally.  
There are two common methods for measuring drug use. Firstly, there is self-report and 
secondly there is biological screening with methodologies such as saliva or urine drug 
toxicology screenings. There are strengths and weaknesses with both methods.  For 
biological screens, there may be concerns regarding the integrity of the screening process. 
For example, a urine sample may be tampered with by the patient or food may be 
consumed prior to provision of a saliva sample. The half-life for different substances varies 
greatly and the detection window will consequently be very different across a range of 
substances. Results of biological screens tend to be dichotomous, being simply positive or 
negative, and do not quantify level of use. The main concerns with self-report relates to 
under-reporting of use, which may be deliberate or accidental (forgetting).  
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Although urine screening is frequently conducted in YoDA it is not mandatory for patients 
and its frequency varies from patient to patient. Two self-report instruments were routinely 
used during assessment at YoDA. These were the Maudsley Addiction Profile (MAP) & the 
ASSIST. Both have been used with adolescent populations previously. Both seek to explore 
for use of a wide range of substances and they also provide quantification data on the level 
of recent use. Consequently, these self-report measures constituted the cornerstone of the 
assessment of outcome in the YoDA study (chapter 4). 
In the study examining outcome of OST in adolescents (Chapter 5), we used urine drug 
screens as the main outcome measure. These had the advantage of being conducted 
routinely twice per week in the clinic. Routine clinical practice at this clinic at the time of this 
study involved provision of a urine sample which was supervised by a staff member of the 
same gender. This reduced the concerns regarding sample integrity outlined above. The 
frequency of testing also made it quite unlikely that drug use by patients would go 
undetected, even for drugs with a relatively short window of detection. 
 
3.1.3 Control and comparison groups 
Ideally in clinical outcome studies, a control or comparison group will be identified. If such 
groups had been included in the studies in this PhD, it would have allowed exploration of 
the question: “does the outcome of patients at this service differ from the outcome of those 
who received treatment X or no treatment?” The gold standard study would also include 
random assignment of patients and blinding of patients, treatment providers and outcome 
assessors.  
A double blind RCT was quickly dismissed as a viable methodology in the treatment studies 
in this PhD. The reasons for this included:- 
 Deemed unethical to provide no treatment to a control group 
 No other comparison gold standard treatment available to the researcher. 
 Minimal or no research funding to ensure blinding of a team of research assistants 
Active consideration was given to including a comparison group of adolescents with 
untreated substance use disorder in the YoDA outcome study (chapter 4). I sought to 
identify adolescents with substance use disorders who were uninterested in treatment to 
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create a control group. I approached the paediatric emergency department at a nearby 
general hospital. I met with the consultant in paediatric emergency medicine. Agreement 
was obtained to recruit into the study adolescents who were admitted into hospital 
following a drug or alcohol related event. Ethical approval was obtained for this. We 
planned to interview adolescents with parental consent. One of the co-authors (CD) was 
available to interview adolescents the day after admission. Medical students also 
volunteered to conduct interviews out of hours, over weekends and during school holidays 
in the hope of recruiting increased numbers. Although hospital admission data and the 
estimates provided by the consultant in paediatric emergency medicine had indicated that 
sufficient numbers would be forthcoming, this did not materialise. Having invested many 
weeks in this process and recruiting less than five participants, we abandoned pursuit of this 
comparison group. 
Simultaneously, with co-author CD, we approached An Garda Siochana and set up a meeting 
with the team of Juvenile Liaison Officers (JLO) in South West-Dublin. They indicated a 
willingness to recruit into the study young people who were referred to the JLO team who 
had a history of significant substance use. Unfortunately this also failed to yield reasonable 
numbers of participants. In practice, many of the JLOs were reluctant to discuss study 
participation with the young people they encountered, often on just one occasion. Many 
young people and their parents indicated to them that they were not interested in 
participating. Among the small number who reported interest to the JLO and agreed to be 
contacted by the interviewer (CD), they then refused to or failed to participate in a 
structured interview. Consequently, we also abandoned pursuit of that comparison group. 
This then left us without any comparison group. We were therefore only able to conduct a 
within group comparison. Even for individuals with substance use disorders, their drug use 
tends to fluctuate over time. Given the nature of referral into addiction treatment, this 
tends to coincide with acute problems for the patient, or to occur at a time when their drug 
use is relatively increased. Consequently there are very real issues with regression to the 
mean. While this has been demonstrated primarily in adults, there is a tendency for the 
mean level of substance use across a group to reduce over time, even without treatment. 
For this reason, we sought to identify methodologies which would take this phenomenon 
into account. While primarily used in the realms of psychology, a small number of addiction 
outcome studies have utilised measurement of the ‘reliable change index’. We consequently 
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opted to use this approach. The method for same is described in the research paper 
(Chapter 4). 
In the study examining changes in psychological wellbeing, we also had no capability to 
obtain a control group, primarily for ethical reasons. The study was hampered by declining 
number of potential participants as the incidence of heroin dependence among adolescents 
in Dublin continued to decline. Consequently, it became challenging to recruit even the 
target number of participants indicated by the power calculations for a simple pre- and 
post- comparison.  
It seems likely that the relatively low incidence of heroin dependence in adolescents 
internationally explains the absence of any controlled clinical trials of OST in adolescents 
beyond a 12 week period, and the typically very small number of participants included in the 
few ‘open label’ studies published over the past 50 years (see Table 2.2 in previous 
chapter).(99, 142) The very limited existing scientific literature made it difficult to generate 
specific hypotheses for testing in the study of OST outcome. Consequently, the examination 
of baseline or treatment characteristics which might be associated with better outcome was 
deliberately exploratory. For this reason, simple associations, odds ratios, confidence 
intervals and p values are reported. For the same reason, a Bonferroni adjustment was not 
made.(143) If study sample sizes increase in future studies, those research teams can opt to 
examine the significant associations found in this and the few other studies in a priori or 
hypothesis driven manner.(144)  
 
3.2 Exploration of Temporal trends 
3.2.1 Determining the beginning and end of ‘the head shop era’ 
In the NPS papers (Chapters 7-9), decisions had to be made regarding how best to explore 
for change over time. The key focus of the Thesis related to the arrival and departure of the 
head shops. This posed a number of challenges. It was difficult to determine both the start 
point and the end point of the head shop phenomenon, what I have called ‘the head shop 
era’. Meetings were held with the Garda National Drug Unit. They provided useful 
information on the number of head shops at multiple time points and this has already been 
summarised in Chapter 2 (Figure 2.16). However, the exact timing of the increase in 
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numbers of head shops in 2009 remained unclear. It was also unclear when the pre-existing 
head shops began selling NPS.  
Ideally in time series analysis there is a clear and absolute point of change when a policy is 
implemented. There were two pieces of legislation which appeared to act cumulatively to 
end widespread sale of NPS by head shops in Ireland. This staggered policy implementation 
complicated the estimation of the intervention point, something which is necessary for 
many of the standard or common time series modelling approaches.  
The understanding of the time frame of the head shop phenomenon evolved over the 
course of the thesis in an iterative manner. An output of the study examining NPS use in 
adolescents attending addiction treatment at YoDA (Chapter 7) was greater clarity regarding 
the apparent beginning and end of the ‘head shop era’. Although that study had 
hypothesised a priori that the key event was the Misuse of Drugs Act in May 2010, and 
which coincided with half of the head shops closing, it indicated that problematic use of 
NPS, especially the cathinone type drugs, remained very evident until the end of August 
2010. This date coincided with the Criminal Justice (Psychoactive Substances) Act and the 
end of sale of NPS by head shops. Consequently, for the subsequent studies (Chapters 8 & 
9), the timeframe of greatest interest for interrogation moved forward slightly to start in 
January 2010 and end in August 2010. 
In addition to the challenge of estimating a beginning and end of the head shop era, further 
problems arise from that fact that this period was so brief, at only eight months. This short 
timeframe resulted in a finite and relatively small number of events occurring during the 
head shop era. This reduces power to identify significant changes.(144) Secondly, for time 
series analysis, one ideally wants a large number of time points from which to determine a 
trend or slope both before and after an intervention or policy change. 
 
3.2.2 Time series analysis methods considered. 
Specialist statistical advice was sought and obtained from an Associate Professor of 
Biomedical Statistics and from an engineer who held a mathematics PhD. Both had 
experience in use of time series analysis methodologies. 
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ARIMA modelling is generally viewed as the gold standard instrument for assessing change 
in a time series after a single policy implementation. It examines change at a specific and a 
priori determined time point. Secondly, it ideally requires data from at least 12 time periods 
(e.g. month or year) before and after the policy implementation under examination. Finally 
it ideally requires a minimum of about 100 events per unit of time (i.e. over a 100 events per 
month, or 100 events per year).(145)  The circumstances of the head shop era in Ireland are 
therefore not ideal as none of these criteria were met for the harms and issues under 
examination. 
Segmented regression time series analysis was also considered. This is capable of factoring 
in changes at more than one time point. However, the time points need to be defined in 
advance. Following implementation of a policy, change may occur immediately or gradually. 
An immediate change is called a ‘step change’ and a gradual change is a ‘slope change’. It is 
possible that both may occur following real world policy changes. Segmented regression 
analysis permits exploration of both step changes and slope changes at each time point 
examined. The final equation which best fits the data may include both step and slopes 
changes. While the data requirements are not as onerous as in ARIMA, the limited number 
of data points and the relatively small number of events per data point reduce the power of 
this technology to detect significant changes.(145) Given the lack of certainty regarding both 
the beginning and end of the head shop era, a null finding with segmented regression would 
have been difficult to interpret. It may mean that the interventions had no impact upon the 
rate of harm or it could mean that we were looking for change at the wrong time location.   
The chosen method of analysis was Joinpoint regression.(146) This is described in the 
relevant research papers (Chapters 8 & 9). Unlike the methods described above, it does not 
require the investigator to determine a priori a time point when a change may have 
occurred. It also has the ability to function where there are very few events per time point. 
Indeed it can be adapted to manage datasets where there are no events at some time 
points. One disadvantage that it has relative to segmented regression is that it only 
examines for presence of ‘slope changes’ in datasets. It does not examine for presence of 
step changes. Consequently, if a real world situation included a clinically significant step 
change, but no real slope change, Joinpoint analysis would likely produce a null finding. 
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4.1 Context within overall thesis 
This chapter provides an overview of the client profile at YoDA, this being one of the two 
key clinical sites from which research participants were recruited in subsequent studies. 
Participants were recruited from this service into the study examining changes in 
psychological well being among patients on OST (Chapter 6) and into the study examining 
changes in NPS use in the adolescent age range (Chapter 7). This study characterises the 
polydrug use typical of treatment attending adolescents. It highlights the level of motivation 
which exists among adolescent treatment entrants and allows exploration of how this varies 
between illegal substances and the legal substance, alcohol. As mental health is a key focus 
of the overall thesis, being central to the studies in Chapter 6 and Chapter 9, this study also 
reports on mental health symptoms among treatment entrants. Most importantly, it 
provides an initial examination of changes in drug use following treatment, focusing on 
alcohol and cannabis. While examining abstinence, it also examines the more harm 
reduction orientated goal of ‘reliable change’.  
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4.2 Abstract 
Background: Alcohol and cannabis are the primary substances contributing to referrals of 
adolescents to substance abuse treatment services. Motivation to change substance use is 
typically poorer in adolescents than adults. Abstinence is only achieved by a minority of 
treatment attenders. It has been suggested that evaluations of treatment outcome should 
seek to measure the proportion of patients who achieve a reliable reduction in their 
substance use. Method: A three month follow-up was conducted in an outpatient 
adolescent treatment program which integrated motivational interviewing, CBT and family 
therapy. The primary outcome measure was days of substance use in the past month. The 
ASSIST was used to identify High Risk users of each substance. SOCRATES was used to 
measure motivation. Results: Among 108 adolescents assessed, we identified 42 (39%) and 
77 (71%) with high risk use of alcohol and cannabis respectively. Among these high risk 
groups, 'problem recognition' was low or very low in 97% of drinkers and 83% of cannabis 
users. Follow-up interviews occurred with 87 (81%) participants. Although the high risk 
drinkers achieved a significant reduction in the median number of days drinking (p=0.004), 
only four (11%) were abstinent at follow up. A further five (14%) achieved a reliable 
reduction in days of drinking of seven or more per month. Among the high risk cannabis 
users, there was also a significant drop in the median days of use (p<0.001), although only 
six (11%) were abstinent at follow up. A further 20 (36%) achieved a reliable reduction in 
days of use of nine or more per month. Conclusions: Motivation among adolescents 
attending substance abuse treatment is poor, especially related to alcohol. Calculation of 
reliable change allows examination of outcomes which fall short of the elusive goal of 
abstinence. 
 
4.3 Introduction 
Irish teenagers demonstrate higher rates of use of both drugs and alcohol compared to most of 
their European counterparts, with 50% of 16 year olds having used alcohol in the past month 
and 18% report lifetime cannabis use.1 Early initiation of alcohol use has been shown to be 
linked to later alcohol-related problems and substance use disorders. 2-3 Drug and alcohol abuse 
can have a negative impact on many domains of a young person’s life, including their health, 
educational attainment and psychological well-being.4  
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While heroin emerged as a substantial problem among adolescents in the 1990s in Dublin, 
cannabis has become the dominant drug leading to referrals into adolescent addiction 
treatment services in the past 10 years.5-6 Polysubstance use is however common for people 
entering addiction treatment, being evident in 68% of cases across all age ranges. 7 Adolescents 
accessing treatment for substance use disorders are heterogeneous, typically presenting with 
multiple and complex problems.8 Motivation among adolescent treatment attenders tends to 
be poorer than among adults. 8-9 For example, only 20% of the adolescents in the large 
‘Cannabis Youth Treatment’ study in USA perceived any need for help with problems associated 
with their drug or alcohol use.8 
In large clinical trials examining the impact of treatment on adolescent cannabis use, 
therapeutic interventions tend to yield reductions of 25-38% in the mean number of days of 
cannabis use per month.10-11 Heterogeneity in treatment interventions and in measured 
outcomes makes it difficult to provide succinct comment on treatment outcome for adolescents 
with alcohol use disorders.12-13 Some interventions show no change, while others report up to 
50% abstinence at three months.13 Abstinence is rarely sustained in adolescents.14 
Consequently, harm reduction approaches have been advocated in adolescent treatment 
settings.15  
It has been argued that evaluations of addiction treatments should seek to measure the 
proportion of patients who achieve reductions in substance use which are of clinical and 
statistical importance, but fall short of abstinence. To achieve this, Marsden et al propose more 
widespread use of statistical methods to measure the proportion of patients who achieve 
reliable change in their substance use.16 
The primary aim of this study was to assess the three-month outcomes for patients 
presenting with high risk alcohol and high risk cannabis abuse following attendance at a 
specialist community treatment service for adolescents. We also sought to examine 
motivation in this patient group. 
 
4.4 Methods 
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4.4.1 Participants 
Adolescents who completed assessment at a specialist outpatient community drug and 
alcohol treatment facility for adolescents were eligible to participate. Patients were 
excluded from the study if living outside of Dublin, acutely intoxicated during assessment, 
poor literacy, living in a secure setting, judged to have no substance use disorder or were 
aged over 19 years or under 12 years. 
 
4.4.2 Design 
This study employed a before and after comparison of scores on related measures from 
baseline assessment (T1) to three months follow-up (T2). The primary outcome measure 
was the number of days consuming alcohol and/or cannabis in the previous month, as 
assessed by the Maudsley Addiction Profile.17 
 
4.4.3 Setting & Intervention 
The setting for this study is a specialist outpatient treatment service for young people 
experiencing problems related to their drug or alcohol use. It is located within an urban 
setting in Ireland. The service is provided by Ireland’s Health Service Executive. Patients 
attending are not charged any fee for the treatment. There is an open referral system, with 
referrals being accepted from medical and other professionals, from parents and from 
young people themselves. The services provided include individual counselling (utilising 
motivational interviewing and cognitive behaviour therapy), family therapy and psychiatric 
assessment and treatment as needed. While abstinence is encouraged, there is no demand 
on patients to accept this treatment goal. Harm reduction goals were also accepted.  
A bio-psycho-social clinical assessment typically occurs over two appointments. Involvement 
by parents, and other significant adults, in assessment and treatment is encouraged but is 
not mandatory. The treatment intervention is not manualised. Most treatment sessions 
involve one-to-one work with the young person, comprising weekly one-hour appointments. 
In parallel with this, family therapy is often offered, especially where there is evidence of 
poor communication or relationship problems between parents and teenager. While 
75 
 
treatment is tailored to the individual's needs, a basic treatment episode involves about six 
sessions in total, with family input into two or three of these. Therefore, for the purposes of 
this study, we viewed patients who left treatment in an unplanned manner prior to their 
sixth appointment as having had an 'inadequate dose of treatment'.  
Consistent with practice in treatment approaches such as Adolescent Community 
Reinforcement Approach (ACRA) and Multi-Dimensional Family Therapy (MDFT), where 
adolescents are involved with other services in education, criminal justice or social work 
sectors, active efforts are made to work in a collaborative and interagency manner with 
those services.18 This can involve meetings off-site with other agencies, typically including 
the adolescent and their family. 
  
4.4.4 Procedure 
Members of the clinical team within the treatment service conducted a baseline assessment 
of all patients entering the treatment service. We repeated an interview at a three-month 
follow up (T2) to assess any potential changes in drug and alcohol profile. This interview was 
conducted by a member of the clinical team or by one of the researchers (CD). Telephone 
interviews were conducted by a researcher (CD) at follow-up in instances where the young 
person was unavailable for face-to-face interview. Telephone interviews were briefer and 
focused upon the key outcome information regarding recent substance use.  
All participants and parents gave their written informed consent to participate in the study 
and for all study materials to be passed to the research team. Ethical approval was obtained 
from the Research Ethics Committee of the National Drug Treatment Centre, Dublin. 
 
4.4.5 Measures  
The study instrument included:  
(a) Maudsley Addiction Profile (MAP),17 a brief, multi-dimensional instrument for assessing 
treatment outcomes for people with drug and/or alcohol problems which has been utilised 
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in many studies and has been found to be reliable and valid.19 We used it to provide a 
measure of past month substance use. 
(b) Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) which provides 
life-time, as well as current, estimates of substance-related risk.20 The ASSIST has been 
found to be a valid screening test for identifying psychoactive substance use in individuals 
who use a number of substances and have varying degrees of substance use. 21 It generates 
a separate score for each substance being used. It has been suggested that the ASSIST be 
modified slightly when used in adolescent cohorts, with removal of Question 7 and the 
application of lower, more age appropriate cut offs.22  In our use of the ASSIST to identify 
'high risk' users of each substance, we applied these modifications. For children aged 15-
17yo, the high-risk cut offs for alcohol and cannabis are 18 and 12 respectively. The cut-off 
for amphetamines, inhalants and hallucinogens is 9. It is 7 for all other substances. For 
children aged under 15 years, the high risk cut-off is 6 for alcohol and inhalants. It is 2 for all 
other substance categories. 
(c) Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)23 assesses an 
individuals motivation to change their substance use related behaviour. It examines alcohol 
and drugs separately, providing subscale scores including Problem Recognition and Taking 
Steps. SOCRATES has been found to be both reliable and valid. 24-25 
(d) Beck Youth Inventory (BYI)26 assesses emotional and psychological impairment in 
adolescents. The BYI contains five subscales to measure self-concept, depression, anxiety, 
anger and disruptive behaviour. It has been shown to have good reliability and validity when 
tested.27  
 
4.4.6 Analysis 
The analyses were conducted within SPSS (version 19).  To examine changes in days and 
quantity of use, we utilised the Related Sample Wilcoxin Signed Rank Test.  
The phenomenon of ‘regression to the mean’ complicates assessment of behaviour change 
in simple pre / post study designs and thus when assessing treatment impact, it is useful to 
determine the proportion of patients who achieve a 'reliable change' in their baseline 
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substance use.16 Hageman & Arrindell provide details of the computation involved in 
identifying individuals who have reliably improved, dis-improved and remained 
unchanged.28 The calculations are contingent on estimating an appropriate standard error 
of the difference (score at time 2 minus score at time 1) from which the required 95% 
confidence interval for the difference is obtained.  The standard error of the difference is 
derived from the standard deviation of the time 1 scores for all participants and the known 
reliability of the test instrument – see Hageman & Arrindell for details. 28 
We had limited power to detect factors associated with poorer outcome. We needed a 
sample of 58 patients to have 80% power to detect a dichotomous factor associated with 
good outcome with an odds ratio of 2.0, with p value set at 0.05. 
 
4.5 Results 
4.5.1 Characteristics of Baseline group 
There were 143 consecutive patients assessed at the service during the recruitment period 
who were eligible to participate. Thirty-five of these did not enter the study. Of these, 16 
adolescents refused to participate and we were unable to obtain consent from a person in 
parental authority in 14 cases. In five cases, the reason for non-participation was unclear.  
There were 108 adolescents included in the study and their mean age was 16.4 years (Range 
13 to 19 years). There were six (5%) participants aged under 15 years and 13 (12%) were 
aged 18 or 19 years. Other demographic details are presented in Table 4.1.  
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Table 4.1. Baseline demographic profile of 108 adolescents attending for specialist community based 
addiction treatment and route of exit from treatment. 
       N (%)  Mean (Range) 
Age (years)        16.4 (13-19) 
 
Male        84 (78) 
 
Living with parents or family    99 (92) 
 
Ethnic background - white Irish    98 (91) 
 
Employment status 
 In school or college    57 (53) 
 Vocational training course   16 (15) 
 Working     6 (6) 
 Neither working nor in education  27 (25) 
 
Referral sources 
 Family      39 (36) 
Social services     18 (17) 
Probation services    13 (12) 
 Mental health services    11 (10)   
 GP & other medical services   9 (8) 
Self       7 (7) 
School      6 (6) 
Other      4 (4) 
 
Previous treatment for an alcohol problem  9 (8) 
 
Previous treatment for a drug problem   16 (15) 
 
Route of exit from treatment 
 Planned discharge    53 (49) 
 Refusal to attend    6 (6) 
 Repeated non-attendance    35 (32) 
 Referred elsewhere    5 (5) 
 Other reason (e.g. moved away, prison)  9 (8) 
 
Adequate Treatment Intervention* 
 Adequate dose of treatment   82 (83) 
 Inadequate dose of treatment   17 (17) 
 
* Patients were defined as having had an adequate dose of treatment if they attended at least six 
appointments or had a planned discharge prior to their 6th appointment. Nine cases could not be assigned due 
to missing data. 
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Table 4.2 presents information on the range of substances used and proportions of patients 
using these individual substances in a high risk manner. Among those reporting alcohol use 
in the past month, the median number of standard drinks per drinking day was 11 (Inter-
Quartile range [IQR] 7 -15), which is 110 grams of alcohol. Excluding tobacco, 47 (44%) 
patients were identified as having 'high risk' use of a single substance, while 28 (26%) were 
demonstrating high risk use of two substances and 21 (19%) were using at least three 
substances in a high risk manner.  
As outlined in Table 4.2, motivation to ‘Take Steps' and ‘Problem Recognition’ were low or 
very low among the majority of high risk users of each individual substance apart from high 
risk opioid users. Among those reporting high risk use of alcohol and high risk drug use, both 
‘Problem Recognition’ and ‘Taking Steps' subscale scores were significantly higher regarding 
the drug problem compared to the alcohol problem (p=0.01 in each case). 
Fifty-one per cent reported criminal activity in the month prior to treatment entry, with sale 
or distribution of drugs (30%) and shoplifting (22%) being most common. There was 
evidence of moderate to severe mental health problems in the areas of depression (33%), 
anxiety (32%), anger (29%), disruptive behaviour (52%) and self concept (47%) on the BYI 
subscales.  
The median number of appointments attended by patients was seven (IQR 5-12). The 
median number of appointments attended by parents was three, and in 34% of cases 
parents did not attend any clinical appointments.  
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Table 4.2. Baseline substance use and motivation among 108 adolescents attending a specialist community based treatment service  
 Ever Used 
(%) 
Current Users - 
Any use in past 
Month (%) 
Mean Days 
use in past 
month (SD) 
Current Users 
with High Risk 
Usea (%) 
Motivation among those with 'High Risk' Useb 
Low or Very Low Problem 
Recognition (%) 
Low or Very Low on 
'Taking steps' (%) 
Alcohol  104 (96) 95 (88) 7 (7) 42 (44) 35 (97) 29 (78) 
Tobacco  100 (93) 90 (83) 27 (7) 80 (89) NA NA 
Cannabis  98 (91) 87 (81) 20 (10) 77 (89) 57 (83) 43 (62) 
Benzodiazepines 49 (45) 23 (21) 9 (8) 21 (91) 13 (68) 11 (61) 
Cocaine  59 (55) 19 (18)  5 (6) 15 (79) 9 (75) 5 (38) 
Amphetamine  56 (52) 13 (12) 3(5) 13 (100) 10 (83) 6 (50) 
Opioids 9 (8) 7 (6)  24 (11) 7 (100) 2 (29) 2 (29) 
Hallucinogens  20 (18) 4 (4) 1 (1) 0 (0)   NA NA 
Inhalants  21 (19) 3 (3) 1 (0) 2 (67) 2 (100) 0 (0) 
Other substances  14 (13) 10 (9) 5 (9) 4 (40) 3 (75) 2 (50) 
a
 Categorisation as a 'High Risk' user was determined by the ASSIST questionnaire.
 
b
 13 participants did not complete the SOCRATES Questionnaire 
NA = not applicable 
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4.5.2 Substance use outcomes 
We conducted follow-up interviews with 87 (81%) participants. Follow-up interviews 
occurred over the telephone in 65% of cases. Those interviewed did not differ from those 
lost to follow-up by any socio-demographic, substance use, treatment adherence or 
motivation measure. The follow-up group did demonstrate greater baseline anxiety 
symptoms (p=0.04), but did not differ on other measures of psychological well-being. 
 
4.5.2.1 Alcohol 
Among those identified as High Risk drinkers, alcohol was their most problematic substance 
in just 52% of cases based upon ASSIST scores. Among these High Risk Drinkers, we had 
follow-up information in 35 (83%) cases. The median days of use reduced from 12 (IQR 6-15) 
at baseline to 7 (IQR 4-14) and this was statistically significant (p=0.004). The mean days 
dropped by 27%, from 11 days per month to 8 days. Among this group there was also a 
significant reduction in the number of standard drinks per month (p=0.007), reducing from a 
median of 120 (IQR 30-240) to 60 (IQR 24-105).  
Calculation of the reliable change index for alcohol indicated that a change in days of use 
per month of seven or greater was reliable. Only four (11%) of the high risk drinkers were 
abstinent at follow-up, but a further five (14%) were reliably improved. One person had 
reliably deteriorated while 25 (71%) were unchanged. Nine of the high risk drinkers were 
drinking on seven days or less per month at baseline and therefore could not reliably 
improve even if they reduced their drinking to just one day per month. 
There was no significant change in the drinking among those who reported baseline alcohol 
use in the Moderate Risk group. 
 
4.5.2.2 Cannabis 
Among those identified as high risk cannabis users, cannabis was the substance which had 
the highest ASSIST score in 79% of cases. Among this High Risk group, we had follow-up 
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information on 55 (71%) people. The median days of use reduced from 25 (IQR 15-30) at 
baseline to 15 (IQR 4-30) and this was statistically significant (p<0.001). The mean days 
dropped by 32%, from 22 days per month to 15 days.  
Calculation of the reliable change index for cannabis indicated that a change in days of use 
per month of nine or greater was reliable. Six people (11%) were abstinent at follow-up and 
a further 20 (36%) had reliably improved. There were four (7%) patients who reliably 
deteriorated, while 25 (45%) were unchanged. Seven of the high risk group were using 
cannabis on nine days or less per month at baseline and therefore could not reliably 
improve even if they reduced their cannabis use to just one day per month. 
We grouped together the 26 (47%) high risk cannabis users who either were abstinent or 
reliable improved to generate a "good outcome group" and the remaining patients were 
categorised as a "poorer outcome group". There was no statistically significant difference 
between the these groups in terms of gender, referral source, baseline mental health 
symptoms, baseline motivation, family involvement in treatment or dose of treatment. 
There was no significant change in cannabis use among the 13 individuals who reported 
baseline use in the moderate risk category. 
 
4.6 Discussion 
4.6.1 Clinical Profile 
 
Patients were typically male and lived with their parents. Despite their young age, almost 
one quarter were not in education, work or training. While referral sources were varied, 
parents, social services and probation  were the largest source of referrals. Consistent with 
other Irish treatment settings, polysubstance use was the norm.7 Co-existing problems with 
mental health and criminal behaviour were also regularly reported, in common with other 
treatment-attending cohorts internationally.8 Motivation was very poor when compared to 
adult treatment-attending groups. 23 Motivation regarding alcohol problems was particularly 
poor. Although half the patients had a planned discharge following treatment completion, 
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about two in five left in an unplanned manner. Unfortunately poor treatment adherence is 
widespread in substance abusing adolescents.29 
 
4.6.2 Alcohol 
Daily drinking was very unusual even in the group with high risk drinking patterns, who 
typically reported drinking about three times per week at baseline. This is in contrast to 
adults entering alcohol treatment programs but in common with other adolescent 
treatment attending cohorts.13,30 Half of those with a high risk drinking pattern had a 
coexisting and more problematic drug use problem. Where drug and alcohol problems co-
occurred, patients were more motivated to address the drug problem. This highlights the 
complexity of motivation in real world clinical settings, where patients may be very 
motivated to make some changes while being unmotivated to address other issues. To 
complicate matters further, there is some evidence that drinking may increase in people 
who are seeking to reduce drug use.31 Although high risk drinkers did reduce their days of 
drinking and total monthly alcohol consumption in this study, the magnitude of 
improvement was quite modest. While pharmacological agents to treat alcohol use 
disorders, such as disulfiram or Naltrexone, were not prescribed to this patient group, some 
have argued that they should be utilised more regularly in the adolescent age range.13 
 
Only one in nine achieved abstinence, highlighting the elusive nature of this goal in these 
cohorts.29 Our outcomes are probably poorer than those reported in studies internationally, 
although the vast majority of the outcome research has been conducted in USA.12-13 The 
wider cultural approach and context of youth drinking is very different in USA, where the 
legal drinking age is 21 years compared to Ireland where people can buy alcohol at the age 
of 18 years. In recent decades in Ireland, the age of onset of drinking has moved 
progressively into earlier adolescence, while adult drinking has increased.32 The majority of 
young Irish adults drink in a hazardous or harmful manner.33 This 'wet' society may impact 
negatively on the ability of Irish adolescents to recognise their own unhealthy drinking and 
to change it when they do. 
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4.6.3 Cannabis 
 
As expected, cannabis was the most frequently identified substance use problem in our 
patients. Although only one in nine of the high risk cannabis users were abstinent at follow-
up, a further one third achieved substantial reductions in their cannabis use. Across the 
group of high risk cannabis users, the mean days used per month fell by 32%. While 
motivation to address cannabis problems was better than that to address alcohol, it was 
nevertheless low or very low in most cases. 
 
The largest and most comprehensive evaluation of the treatment of adolescent cannabis 
use disorders was the  Cannabis Youth Treatment (CYT) study conducted in USA.8 Compared 
to the CYT study group, the adolescents in our study were older, less likely to be in 
education but had similar levels of criminal involvement. Our group reported more frequent 
alcohol and cannabis use at baseline. The treatment interventions used in CYT generally 
demonstrated higher rates of treatment adherence and treatment contact compared to our 
intervention. In the CYT study, almost one quarter of participants were "in recovery" at 3 
month follow-up and mean days of cannabis use dropped 35% to 8 days per month. 
Compared to a recent Dutch study, our participants were similar in terms of age, gender and 
academic profile.10 Our group had much higher alcohol use. The Dutch CBT group had 
similar dose of treatment but greater family input than our group. In their CBT intervention, 
the mean days use per month dropped 27% to 15 days per month. 
 
Our study did not identify any patient or treatment adherence characteristics significantly 
associated with better treatment outcome, but it had very limited power to do so. Other 
studies have found that baseline mental health problems, lower motivation and low 
treatment adherence are associated with poorer outcome.34 While we did not demonstrate 
improved outcome with greater family involvement in treatment, others have 
demonstrated such an effect.35 Continuing care was not routinely offered to this patient 
group, but others have demonstrated that it is feasible and effective, whether by telephone 
or face-to-face.36 
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4.6.4 Limitations. 
 
The treatment intervention was not manualised. This makes comparison with other studies 
and other treatment providers difficult. For ethical and practical reasons there was no 
control group in this study. Consequently, it is not possible to determine whether or not this 
treatment was better than no treatment. However, the use of the reliable change 
methodology compensates for this deficiency to some extent, by identifying the magnitude 
of change that is likely to be independent of the 'regression to the mean' phenomenon.16 
One of the weaknesses of the reliable change method is that it makes it impossible for 
participants with baseline use of less than the amount needed for a reliable change to 
achieve this outcome. Changes in substance use were reliant upon self report. However, 
studies have found that there is a high concordance between self-reported drug use and 
toxicology in young people.37 Although the SOCRATES has been validated in adolescent 
patient groups, it did tend to cluster the vast majority of participants in this study into the 
low or very low categories.25 Studies of cohorts such as this would benefit from an 
instrument which could better discriminate varying levels of motivation among participants. 
 
4.6.5 Treatment Implications 
 
In light of the frequency of polysubstance use among clinical populations in Ireland, services 
for adolescents with substance use disorders should be integrated, dealing with both 
alcohol and drugs together within the one service. As comorbid mental health problems are 
encountered with great frequency, adolescent services should have the capacity to assess 
and manage common mental health problems in this group.  
 
As motivation tends to be quite low, especially for alcohol use disorders, services should 
assess it at the outset of treatment and target poor motivation where it does exist. Although 
the average reduction in substance use was modest and broadly in line with international 
studies, the proportion of patients who achieved abstinence was quite low. It is important 
that patients, parents, referrers and funders of adolescent drug and alcohol services have 
realistic expectations of treatment. 
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5.1 Context of this chapter within overall Thesis 
This study presents findings on changes in drug use among heroin dependent adolescents 
treated with OST. As one of the largest studies reporting twelve month outcome of this 
treatment group, it constitutes an important addition to the international literature. It 
provides further context for the study reported in Chapter 6, describing the treatment 
program and patient group attending the Young Person’s Program (YPP), most patients in 
the Chapter 6 study being recruited from the YPP. Similar to the previous study in Chapter 4, 
it examines abstinence from the main drug of use at three months. Given that OST is 
typically a longer term treatment, it describes the patient group who persist with this 
treatment for a 12 month period and examines the achievement of heroin abstinence at 
that point. It seeks to identify patient and treatment characteristics which may be 
associated with heroin abstinence and with premature drop out from treatment in an 
exploratory analysis. 
 
5.2 Abstract 
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Introduction and Aims: Few studies have examined opiate substitution treatment (OST) in 
adolescents, a controversial treatment internationally. We sought to measure changes in 
drug use among adolescents receiving OST and also to examine treatment attrition.  
Design and Methods: We included all heroin dependent patients aged under 18.5 years 
commencing OST at one outpatient adolescent addiction service. Drug use was monitored 
by urine drugs screens (UDS). Change in the proportion of UDS negative for heroin was 
examined using the Wilcoxon signed rank test. Attrition was explored via a Cox Regression 
multivariate analysis.  
Results: OST was commenced by 120 patients and 39 persisted until month 12. At month 
three, heroin abstinence was 21% (95% confidence interval [CI] = 9,36%) and it was 46% 
(95% CI=30,63%) at month 12. Heroin use declined significantly from baseline to month 
three (p<0.001) and from month three to month 12 (p=0.01). Use of other drugs did not 
change significantly. Unplanned exit occurred in 25% patients by 120 days. The independent 
predictors of attrition were having children, single parent family of origin, not being in a 
intimate relationship with another heroin user and evidence of baseline cocaine use.  
Discussion and Conclusion: Adolescent patients who persist with OST achieve significant 
reductions in heroin use and these improve incrementally over the first year of treatment. 
While patient drop out remains a challenge, as it is in adults, it appears unreasonable to 
impose a time limit of less than one year of OST in this age range. 
 
5.3 Introduction 
There is global ongoing concern regarding opioid dependence. The prevalence of heroin 
dependence tends to fluctuate over time and is much more common in adults than 
adolescents.[1,2] In Dublin, heroin use first emerged as a concern among adolescents in the 
1990s, in the midst of a dramatic increase in heroin dependence among adults.[2,3] 
Opiate substitution treatment (OST) is now the main first line treatment intervention for 
heroin dependence among adults.[4] Among adolescents there is very little evidence to 
confirm its benefit and especially when used longer term.[1,5]  
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There are no clinical trials examining outcome of OST beyond three months in people aged 
under 18 years old.[5] There are a small number of ‘open label’ longer term studies. The 
largest study has involved just 153 patients and was conducted over 40 years ago.[6] The 
primary goal of OST is to assist the patient in reducing their heroin use but few studies 
provide any firm information on this issue. The DARP study did report a progressive decline 
in heroin use over the first year of methadone treatment (MT) but failed to provide any 
specific information on rates of heroin use during treatment.[7] More recently, the NIDA 
multisite buprenorphine/naloxone treatment (BT) trial examined treatment of youth over a 
three month period and included 12 under eighteens. At week eight, 77% of those retained 
on BT provided an opiate negative urine drug screen.[8] Abstinence from heroin at the end 
of the trial was associated with greater baseline medical and psychiatric problems, a history 
of recent injecting and evidence of early cessation of heroin use during BT.[9]  
Treatment drop out has been examined by a few studies of OST in this age range. Studies of 
MT indicate that 25% of patients drop out within approximately four months.[6,7,10] Bell & 
Mutch found that the drop out from BT was significantly greater than from MT.[11] Other 
studies of BT in this age range also indicate frequent early drop out from treatment, with 
typically a quarter of patients exiting within 4 to 8 weeks.[12-14]  
Given this paucity of outcome studies of OST in adolescent heroin dependence, we sought 
to address a number of questions which are of importance to clinicians and patients. What 
proportion of adolescents cease heroin use while on OST? Does abstinence increase 
incrementally or simply stabilise beyond three months on OST? What is the rate of drop 
out? Are there any baseline or treatment characteristics which are associated with either 
abstinence or drop out? 
 
5.4 Method 
5.4.1 Treatment context 
5.4.1.1 Treatment Setting 
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The evolution of the heroin problem in Dublin commenced in the 1970s and is described in 
detail by O’Kelly & O’Kelly.[15] In 2000, due to the large number of heroin dependent 
adolescents presenting to treatment services in Dublin, and the growing recognition that 
their treatment needs differed to that of the adult population, the Young Persons’ 
Programme (YPP) was developed at the National Drug Treatment Centre (NDTC) this 
programme provided a multi-disciplinary adolescent treatment service, working in a manner 
which was broadly consistent with the subsequently published UK guidelines on 
psychopharmacology in adolescent addiction treatment.[16] The team was led by a 
consultant child & adolescent psychiatrist and had input from nursing, clinical psychology, 
social work, project workers, counsellors and family therapy. The staff to patient ratio was 
over double that which existed in the adult MMT programs in NDTC. The YPP was based in 
central Dublin and provided treatment to opiate dependent teenagers from the greater 
Dublin area, which included the surrounding counties. Patients travelled up to 80 kilometres 
to attend the service. 
National guidelines on the treatment of addiction in adolescents emphasise the need for 
multidisciplinary input into treatment.[17] Consequently, GPs or office based practitioners, 
rarely prescribe methadone to heroin dependent adolescents and they are not permitted to 
prescribe buprenorphine.  
Patients were expected to be under the age of 18.5 years when they commenced 
attendance at the YPP. There was an expectation that patients progress from the service 
prior to their twentieth birthday. If there was a need for ongoing opiate substitution 
treatment, they were facilitated with a planned transfer to an adult addiction service. With 
declining incidence of adolescent heroin dependence in Dublin, these age limits were 
moved upwards in 2010. 
 
5.4.1.2 Assessment 
There was an open referral system to the YPP, with family and social workers the most 
common sources of referral. There was no waiting list. There were no exclusion criteria for 
opiate dependent patients, although patients who were deemed to need acute inpatient 
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treatment of a co-occurring medical or psychiatric disorder had their assessment postponed 
until this disorder was stabilised. Treatment was provided free of charge. Assessment 
occurred over a seven to ten day period, during which patients typically attended on three 
occasions to meet different members of the multi-disciplinary team. In addition to being 
assessed for heroin dependence using ICD-10 criteria, patients also provided three 
supervised urine samples as confirmatory evidence of regular heroin use. Assessment also 
sought to identify co-existing psychological, developmental, social and physical needs and 
where appropriate, provide or facilitate appropriate treatment.  
 People aged 16 years and above may consent to medical treatment on their own behalf in 
Ireland. However, we also sought parental agreement to treatment in these cases. Parental 
consent was required for patients under the age of 16 years.  
The main pillars of treatment involved opiate agonist medication (methadone or 
buprenorphine), counselling (CBT, motivational interviewing or humanistic person centred 
therapy) and in some cases, family therapy. The psychosocial aspects of treatment are 
consistent with those outlined in James et al.[18] While patients were expected to attend 
counselling sessions on a weekly basis, failure to do so did not result in termination of 
treatment. In practice, it was our experience that approximately 50% of patients availed of 
individual counselling sessions per week. There were group activities during afternoons, 
which included art therapy and life-skills training. Attendance at groups was encouraged but 
not compulsory. Participation rates at groups were typically 40 to 60%. 
 
5.4.1.3 Approach to Opiate Substitution Treatment 
Initial methadone treatment typically commenced with a dose of 20mgs on day one, which 
was then increased by 10 mgs every three to four days, titrated against withdrawal 
symptoms, cravings, ongoing heroin use, while also monitoring for evidence of sedation. 
Stabilisation doses generally ranged between 40-70mgs. While this was lower than 
stabilisation doses typically recommended for adults, patients at lower doses had a personal 
preference for a relatively low dose and achieved stabilisation (i.e. absence of withdrawal 
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symptoms, control of cravings and heroin abstinence) on this dose. There was no pre-
imposed upper limit on methadone dose.  
Buprenorphine became available as a treatment option in 2005, initially as the sublingual 
mono buprenorphine tablets (Subutex®, Reckitt Benckiser Healthcare [UK] Ltd). In 2007, we 
switched to use of the buprenorphine-naloxone combined preparation Suboxone® (Reckitt 
Benckiser Healthcare [UK] Ltd). Induction typically involved provision of 2-4mgs 
buprenorphine during the morning of day 1, with a further 2-4mgs later that afternoon. 
Single daily doses of up to 8 to 12mgs were administered from day 2. Stabilisation doses 
were typically in the region of 6 to 12 mgs. Consistent with the recent guidelines on OST, 
buprenorphine was offered where patients had shorter heroin use histories and were 
striving towards detox on the short to medium term.[19,20,21] We found that about 40% of 
patients were unwilling to agree to buprenorphine treatment when it was recommended by 
the clinical team. In such cases, we then offered methadone.  
If patients continued to use heroin or resumed use after a period of abstinence, an increase 
in dose of opiate substitution treatment was considered. They were also encouraged to 
participate in increased counselling sessions with a focus on functional analysis of drug use 
episodes and on relapse prevention skills.[22] Use of alcohol and other drugs is also 
addressed. Where the initial opiate agonist medication option was associated with a poor 
treatment response, the patient was offered the option of switching to the alternative.  
Patients provided two supervised urine samples per week for on-site drug toxicology 
testing. These samples were screened for opiates, EDDP (a methadone metabolite), cocaine, 
benzodiazepines and alcohol. They were intermittently screened for amphetamines and 
cannabis. The provision of ‘take-away’ doses of medication was utilised as a contingent 
reinforcer of drug abstinence, as evidenced by urine toxicology. As patients established a 
period of opiate abstinence, they incrementally earned increased ‘take-away’ doses of 
medication. After two weeks of heroin abstinence, they received one ‘take-away’ dose, 
typically on a Saturday or Sunday. Once they attained a period of four weeks abstinence, 
they obtained a second ‘take-away’ dose. A subsequent lapse to heroin use resulted in an 
immediate loss of one of their ‘take-away’ doses. Ongoing heroin use resulted in loss of all 
‘take-aways’. Use of cocaine or benzodiazepines could also result in reduced ‘take-aways’. 
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Patients were also provided with treatment of co-morbid medical or psychiatric problems. 
[23] They were actively supported in addressing co-existing housing, vocational and criminal 
justice related needs as part of their care plan. They were actively supported to re-engage 
with work, training or further education and, if they did so, they were provided with take-
away doses of medication to facilitate their participation in same. Such patients typically 
attended the program just one or two days per week, receiving ‘take-aways’ for the 
remaining days. 
We wished to avoid ‘disciplinary discharges’, and only considered this option where clients 
were seriously jeopardising the safety of other patients via drug dealing on the premises 
and acts of violence towards others. Where clients presented with high levels of aggression, 
transfer to the adult treatment service was considered. 
The service was harm reduction oriented. Nevertheless, it held an aspiration, but not an 
insistence, that all patients progress towards complete abstinence via detoxification. Prior 
to detoxification, patients typically spend a number of months stabilising on OST, during 
which time they are expected to cease use of heroin and other drugs, while also addressing 
the co-existing psychological and social problems which might leave them vulnerable to 
relapse. Where detox, or dose tapering, occurred, it was generally conducted slowly on an 
outpatient basis over a period of about three months, negotiated with the individual 
patient. If the patient returned to heroin use during a detox, it was recommended that 
detox halt temporarily or else revert to a further period on a stabilisation dose. Where 
patients insisted on finishing a detox and leaving treatment despite evidence from urinalysis 
of ongoing heroin use, they were viewed as treatment drop outs. Patients had the option of 
referral to a residential specialist addiction treatment unit, under the care of the consultant 
child and adolescent psychiatrist, to commence and complete detox. In practice, about one 
third of the patients who complete detoxification utilise this latter option. Following detox, 
the YPP either provided ongoing psychological support or facilitated the patient in accessing 
same at an alternative, more locally accessible service. Where patients relapsed following 
detox, we strived to promptly re-engage them back into treatment. [24] 
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5.4.2 Patients 
The inclusion criteria were:- heroin dependence, aged under 18.5 years and commenced 
treatment with opioid agonist medication. The cohort under study included patients who 
commenced treatment between May 2000 and June 2016. Patients with a primary diagnosis 
of dependence on prescription opioids were excluded.  
 
5.4.3 Data Collection 
The study was approved by the Research Ethics Committee of the NDTC. Baseline 
descriptive characteristics were obtained from the patients’ initial structured assessment, 
this being adapted from the Maudsley Addiction Profile.[25] We recorded information on 
patient treatment participation at three, six and twelve months. If a patient was not 
attending the service on these dates, we noted the date of and reason for exit.  
Those who were referred to and commenced on another opiate substitution treatment 
program were categorised as “transfers for ongoing treatment”. Patients were categorised 
as exiting via “detox” if they completed the prescribed detox regime and showed urinalysis 
evidence of opiate abstinence at discharge from the treatment program. Patients who 
ended treatment because they were incarcerated were categorised as exiting due to 
“prison”. Finally, patients who simply stopped attending, relocated without arranging 
alternative treatment or left treatment prematurely against medical advice were all 
categorised as being “drop outs”. Patients were generally not deemed to have dropped out 
of their index treatment episode unless that had failed to attend for four weeks. If they 
were deemed a drop out, then the date of last attendance for medication was recorded as 
the date of discharge. Although many patients re-entered treatment after dropping out or 
following a relapse to heroin use after a successfully completed detox, only their first or 
index treatment episode was included for the purposes of this study.[24] If a patient 
switched from BT to MT or vice versa, but continued in treatment, this was not viewed as a 
treatment exit.  
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To examine changes in drug use, five periods during the first year of treatment contact were 
examined for each patient. The results of all urine drug screens (UDS) provided by each 
patient during each period was collated. The periods in question were (a) pre treatment 
assessment phase which was typically 7 to 10 days in duration and involved provision of 2-4 
UDS, (b) induction phase which comprised the remaining days in that first month of patient 
contact after commencing OST, (c) third month of treatment, (d) sixth month of treatment 
and (e) twelfth month of treatment. During phases (b) to (e), patients were usually providing 
two UDS per week. For each patient, a dichotomous outcome variable to indicate 
abstinence/use was created for each of the phases they were being treated (a) to (e). They 
were deemed to be using heroin if any one UDS sample tested positive for opiates during 
that phase. If all UDS was opiate negative, they were deemed heroin abstinent. Similarly, a 
single positive for cocaine in a month resulted in that month being deemed one of cocaine 
use. 
 
5.4.4 Statistics 
In order to conduct an exploratory analysis, we used Pearson chi square test to examine 
association between categorical covariates and dichotomous outcome variables of interest, 
except in instances where a predicted cell value was less then 5, where Fisher’s Exact test 
was utilised. Odds ratios and their 95% confidence intervals were calculated to indicate the 
direction and magnitude of associations. Continuous variables were converted into 
categorical variables, by choosing the median value as the point of split, apart from age 
where we used 18th birthday as the cut-off.  
When reporting the proportion of patients who were heroin abstinent, we also calculated 
the 95% confidence intervals of those rates using the exact confidence limits for binomial 
proportions. McNemar’s paired proportions test with continuity correction was employed to 
determine whether OST was associated with changes in the binary category of drug use. We 
sought to confirm that heroin abstinence in month three was greater than baseline, and 
that abstinence at months six and twelve were greater than month three. We also examined 
changes in the proportion of samples which tested negative for heroin using the related 
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samples Wilcoxon signed rank test. For each period, we calculated this proportion by 
dividing the number of negative tests by the total number of UDS obtained. All of these 
analyses were confined to patients who persisted with OST.  
To examine drop out and factors associated with same, the Kaplan-Meier test was 
conducted. The event of interest was unplanned exit from treatment via drop out or 
imprisonment. The time to treatment exit, in days, was recorded for each patient who left 
their index treatment episode during the first year, whether by unplanned exit or via 
planned exit (following detox completion or via transfer to another OST service). For 
patients who persisted with OST, the number of days entered was 365 days. The Log Rank 
was used to test for the equality of the survival distributions within each covariate. To 
facilitate interpretation of these differences, the estimated number of days to drop out by 
25% is reported. In order to explore independent predictors of unplanned exit, we then 
conducted a multivariate analysis using Cox Regression. Covariates were selected for entry 
into the final equation using the forward and backward selection technique.  
 
5.5 Results 
There were 120 eligible patients who commenced OST. Their characteristics are provided in 
Table 5.1. Eight-eight per cent were using heroin daily at treatment entry. Thirty-nine 
patients persisted with treatment to month 12 and their profile is also outlined in Table 1. 
Twenty-nine (24%) left following detox completion and nine (8%) were transferred 
elsewhere for ongoing OST. There were 43 unplanned treatment exits, with 36 (30%) 
dropping out and 7 (6%) going to prison. There were no deaths during treatment. 
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Table 5.1. Characteristics of 120 adolescents commencing opiate substitution treatment, and 
subgroup who persisted in treatment until month 12. 
   Total 
Group 
Missing 
data 
In treatment until month 12 
   N (%) N (%) OR 95% CI OR P value 
         
Number in Treatment    120  39 (33)    
       
Socio-demographic characteristics       
 Female 61 (51)  25 (41) 2.0 (0.9,4.4) 0.07 
 Aged under 18.0 years 104 (87)  35 (34) 1.5 (0.5,5.1) 0.49 
 Left school under 15 years  51 (46) 8 18 (35) 1.0 (0.5,2.3) 0.92 
 Not in employment, education or training 81 (70) 4 29 (36) 1.7 (0.7,4.1) 0.24 
 Two parent family support   59 (50) 1 27 (46) 3.8 (1.6,8.6) 0.001 
 Has a child   6 (5)  0 (0) n/a  0.18 ^ 
 Has been in care  38 (32) 2 10 (26) 0.7 (0.3,1.6) 0.35 
 Sibling Opiate Use   45 (39) 4 17 (38) 1.4 (0.6,3.0) 0.45 
 Parental Opiate Use     25 (22) 4 6 (24) 0.6 (0.2,1.5) 0.25 
 Partner uses heroin   47 (39) 1 18 (38) 1.5 (0.7,3.3) 0.30 
 Homeless or hostel in past month   34 (28)  11 (32) 0.9 (0.4,2.2) 0.89 
 Previous criminal convictions  46 (41) 8 14 (30) 0.9 (0.4,2.0) 0.80 
 Ever incarcerated   31 (27) 6 8 (26) 0.8 (0.3,1.9) 0.55 
       
Psychiatric History       
 Ever assessed by a psychiatrist      62 (53) 2 22 (36) 1.4 (0.6,2.9) 0.44 
 Inpatient psychiatric admission    10 (9) 4 6 (60) 3.2 (0.8,12) 0.09^ 
 Past DSH    36 (31) 5 12 (33) 1.1 (0.5,2.5) 0.86 
        
Substance Use       
 Lifetime Drug Use       
  Non-prescribed benzodiazepines  107 (90) 1 36 (34) 1.0 (0.3,3.6) 1.0^ 
  Non-prescribed methadone  90 (78) 5 30 (33) 0.8 (0.3,1.9) 0.54 
  Cocaine use    76 (68) 8 30 (40) 2.7 (1.1,7.0) 0.04 
  Injected    53 (45) 2 17 (32) 1.0 (0.5,2.2) 0.99 
  Commenced heroin under 15 years of age  43 (36) 2 20 (47) 2.6 (1.2,5.7) 0.02 
  Regular heroin use for more than 12 mnts  73 (64) 6 26 (36) 1.2 (0.5,2.7) 0.67 
        
 Past Month Drug Use       
  Non-prescribed benzodiazepines  71 (60) 1 26 (37) 1.4 (0.6,3.1) 0.40 
  Non-prescribed methadone  71 (60) 1 27 (38) 1.7 (0.7,3.7) 0.22 
  Cocaine   31 (26) 2 10 (32) 1.0 (0.4,2.3) 0.91 
  Cannabis    80 (73) 11 27 (34) 1.3 (0.5,3.4) 0.54 
  Amphetamine  9 (9) 19 4 (44) 1.9 (0.5,7.7) 0.45^ 
  Alcohol    46 (45) 18 17 (37) 1.2 (0.5,2.8) 0.61 
  Injecting      35 (29) 1 13 (37) 1.5 (0.7,3.4) 0.34 
  Using > 3 ‘bags’ heroin per day  60 (53) 7 18 (30) 0.9 (0.4,2.0) 0.81 
         
 Pre-treatment UDS* positives       
  Benzodiazepines  71 (59)  26 (37) 1.6 (0.7,3.6) 0.25 
  Methadone  67 (56)  20 (30) 0.8 (0.4,1.6) 0.49 
  Cocaine 13 (11)  3 (23) 0.6 (0.2,2.3) 0.54^ 
  Cannabis  47 (47) 20 13 (28) 0.7 (0.3,1.6) 0.38 
         
Early Treatment       
  Suboxone Commenced 32 (27)  7 (22) 0.5 (0.2,1.3) 0.13 
  At least one heroin negative UDS during 
induction 
50 (46) 12 14 (28) 0.6 (0.3,1.4) 0.28 
        
^ 
P value calculated using Fishers Exact Test Statistic as estimated value in cell was less than 5 
* UDS = Urine drug screen
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Table 5.2 presents the results of urine drug screens from the subgroup of patients who 
persisted with OST for at least 12 months. This table indicates the proportion demonstrating 
abstinence from each drug at each time period examined. During the third month of treatment 
8 (21% [95% confidence interval (CI) = 9,36%]) were abstinent from heroin. Six (15% 
[95%CI = 6,31%]) were abstinent from heroin, cocaine and benzodiazepines. At month 12, 
there were 18 (46% [95%CI=30,63%]) abstinent from heroin, of whom nine (23% 
[95%CI=11,39%]) were also abstinent from cocaine and benzodiazepines. Heroin abstinence 
increased significantly from baseline to three months, from baseline to twelve months and 
from third month to twelfth month. Rates of use of other substances did not change 
significantly from baseline. When looking beyond heroin abstinence to examine changes in 
the proportions of negative urine screens, it also emerged that there were significant 
reductions in heroin use between baseline and month 3 and from month 3 to month 12. 
However, there was no significant change in heroin use between months 3 and 6. When 
comparing the proportions of  heroin negative urine screens between months 3 and 12, we 
found that eight (21%) patients deteriorated, six (15%) were unchanged and 25 (64%) 
improved. 
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Table 5.2. Evidence of drug use from urine drug screens (UDS), at baseline and during treatment, among 39 patients who persisted with treatment for 12 
months. 
 Month 1  
Month 3 
 
Month 6  
 
Month 12  
Baseline vs 
Month 3 
Baseline vs 
Month 12 
Month 3 
vs Month 6 
Month 3 
vs Month 12  Pre-treatment 
baseline 
Induction 
phase
#
 
               
Median number of UDS conducted 
(range) 
3 (2-4) 4 (0-7) 7 (2-10) 7 (1-9) 8 (1-11)     
           Related samples Wilcoxon signed rank test p value 
Median % of UDS heroin negative 
(interquartile range) 
0 (0-0) 0 (0-33) 50 (0-89) 40 (0-100) 87 (33-100) <0.001 <0.001 0.86 0.01 
               
All UDS negative during period           p value from McNemar test 
 Heroin  1 (3) 4 (11) 8 (21) 12 (31) 18 (46) 0.04 <0.001 0.34 0.04 
 Benzodiazepine  14 (36) 19 (53) 15 (38) 18 (46) 15 (38) 0.77 0.79   
 Cannabis
 ^
 19/32 (59) 18/28 (64) 21/38 (55) 16/33 (48) 14/36 (39) 0.69 0.11   
 Cocaine 36 (92) 36 (100) 32 (82) 31 (79) 33 (85) 0.22 0.45   
 Heroin, benzos & cocaine 0 (0) 1 (3) 6 (15) 8 (21) 9 (23)   0.63 0.55 
^ urine drug screens were randomly tested for cannabis, which caused information on use to be missing for some patients during each period. 
#
 Three patients did not have any urine screens during induction.  
102 
 
 
 
There were very few pre-treatment characteristics significantly associated with heroin 
abstinence at month 12. Full results of this analysis are presented in Table 5.A1 in an 
appendix at the end of this paper. None of the patients who had a previous psychiatric 
admission were abstinent (p=0.02). Abstinence was not significantly associated with 
medication dose (p=0.88). All of the patients who were using cocaine during month 12 were 
also using heroin (p=0.02). Early reductions in heroin use, as evidenced by provision of at 
least one heroin negative sample during induction tended to be associated with reduced 
likelihood of heroin abstinence at month 12 (p=0.07).  We repeated the analysis, with 
imputed positive heroin results for the 43 patients who had an unplanned discharge.  This 
indicated that heroin abstinence was significantly associated with being in an 
intimate/sexual relationship with another heroin user (OR 3.4 [95%CI 1.1,10.0], p=0.02). No 
other baseline characteristic was significantly associated with abstinence in that analysis 
with imputed results.  
Information on attrition during treatment is reported in Table 5.3. Overall, the estimated 
length of time to 25% leaving treatment in an unplanned manner was 120 (Standard Error 
41) days. The table only presents results of the covariates where the Log Rank test indicated 
a p value of less than 0.2, although all covariates in Table 5.1 were explored. There was no 
significant difference between those commenced on Buprenorphine or methadone (log rank 
test 1.04, p=0.31). The Cox regression analysis indicated that patients who had no children, 
grew up in families with two parents, were in a intimate relationship with another heroin 
user and were abstinent from cocaine in pre-treatment drug screens demonstrated 
significantly lower rates of unplanned exit from treatment.  
Of the 20 people commenced on buprenorphine who persisted with treatment for three 
months, six (30%) had switched to methadone at that point. Only one person (2%) had 
switched from methadone to buprenorphine by month three. Seven people who 
commenced buprenorphine remained in treatment for 12 months, by which time six has 
switched to methadone. Only two of the 32 commenced on methadone had switched to 
buprenorphine by month 12. 
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Table 5.3. Unplanned treatment exit among 120 heroin dependent adolescents during the first year on OST 
   Univariate analysis# Multivariate Cox Regression  
   Estimated 
25% drop out 
Log 
rank 
statistic 
 
P 
value 
Odds 
ratio 
(OR) 
 
(95% CI 
of OR) 
 
P 
value 
 
 Days (SE)  
         
Overall 120 (41)       
         
Socio-demographic characteristics         
           
 Sex         
  Female 75 (9)       
  Male 225 (55) 2.36 0.13     
           
 Age         
  Under 18 years 120 (45)       
  Aged 18 years 62 (69) 0.14 0.70     
           
 Early school leaver         
  Left Education under age 15 75 (18)       
  Left school after 15th birthday 197 (69) 1.83 0.18     
           
 Family of origin         
  Has two parents  270    1.0    
  Single parent/other relative/adopted 75 (19) 8.56 0.003 3.5 (1.7,6.9) 0.001  
           
 Own children         
  Has a child 72 (61)   5.3 (1.9,14.8) 0.001  
  No children 123 (40) 5.11 0.02 1.0    
           
 History of being in social care         
  Has been in care 75 (28)       
  Never in social care  155 (41) 3.52 0.06     
           
 Parental heroin use         
  No heroin use by parents 186 (66)       
  A parent has heroin problems 72 (52) 2.91 0.09     
           
 Heroin use by partner         
  Partner has used heroin 270 (89)   1.0    
  No partner/No heroin use by partner 86 (19) 3.53 0.06 2.1 (1.1,4.3) 0.03  
           
 Accommodation in past month         
  Homeless or hostel 69 (25)       
  Stable accommodation 176 (54) 2.40 0.12     
           
 Deliberate self harm (DSH)         
  Has a history of DSH 75 (28)   1.8 (1.0,3.3) 0.07  
  No history of past DSH 176 (67) 2.21 0.14 1.0    
           
Pre-treatment Drug Use         
           
 Lifetime Cocaine         
  Use 103 (29)       
  No use 176 (69) 2.99 0.08     
           
 Past month non-prescribed methadone use         
  Self reported Use 197 (29)       
  No self reported use 73 (23) 3.42 0.07     
           
 Cocaine         
  Positive baseline urine drug screen  50 (15)   3.2 (1.4,7.4) 0.006  
  All baseline urine drug screens negative 176 (55) 3.97 <0.05 1.0    
           
 Quantity of heroin use per day         
  Using 3 ‘bags’ or more per day 69 (19)       
  Using less than 3 ‘bags’ day 225 (40) 5.77 0.02     
           
 Dose of OST at month three^         
  On greater 50mgs methadone (or equivalent) 239 (24)       
  On up to 50mgs methadone (or equivalent) >365  2.90 0.09     
           
# Kaplan Meier Survival analysis. The model estimate of the number of days to unplanned discharge by 25% of patients with 
that characteristic is reported, for comparison. 
^ includes the 72 people being prescribed OST after 90 days, with methadone equivalent dose for those on Suboxone being 
multiplied by 5 (i.e. if on 12mgs of Suboxone, assigned value of 60mgs in methadone equivalents)  
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5.6 Discussion 
We found that half of the adolescents who persisted with OST demonstrated a sustained 
period of heroin abstinence throughout their twelfth month of treatment. Previous studies 
of OST in adolescent heroin dependence have largely ignored the issue of abstinence during 
treatment.  In a slightly older cohort, Kellogg et al reported that patients who persisted with 
OST were heroin abstinent every other month on average, although urine drug screens were 
conducted inconsistently which increases the possibility that occasional use was not 
detected in that study.[10]   
The rate of heroin abstinence in month twelve constituted a significant improvement 
compared to the third month of treatment. This is consistent with some other research in 
adolescents and also research on adult patients showing that longer treatment with OST 
builds incremental improvements in outcome.[7,10,26,27] In the NIDA clinical trial, Woody 
et al found a rapid return to heroin use once patients were tapered off their three months 
of buprenorphine treatment.[8] 
Half of those who were heroin abstinent demonstrated some ongoing use of either cocaine 
or benzodiazepines. The rates of abstinence from drugs other than heroin did not increase 
significantly from pre-treatment levels. Studies of OST in adults suggest that they can 
achieve reductions in use of other drugs.[26,27] However, previous research on younger 
cohorts has also failed to demonstrate reductions in use of other drugs and the DARP study 
found some evidence of increased use of cannabis and alcohol at follow-up.[10,7] 
In the exploratory analysis of baseline correlates of 12 month abstinence, there were few 
significant associations, mirroring the finding of others.[13] Those who had a previous 
psychiatric admission appeared less likely to be abstinent. Crome et al also reported better 
outcome in those without a psychiatric history.[28] However, Subramaniam et al found that 
greater baseline psychiatric problems was associated with better outcome in the NIDA 
clinical trial of buprenorphine.[9] Our previous research has indicated that there are 
improvements in mental health symptoms among the adolescents attending OST at this 
service.[23] 
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Our finding of increased abstinence, and better treatment retention, in those with a heroin 
using sexual partner was unexpected. The general view in addiction treatment is that 
increased social ties with other drug users brings poorer outcome.[29] In view of the large 
number of statistical tests conducted, and the decision not to alter the p value via a 
Bonferroni correction, this raises the possibility that the finding could constitute a type 1 
statistical error. However, in a separate study examining outcome after inpatient 
detoxification of heroin dependent adults in Ireland, it also emerged that being in a 
relationship with another heroin user was associated with better outcome.[30] Although 
this finding is counter-intuitive it may warrant further exploration by other researchers. 
We found that cocaine use during month 12 was associated with heroin use. The correlation 
between ongoing heroin use and cocaine use has been shown by others in both adolescents 
and adults.[10,31,32] We found no indication of a relationship between medication dose 
and heroin abstinence. There was no upper ceiling dose used in this service and our finding 
may indicate that dose was appropriately titrated against clinical need. There is research to 
indicate increased heroin use at lower doses in both adolescents and adults.[13,32] In 
contrast, Kellogg et al detected greater heroin use among those on higher methadone 
doses.[10] 
The second main focus of this study was treatment retention. We found that 25% of 
patients had an unplanned treatment exit by 120 days. Retention rates were similar in DARP 
in the 1970s and in the more recent study by Kellogg et al.[7,10] Both of these studies 
examined methadone treatment. A number of studies report much higher rates of patient 
attrition and these have primarily examined buprenorphine treatment.[11-13] In contrast to 
Bell & Mutch, we found no significant difference between the two opioid agonist 
medications, although many patients did switch from buprenorphine to methadone during 
treatment.[11] One factor which complicates comparisons in retention rates across these 
studies relates to the variable criteria used to define ‘drop out’. In this study, patients who 
recommenced regular attendance after a period of up to four weeks non-attendance were 
viewed as still being in their index treatment episode. Other studies have viewed patients as 
having dropped out with much shorter periods of non-attendance.  
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We found that adolescents from families with two parents had better retention. Crome et al 
also found better outcome with increased family support.[28] Involvement of parents in 
both assessment and treatment was prioritised by the service. Efforts were made to include 
parents in the care plan. Family involvement in adolescent addiction treatment has been 
shown to improve outcomes. [33]  
While cocaine use during treatment was associated with ongoing heroin use, cocaine use 
prior to treatment was associated with increases risk of drop out. This adverse association 
between cocaine use and poorer treatment adherence was also reported by Kellogg et 
al.[10] Adult studies have noted similar findings.[34,35] 
The strengths of this study include the sample size which is quite large relative to other 
studies of OST in this age range. However, the sample size is still relatively small for 
statistical purposes and it is possible that some of the significant findings in the exploratory 
analyses constitute type 1 statistical errors. The treatment intervention was delivered at a 
single site making it easier for clinicians elsewhere to determine how applicable our findings 
may be to their own treatment setting. The monitoring of drug use by twice weekly 
supervised UDS constitutes a very thorough level of scrutiny and we can be reasonably 
confident that the patients whom we determined to be abstinent are truly abstinent. A 
limitation can arise from assessing change via urine screens. A patient could change from 
injecting heroin four times a day at treatment entry to smoking heroin just twice a week but 
urine screens would remain constantly positive in such a case indicating complete treatment 
failure in spite of the major harm reduction gains.  
This study adds to the currently limited evidence for OST in adolescents who are heroin 
dependent. The positive outcomes appear broadly similar to those achieved in adults, 
among whom there is widespread acceptance of this treatment. There are concerns that it 
is underutilised internationally in adolescent populations for a range of reasons which 
include wariness by clinicians, political objections and many legislative obstacles.[1] Since 
DARP one of the lingering doubts about OST in adolescents relates to the limited success in 
achieving reductions in use of other drugs.[7] In spite of our efforts to address this use, we 
also found that levels of use of other substances remained stubbornly elevated. This does 
not negate the fact that the reductions in heroin use were substantial. Importantly, 
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abstinence increased significantly from month three to one year. It seems difficult to predict 
which patients are going to persist with this treatment and have better outcomes. However, 
use of cocaine, both prior to and during treatment, appears to be a negative prognostic 
factor. Overall, we echo the view of Woody et al that “clinicians should be in no hurry to 
stop an effective medication simply because the patient is young”.[8] 
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Paper Appendix 5.1 
 
Table 5.A1. Heroin abstinence during month 12 among 39 heroin dependent adolescents on 
opiate substitution treatment 
   Total Heroin Abstinent during month 12 
   N (%) N (%) OR 95% CI OR P value 
        
Number in Treatment    39 (100) 18 (46)    
      
Socio-demographic characteristics      
 Female  25 (64) 13 (52) 2.0 (0.5,7.5) 0.33 
 Aged under 18.0 years  35 (90) 16 (46) 0.8 (0.1,6.7) 1.0^ 
 Left school under 15 years  18 (47) 9 (50) 1.2 (0.3,4.4) 0.76 
 NEET  29 (76) 14 (48) 1.2 (0.3,5.2) 1.0^ 
 Two parent family support    27 (71) 11 (40) 0.6 (0.1,2.4) 0.49 
 Has a child   0 (0) N/a    
 Has been in care   10 (27) 6 (60) 2.6 (0.6,11.3) 0.27^ 
 Sibling Opiate Use     17 (45) 7 (41) 0.8 (0.2,2.8) 0.69 
 Parental Opiate Use      6 (16) 3 (50) 1.3 (0.2,7.4) 1.0^ 
 Partner uses heroin    18 (47) 11 (61) 2.9 (0.8,10.9) 0.11 
 Homeless or hostel in past month   11 (28) 5 (46) 1.0 (0.2,3.9) 0.96 
 Previous criminal convictions   14 (38) 5 (36) 0.6 (0.2,2.4) 0.47 
 Ever incarcerated   8 (22) 2 (25) 0.4 (0.1,1.8) 0.24 
      
Psychiatric History      
 Ever seen a psychiatrist       22 (56) 9 (41) 0.6 (0.2,2.2) 0.46 
 Inpatient psychiatric admission     6 (15) 0 (0)   0.02^ 
 Past DSH    12 (33) 4 (33) 0.4 (0.1,1.8) 0.24 
       
Substance Use      
 Lifetime Drug Use      
  Non-prescribed benzodiazepines    36 (92) 17 (47) 1.8 (0.1,21.5) 1.0 
  Non-prescribed methadone 30 (77) 14 (47) 1.1 (0.3,5.1) 0.71 
  Cocaine   30 (83) 12 (40) 0.1 (0.01,1.3) 0.08 
  Injected   17 (44) 8 (47) 1.1 (0.3,3.8) 0.92 
  Commenced heroin under 15 years of age  20 (51) 10 (50) 1.4 (0.4,4.9) 0.62 
  Regular heroin use for more at least 12 
months  
26 (67) 11 (42) 0.6 (0.2,2.4) 0.50 
       
 Past Month Drug Use      
  Non-prescribed benzodiazepines    26 (67) 12 (46) 1.0 (0.3,3.8) 1.0^ 
  Non-prescribed methadone 27 (69) 13 (48) 1.3 (0.3,5.1) 0.71 
  Cocaine   10 (26) 4 (40) 0.8 (0.2,3.3) 1.0^ 
  Cannabis    27 (80) 12 (44) 0.3 (0.1,1.9) 0.40^ 
  Amphetamine  4 (13) 1 (25) 0.3 (0.03,3.1) 0.60^ 
  Alcohol    17 (50) 6 (35) 0.4 (0.1,1.5) 0.17 
  Injecting      13 (33) 5 (38) 0.6 (0.2,2.4) 0.50 
  Using more than 3 ‘bags’ heroin per day  18 (51) 4 (44) 0.7 (0.2,2.7) 0.62 
        
 Pre-treatment urine drug screen (UDS)
~  
positives 
     
  Benzodiazepines  26 (67) 14 (54) 2.6 (0.6,10.7) 0.17 
  Methadone  20 (51) 10 (50) 1.4 (0.4,4.9) 0.62 
  Cocaine  3 (8) 0 (0)   0.24 
  Cannabis  13 (41) 6 (46) 0.6 (0.2,2.6) 0.51 
        
Treatment      
  Suboxone Commenced 7 (18) 4 (57) 1.7 (0.3,8.9) 0.68 
  At least one opiate negative UDS during 14 (39) 4 (29) 0.3 (0.1,1.2) 0.07 
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induction  
  Heroin abstinent throughout month 3 8 (21) 3 (38) 0.6 (0.1,3.2) 0.70 
  Heroin abstinent throughout month 6 12 (31) 8 (67) 3.4 (0.8,14.3) 0.09 
  Methadone dose at month 12 >50mgs # 20 (51) 9 (45) 0.9 (0.3,3.2) 0.88 
  UDS  at month 12 indicate Benzodiazepine 
use 
24 62) 9 (38) 0.4 (0.1,1.5) 0.17 
  UDS at month 12 indicate cocaine use 6 (15) 0 (0)   0.02^ 
  UDS at month 12 indicate cannabis use 22 (58) 10 (46) 0.8 (0.2,3.0) 0.78 
       
^ 
P value calculated using Fishers Exact Test Statistic as estimated value in cell was less than 5 
#
 For those patients on buprenorphine, dose is multiplied by 5 to approximate to equivalent methadone dose  
~ 
UDS = Urine drug screens, which were conducted twice weekly on average. 
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6.1 Context of this chapter within overall Thesis 
Having presented findings on changes in use of heroin and other drugs during OST in 
Chapter 5, this study examines another important outcome for this same patient group. 
Although mental health problems are known to be very prevalent among heroin dependent 
adolescents, previous international studies have failed to examine the impact of OST on 
such problems. This study sought to address that gap in the literature. 
 
6.2 Abstract 
Aim: Heroin dependent adolescents demonstrate high rates of comorbid psychological 
problems. Among heroin dependent adults, opiate substitution treatment (OST) programs 
appear to reduce mental health problems. We sought to examine the impact of OST on 
psychological wellbeing in adolescents, as this is unknown. 
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Methods: We conducted a prospective study examining psychological wellbeing in heroin 
dependent adolescents, aged 18 years or younger, engaged in outpatient psychologically 
supported OST. Patients were treated with either methadone or buprenorphine. This was 
complimented with individual key working and counselling (Motivational interviewing and 
CBT) and group work focusing on life skills. The Becks Youth Inventory was used to measure 
psychological well-being at treatment entry and repeated after four months of treatment. 
Results: Among 55 consecutive treatment episodes, we examined the 32 episodes where 
the patient persisted with the OST program. Polysubstance use was the norm at treatment 
entry. At follow-up, the median doses of methadone and buprenorphine were 50mgs and 
8mgs respectively. Only three patients were treated with antidepressant medication. There 
was significant improvement in the mean depression (65.0 to 57.9, p=0.001), anxiety (61.7 
to 57.0, p=0.006) and anger (57.8 to 54.6, p=0.009) subscale scores. The self concept and 
disruptive behaviour subscale scores did not improve significantly.  
Conclusion: In this relatively short-term follow up, psychosocially assisted OST appears to be 
associated with improved psychological wellbeing in heroin dependent adolescents, 
especially in the area of depressive and anxiety symptoms. 
 
6.3 Introduction 
Substance use disorders (SUDs) and mental health problems co-occur with great frequency, 
especially amongst adolescents.1 ‘Common factor’ genesis, ‘primary versus secondary 
causality’, ‘bidirectional’ models and neurobiological alterations have been proposed to 
explain this comorbidity in adolescents.2-4  
When contrasted with other drugs, opiate dependence is typically associated with poorer 
outcomes in all domains.5 Heroin dependent adolescents experience greater baseline 
problems and psychological distress than adolescents with other SUDs, with depression 
being particularly evident.6-7 Darke proposes that self medication of psychological problems 
plays a prominent role in the development and maintenance of heroin dependence.5  
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Albeit divisive, opiate substitution treatment (OST) has been thoroughly evaluated as a 
treatment modality.8-9 There is considerable evidence in adults that OST has a significant 
effect in reducing all cause mortality, illicit opioid use, viral transmission, drug overdoses, 
criminality, other risk behaviours as well as increasing treatment retention.9-11 Most studies 
with heroin dependent adults have shown that both psycho- social functioning and mental 
health improves following commencement of OST.12-13 However, an examination of the 
impact of methadone maintenance treatment (MMT) in adults in Ireland failed to 
demonstrate any improvement in psychological wellbeing one year after treatment entry.14 
When compared with adult-specific treatments, far less is known about the nature and 
extent of effective treatments for drug-abusing youth, 15 especially those with heroin use 
disorders.16 Although there are a small number of studies suggesting the general efficacy of 
OST in adolescent populations,17-18 further research on adolescent OST is considered an 
imperative.19-20 While OST yields improvements in psychological wellbeing in adults, it 
cannot be assumed that it will do so in adolescents. There are examples in other areas of 
mental health where treatment effectiveness does not translate into adolescent 
populations.21 
We are only aware of one study which has sought to systematically examine the impact of 
OST on psychological wellbeing in adolescents.22 Moore et al looked at changes in mental 
health symptoms, using the Youth Self-Report (YSR) scale, over a 4-week period during a 
RCT comparing opioid detoxification treatments. 22 They found significant improvements in 
internalising symptoms overall, but there was no significant improvement in the anxiety or 
withdrawn YSR subscales. While the change in externalising symptoms approached 
significance, there was no significant improvement in aggression and rule-breaking.  
Given the above context, this study seeks to address the knowledge gap on the impact of 
psycho- socially supported OST on measures of psychological wellbeing among heroin 
dependent adolescents. We hypothesised that psychological wellbeing would improve 
following exposure to this intervention.  
 
6.4 Method 
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6.4.1 Study Design 
We conducted a pragmatic prospective analysis of psychological well-being among heroin 
dependent adolescents during outpatient OST treatment in Dublin, using a pre- and post 
intervention methodology. We utilised the Beck Youth Inventories, 2nd edition [BYI-II] to 
assess psychological symptoms and impairment.23  Baseline pre- treatment BYI-II scores 
obtained at intake (T0 scores) were compared with the first set of analogous of BYI- II scores 
obtained following commencement of treatment (T1 scores). These T1 scores were 
measured as a routine component of the first structured multi- disciplinary treatment plan 
review which occurred after four months of OST. This review was a collaborative treatment 
response appraisal process conducted with the patient, held approximately every four 
months throughout the course of treatment. The study was approved by the Research 
Ethics Committee of the National Drug Treatment Centre (NDTC).  
 
6.4.2 Settings 
6.4.2.1 HSE National Drug Treatment Centre -Young Persons Programme. 
In 2000, due to the large number of heroin dependent adolescents presenting to treatment 
services in Dublin, and the growing recognition that their treatment needs differed to those 
of the adult population, 24 the Young Persons Program (YPP) was established at the NDTC, 
catering to the needs of young people aged 14 to 20 years.  The team was led by a 
consultant child & adolescent psychiatrist and had input from a trainee psychiatrist, nursing, 
clinical psychology, social work, project workers, counsellors and family therapy. The staff to 
patient ratio was over double that which existed in the adult MMT programs in NDTC, with 
prompt and intensive treatment intervention being a core objective. 2 A decline in the 
incidence of adolescent heroin use disorders since 2000 resulted in a progressive fall in the 
numbers entering treatment over subsequent years. 
The main pillars of treatment involved opiate substitution medication (methadone or 
buprenorphine), counselling (CBT, motivational interviewing or humanistic person centred 
therapy) and in some cases, family therapy. On each visit to the YPP, the patient met their 
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individual case manager. While patients were expected to attend counselling sessions on a 
weekly basis, failure to do so did not result in termination of treatment. There were group 
activities during afternoons, using art therapy and delivery of life-skills. Attendance at 
groups was encouraged but not compulsory. Participation rates at groups were typically 40 
to 60%.  Greater detail on the treatment model is provided in Smyth et al.17 
 
6.4.2.2 Youth Drug and Alcohol Service (YoDA). 
YoDA is an adolescent drug and alcohol treatment service of the HSE in South West Dublin. 
The multi-disciplinary team was developed with the aim of providing treatment for under- 
18’s with a range of alcohol or other substance use disorders. There were a small number of 
patients availing of OST in that service and the approach to treatment was very similar to 
that in the YPP, both clinical services being led by the same consultant psychiatrist. 
 
6.4.2.3 Features of treatment at YPP and YoDA 
Whilst it was not possible to individually quantify the 'dose' of the psycho- social treatment 
received be each individual patient over the full period of treatment, all were offered a full 
spectrum of psycho- social supports including key working, CBT based interventions, social 
work resources, counselling and regular psychiatric reviews. Information on clinical contacts 
during the month before the follow-up assessment was recorded for each treatment 
episode included the study. Structured and psychologically informed treatment plans, 
encompassing a range of areas considered active ingredients of treatment,25 were regularly 
reviewed during weekly multi- disciplinary team meetings, as well as by formal treatment 
plan reviews every four months. 
The two OST options utilised at the YPP and YoDA were methadone (1mg/ml) and 
buprenorphine.  The buprenorphine formulation used initially was the sublingual mono 
buprenorphine tablets (Subutex®, Reckitt Benckiser Healthcare [UK] Ltd). In 2007, we 
switched to use of the buprenorphine-naloxone combined preparation Suboxone® (Reckitt 
Benckiser Healthcare [UK] Ltd). Induction onto a stabilisation dose of methadone typically 
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takes two to three weeks. Buprenorphine dose induction is faster, taking two to five days in 
most cases. Daily attendance at the treatment service was required in the first few weeks of 
treatment. Patients could earn take-away doses of medication as they achieved stability in 
their drug use and general lifestyle. 17 Urine drug screens were conducted prior to treatment 
entry and then occurred twice weekly during the course of treatment. 
 
6.4.3 Participants 
All heroin dependent patients commencing OST at either treatment site between May 2006 
and December 2013 were eligible for inclusion. It was in 2006 that we began to incorporate 
the BYI-II into both routine assessment and review. As this instrument is only valid for 
people aged 18 and under, we excluded the small number of patients who were aged 19 
years. Only those patients who persisted with outpatient treatment until their first 
structured treatment plan review were included. Patients who embarked upon a brief 
detoxification based treatment were also excluded. No efforts were made to follow-up 
patients who had had a prior planned or unplanned exit from treatment. Individual patients 
who had more than one treatment episode during the study period were eligible for entry 
into the study a second time.  
 
6.4.4 Measures  
The outcome measure used was the BYI-II.23 This is a self-report instrument of 100 items 
providing five scales to assess the adolescent’s self-concept and experience of symptoms of 
depression, anxiety, anger and disruptive behaviour. Raw scores are converted into a T 
score indicating the level of problem severity and impairment for that psychological domain 
relative to an age and gender matched general population sample. Accordingly, T scores 
may be viewed either as a point on a severity continuum, or in a categorical manner. The 
categories are not diagnostic of psychiatric disorder. For the purposes of this study, a T-
score on the self concept subscale of 44 or less was categorised as 'abnormal' and a T-score 
of 55 or higher on each of the other subscales was deemed 'abnormal'.  
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We examined drug use at baseline via the Maudsley Addiction profile and obtained other 
socio-demographic and clinical characteristics via a structured clinical interview. 26 We 
report the results of the urine drug screen obtained at the initial pre-treatment assessment 
and also at the time of completion of the follow-up BYI-II. 
 
6.4.5 Statistical Analysis 
When contrasting those who completed the follow-up BYI-II with those who did not, we 
utilised the Pearson Chi-square test or Fishers Exact test for categorical variables. We used 
the T-test or Mann-Whitney U test for quantitative variables, dependent upon normality of 
data distribution. 
To test our hypothesis that psycho- socially assisted OST impacted positively on BYI-II 
measures of psychological wellbeing, we examined this from the complimentary 
perspectives of 1) changes in subscale T- scores  and 2) changes in numbers of patients 
whose T- scores characterized them in a binary fashion as being in the 'normal' or 
'abnormal' range. 
Our previous use of the BYI and examination of other research papers using this instrument 
suggested that subscale scores were likely to be normally distributed. We therefore planned 
to conduct a paired sample t-test to examine change in subscale scores. We also computed 
the effect size (Cohen’s d) as determined by a calculation of the standardised mean 
difference of the pre and post treatment groups, using their respective means and standard 
deviations. McNemar's paired proportions test with continuity correction was employed to 
determine whether OST was associated with changes in the binary category of subscale 
measures. We determined that for an effect size of 0.5, where alpha is 0.05 and power is 
0.8, a sample size of 34 pairs was required in this study. 
 
6.5. Results 
6.5.1 Participants and treatment 
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In view of the declining numbers of patients presenting with heroin dependence we closed 
entry into this study in 2013, prior to reaching the optimal number of 34 participants. Figure 
6.1 represents a flow diagram of the participants from assessment of eligibility to 
completion of the BYI-II follow- up. Among the 55 eligible episodes of OST where the 
baseline BYI was obtained, treatment non-adherence accounted for the vast majority of  
non-completion of the follow-up BYI-II. The socio-demographic and clinical characteristics of 
the 32 included treatment episodes are to be found in tables 6.1 and 6.2. These treatment 
episodes were undertaken by 29 individual patients, three patients completing a second 
treatment episode. Twenty-eight of the included treatment episodes occurred in the YPP 
and four in YoDA. 
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Figure 6.1. Overview of episodes of treated heroin dependence in adolescents –  
eligibility & participation  
 
 
Heroin dependent patients 
commencing OST 
N=69 
 
Eligible for inclusion at Baseline 
N = 58 
19 years-old 
n = 6 
Commenced brief detox 
N = 5 
Completed Baseline BYI 
N = 55 
 
Opted not to complete baseline BYI 
N = 3 
Dropped Out of treatment 
N = 15 
 
 
Completed Follow-up BYI 
N = 32 
 
Opted not to do follow-up BYI 
N = 3 
 
 
Poor attendance at 
follow-up 
N = 2 
 
 
Imprisoned 
N = 2 
 
 Administrative discharge 
N = 1 
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Table 6.1. Baseline characteristics of 55 episodes of OST for heroin dependence in teenagers, 
comparing those who completed a follow-up BYI with those who did not. 
Characteristic Total Eligible 
Group 
Study 
Participants 
Completed 
follow-up BYI  
Did not 
complete 
2nd BYI 
   Number (%) Number (%) Number (%) 
         
Total group 55 (100) 32 (100) 23 (100) 
         
Male gender 31 (56) 18 (56) 13 (56) 
         
Accommodation       
 Currently living with a parent 35 (64) 22 (69) 13 (56) 
 Currently Homeless 12 (22) 5 (16) 7 (30) 
 Ever Homeless 15 (27) 5 (16) 10 (43) 
         
Education & Work       
 Currently in School 7 (13) 5 (16) 2 (9) 
 Working 5 (9) 3 (9) 2 (9) 
         
Family Characteristics       
 Parental Support in Family Home       
  Two parents 23 (42) 13 (41) 10 (43) 
  Lone Parent 27 (49) 17 (53) 10 (43) 
  No contact with parents 5 (9) 2 (6) 3 (13) 
 Family substance use problems       
  Parental Alcohol problems e  28 (56) 16 (50) 12 (63) 
  Parental heroin problems a 18 (33) 8 (25) 10 (45) 
  Sibling heroin problems 13 (25) 7 (22) 6 (30) 
  History of being in care c 21 (40) 10 (32) 11 (52) 
         
Relationships       
 Has a current sexual partner 24 (44) 14 (44) 10 (43) 
 Current sexual partner uses heroin 19 (35) 13 (41) 6 (26) 
       
Criminal Behaviour       
 Past Convictions d 17 (33) 8 (26) 9 (43) 
 Past Incarceration b 14 (26) 5 (16) 9 (43) 
         
Psychiatric History       
 Past psychiatric contact for non-SUD 
reasons a 
30 (56) 15 (47) 15 (68) 
 Ever prescribed psychotropic medications c 23 (44) 11 (34) 12 (60) 
 Past inpatient psychiatric treatment a 5 (9) 2 (6) 3 (14) 
 History of deliberate self harm c 24 (46) 13 (43) 11 (50) 
         
Substance Use Characteristics       
        
 Route of heroin Use       
  Currently smoking ('chasing') only 46 (84) 25 (78) 21 (91) 
  Currently Injecting 9 (16) 7 (22) 2 (9) 
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  Ever previously Injected a 20 (37) 13 (41) 7 (32) 
        
 Lifetime Substance use       
  Benzodiazepines 47 (85) 27 (84) 20 (87) 
  Black Market Methadone 32 (58) 15 (47) 17 (74) 
  Cocaine a 34 (63) 20 (65) 14 (61) 
         
 Past Month Use of Substances other than 
heroin 
      
  No secondary illicit drug use 4 (7) 3 (9) 1 (4) 
  Methadone a 27 (50) 12 (39) 15 (65) 
  Benzodiazepine 39 (71) 24 (75) 15 (65) 
  Alcohol b 26 (49) 16 (52) 10 (45) 
  Cannabis 35 (64) 23 (72) 12 (52) 
  Cocaine 20 (36) 9 (28) 11 (48) 
  Ecstasy/Amphetamines 4 (7) 2 (6) 2 (9) 
         
 Drugs detected in Baseline Urine Screen b       
  Opiates  52 (98) 31 (97) 21 (100) 
  Methadone 23 (44) 7 (23) 16 (76) 
  Benzodiazepine  24 (55) 17 (53) 12 (57) 
  Cannabis c 28 (54) 16 (50) 12 (60) 
  Cocaine 7 (13) 0 (0) 7 (33) 
  Amphetamines 0 (0) 0 (0) 0 (0) 
  Opiate Only 7 (14) 6 (20) 1 (5) 
         
 Drugs detected in Urine Screen at follow-up 
BYI f 
      
  Opiates    9 (28)   
  Benzodiazepine    9 (28)   
  Cocaine   1 (3)   
  Abstinent for opiates, benzodiazepines & 
cocaine 
  18 (56)   
         
a 
Data missing in one case.  
b 
Data missing in two cases.  
c 
Data missing in three cases.  
d 
Data missing in four cases.  
e 
Data missing in five cases.  
f
 Cannabis and amphetamines are not routinely screened during the course of treatment.
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Table 6.2. Characteristics of 55 episodes of OST for heroin dependence in teenagers, comparing those who completed a follow-up BYI with those 
who did not - quantitative variables. 
 Characteristic Total Eligible Group Completed follow-up 
BYI  
Did not do 2nd BYI 
   (SD)/(IQR) a  (SD)/(IQR)  (SD)/(IQR) 
        
 Age (mean) 17.5 (0.7) 17.5 (0.8) 17.6 (0.6) 
        
 Age of school leaving (mean) 14.7 (1.8) 14.9 (1.7) 14.4 (1.9) 
        
 Age first illicit drug use (Mean) 12.6 (1.8) 12.8 (1.8) 12.3 (1.8) 
        
 Age first heroin use (mean) 15.1 (1.3) 15.0 (1.3) 15.3 (1.3) 
        
 Days of heroin use in past month (median) 30 (30-30) 30 (25-30) 30 (30-30) 
        
 Months of regular heroin use (median) b 12 (8-24) 12 (7-18) 18 (10-24) 
        
 Number ‘bags’ of heroin per day (median) 3 (2-4) 2.5 (2-3.5) 3.5 (2.5-5) 
        
 Baseline BYI Subscale T Scores       
 Self Concept 36.6 (9.5) 36.4 (10.9) 36.9 (10.7) 
 Anxiety 61.7 (12.2) 61.7 (11.9) 61.8 (12.8) 
 Depression 65.2 (11.8) 65.0 (10.3) 65.6 (13.9) 
 Anger 59.5 (10.6) 57.8 (9.2) 61.7 (12.1) 
 Disruptive Behaviour 63.7 (10.9) 62.6 (9.6) 65.3 (12.5) 
        
a 
IQR = Interquartile range
 
b 
Data missing in two cases
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Those who did not complete the follow-up BYI were more likely to have experienced 
homelessness (p=0.02) and imprisonment (p=0.03). They were more likely to be misusing 
methadone (p<0.001), cocaine (p=0.001) and larger quantities of heroin (p=0.04) at 
baseline. There were no significant differences in baseline BYI subscale scores between 
those who persisted with OST and those who did not complete the follow-up assessment.  
 
Among the included 32 treatment episodes, polysubstance use was the norm at treatment 
entry with benzodiazepines, cannabis, alcohol and methadone being the most commonly 
misused substances in addition to heroin. Their age ranged from 15 to 18 years. Almost half 
the participants had previous contact with psychiatric services for non-addiction reasons, 
one third had been prescribed psychotropic medication in the past and 43% had a history of 
deliberate self harm. 
 
Buprenorphine was the predominant OST for 10 patients; 21 were treated principally with 
methadone, and one patient spent roughly equal periods on each of these medicines. At 
follow-up the median methadone dose was 50mgs (interquartile range [IQR] 40 - 60mgs) 
and the median buprenorphine dose was 8mgs (IQR 6 - 8mgs). Only three patients received 
prescribed antidepressants over the course of this study and other psychotropic 
medications were not prescribed. Table 6.3 outlines the number of formal clinical inputs 
availed of by patients during the included treatment episodes. At follow-up, a minority of 
patients were abusing other substances (see Table 6.1).  
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Table 6.3. Participation by patients in sessions with multidisciplinary team during month before 
follow-up 
   Any Input Number of clinical 
contacts a 
  
   N (%) Median (IQR)   
        
 Psychologist or Counsellor       
  Brief Sessions b 22 (69%) 2 (0-2)   
  Therapy Session 25  (78%) 3 (1-4)   
  Any Session 27 (84%) 4 (3-6)   
         
 Project Worker       
  Brief Contact b 23 (72%) 1.5 (0-4)   
  Review Meeting 21 (66%) 1 (0-4)   
  Any Meeting 28 (88%) 4 (2-7)   
         
 Nursing Review 22 (69%) 1.5 (0-4)   
         
 Medical/Psychiatric Review 26 (81%) 2.5 (1-6)   
         
a
 13 (41%) had at least one meeting with the social worker. Six (19%) participated in family therapy. 
b
 Brief sessions or contacts were 15-29 minutes. Therapy sessions and Review meetings were over 30 minutes 
 
 
6.5.2 Changes in psychological well-being 
Table 6.4 shows statistically significant improvement in the mean score on the anxiety, 
depression and anger subscales of the BYI over the course of OST, with effect sizes in the 0.4 
to 0.6 range. While subscale scores for self-concept and disruptive behaviours each 
improved, these changes were not statistically significant. When examining changes in 
pathological category during treatment, we found significant improvement in the domains 
of depression and anxiety, with about one third of patients with a baseline abnormal score 
moving into the normal range at follow-up (see Table 6.5). 
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Table 6.4. Changes in psychological wellbeing among 32 episodes of OST for heroin dependence in teenagers. 
 Baseline Follow-Up Effect 
Size 
P value 
 Median Mean (SD) Median Mean (SD) 
BYI Subscale scores         
Self Concept 35.5 36.4  (8.7) 37.5 37.5  (10.1) 0.12 0.43 
Anxiety 62 61.7  (11.9) 57 57.0  (11.9) 0.39 0.006 
Depression 65 65.0  (10.3) 59 57.9  (11.8) 0.64 0.001 
Anger 58.5 57.8  (9.2) 54.5 54.6  (9.5) 0.35 0.009 
Disruptive Behaviour 62 62.6  (9.6) 62 59.7  (10.5) 0.29 0.12 
         
 
 
 
        
Table 6.5. Changes in pathological categories of psychological well-being during 32 episodes of OST 
for heroin dependence in teenagers. 
 BYI 
Subscale 
 Follow-up 
Normal  
(% changing) 
Follow-up 
Abnormal  
(% changing) 
P value a 
      
 Self Concept    
  Baseline Normal 3 4 (57)  
  Baseline Abnormal 3 (12) 22  1.0 
      
 Anxiety     
  Baseline Normal 6 0 (0)  
  Baseline Abnormal 9 (35) 17  0.007 
      
 Depression    
  Baseline Normal 3 0 (0)  
  Baseline Abnormal 8 (28) 21  0.01 
      
 Anger    
  Baseline Normal 10 2 (17)  
  Baseline Abnormal 6 (30) 14 0.33 
      
 Disruptive Behaviour    
  Baseline Normal 5 2 (29)  
  Baseline Abnormal 4 (19) 21 0.68 
a
 McNemar's paired proportions test 
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The domain which demonstrated greatest change in mean score was depression. We opted 
to conduct an exploratory post-hoc analysis to examine the association between 
improvement in BYI Depression score and ongoing heroin use at follow-up. A linear 
regression analysis which included baseline BYI depression score in the model, supported 
the existence of such an association with greater improvement evident in those who were 
heroin abstinent (B=7.8 [95% confidence interval 0.8-14.8], p=0.03). The adjusted R2 for the 
model was 0.25. 
 
6.6 Discussion 
Our findings were consistent with the hypothesis that psychosocially supported OST has a 
positive impact on psychological health in adolescents, especially in the domains of anxiety 
and depressive symptoms. This is consistent with findings in the scientific literature for OST 
in adults.12-13 Our results also support and add to the very limited research which has been 
conducted in adolescent OST programs.22 The study by Moore examined outcome during a 
brief four week detoxification treatment, as opposed to the four month period of 
substitution treatment examined in this study.22 
Our participants appear comparable with other populations of treated heroin dependent 
adolescents internationally, with evidence of substantial social adversity, poor educational 
attainment, family problems, criminality and mental health difficulties.19,27-29 OST was a key 
component of the treatment provided. The average doses of methadone and 
buprenorphine used in our patient group are slightly lower than the advised effective 
maintenance doses in adults.30 Adolescents present with shorter histories of heroin use 
resulting in less tolerance to opioids than that seen in adults. Therefore, these lower doses 
seem appropriate. The substitution dose was determined in a collaborative manner, 
consistent with British guidelines, 31 involving doctor and patient and based upon 
assessment of issues such as ongoing heroin use, withdrawal symptoms and cravings.  
Other research groups have noted that depression is particularly prevalent in adolescents 
with opioid use disorders.29, 32 One third of our patients with elevated depression or anxiety 
scores normalised over the first few months of OST. Low mood is a common precursor to 
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episodes of heroin use among treated patients.33 Therefore, there is a possible reciprocal 
relationship between reductions in internalising symptoms and reducing drug use.15, 34 This 
possibility obtained some support from our finding of a greater reduction in depressive 
symptoms being evident in those who ceased heroin use.  
Despite the fact that the majority of patients had abnormal depression scores at baseline, 
we utilised antidepressant medication in only 10% of cases. The two clinical services 
examined in this study have generally sought to minimise use of psychotropic medication. 
This clinical position is informed by both the widespread misuse of such medication among 
adolescents with SUD in Dublin,35 the evidence base indicating reduced efficacy of 
antidepressant medication in adolescents in general 36 and the evidence indicating limited 
efficacy of such medication in depression in adults on OST.37 It is possible that we were 
excessively conservative in prescribing of medication and that outcomes may have been 
enhanced by greater use of psychotropic medication. 
Although anger problems escalated in a small number of cases, the mean subscale score on 
anger decreased significantly. While Moore et al did not find a significant improvement in 
aggression symptoms in their brief detoxification study,22 treatment of general adolescent 
addiction has been shown to generate improvements in measures of hostility.38  
While the mean self-concept scores increased, this did not approach the level of statistical 
significance. Self-concept and self-esteem appear less malleable than mood states such as 
anxiety and depression and it is therefore not surprising that we failed to demonstrate 
significant changes over the relatively short time-frame examined in this study.39,40 Hser et 
al have demonstrated significant improvements in self esteem among adolescents one year 
after treatment of less complex SUDs.38 
Limitations to this study include the small sample size and recruitment within a single city. 
As this service related research was borne out of a ‘scientist- practitioner’ attempt to 
measure the outcomes of routine clinical practice covering many years, it was not possible 
to  fully measure many potential confounders such as treatment adherence, new major life 
events and all ongoing drug use. These limitations appear to be a ubiquitous feature of 
studies examining this population.6,22,41 The multiple, complex and fluctuating needs of 
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these patients may contribute to the striking lack of outcome studies in this important 
clinical group.20 There was no control group, so we cannot determine that the treatment 
program is better than no treatment. The detected improvement in symptoms could 
constitute a simple regression to the mean. The findings of the linear regression analysis are 
best viewed as tentative in view of the small sample and its post hoc origins. 
Our findings suggest that psycho-socially supported OST is associated with an improvement 
in mental health among heroin dependent adolescents who persist with this treatment. This 
improvement is most evident in the areas of depressive and anxiety symptoms. Larger 
multi-centre studies will be required to identify active ingredients within this complex 
intervention. 
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7.1 Context of this chapter within overall Thesis 
This is the first chapter to report a study examining the legislative changes targeting 
headshops. It returns to YoDA, the treatment setting from which patients in the study of 
cannabis and alcohol treatment were recruited in Chapter 4. It examines changes in the 
patterns on NPS use prior to and after the closure of the head shops. It utilises the ASSIST 
questionnaire to examine NPS use, this being the key instrument used to measure drug use 
in Chapter 4. It seeks to identify the attributes of NPS users compared to the other 
adolescent treatment attenders. Given the concern that closure of the head shops required 
ongoing users of NPS to migrate to the black market, and this caused speculation that their 
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problems could become even greater, this study allowed comparison of pattern and 
problems associated with NPS use during both time periods. 
 
7.2 Abstract 
Background: Legislative changes targeting novel psychoactive substance (NPS) use were 
introduced in Ireland over the summer of 2010 and resulted in closure of 90% of headshops. 
We sought to examine use of NPS among adolescents attending addiction treatment both 
before and after this legislation. 
Method: We included all adolescents entering assessment at one outpatient service 
comparing the six months immediately prior to the legislation in May 2010 to the same six-
month period the following year. Clinicians identified problematic use of between one and 
four substances for each patient. Secondly, information was recorded on recent (past three 
months) use of NPS. 
Results: There were 94 treatment episodes included, with mean age of 16.8 years. 
Problematic use of any NPS fell from 14 patients (34%) in the pre-legislation period to zero 
(p<0.001). There was also a significant decline in recent use of any NPS (82% vs 28%, 
p<0.001). Recent use of cocaine and amphetamines also declined, but problematic use of 
these drugs was unchanged. 
Conclusion: Use of NPS among adolescents attending drug and alcohol treatment was 
substantially reduced six to twelve months after the introduction of legislation prohibiting 
sale of NPS and resultant closure of most headshops. 
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7.3 Introduction 
Novel psychoactive substances (NPS) have become a source of international concern in 
recent years (UNODC, 2013; SAMSHA, 2012). While 'new' drugs come into use across 
societies every decade, such as the emergence of Ecstasy in the 1990s, the large number of 
new substances to gain a firm foothold in the drugs marketplace in recent years has been 
without precedent (UNODC, 2013; Munro & Wilkins, 2014). Like Ecstasy, many of these 
substances have been known for decades but it is only in recent years that their use has 
become widespread (Maxwell, 2014: UNODC, 2013; Munro & Wilkins, 2014). 
While NPS are very heterogeneous, they can be broadly grouped by route of use. Firstly, 
there are the powdered stimulant drugs which typically are snorted, many of which are 
members of the cathinone family (Baumann, 2014). The most widely used member of this 
group is mephadrone (Kavanagh, 2014; Winstock, 2011). The next category of NPS are the 
synthetic cannabinoids which are smoked (SAMSHA, 2012; EMCDDA, 2009). Thirdly there 
are a range of tablets or pills with amphetamine and MDMA type effects, many of which are 
piperazines (Sheridan et al, 2007). 
The marketplace for these drugs has also been novel and has posed many challenges for 
legislators across the world (Munro & Wilkins, 2014). As most of these NPS were not 
scheduled in relevant drugs legislation as being illegal, they have been sold commercially in 
a very open manner in many locations, and often being referred to as 'legal highs' (European 
Commission, 2011). In some countries the internet represents a major supply source for 
these drugs (Dargan et al, 2011; Deluca et al, 2012). In other countries, such as Ireland, 
specialist shops, known as 'headshops', opened up in towns and cities to cater for the 
increased demand for these substances (European Commission, 2011; Kelliher et al, 2011).  
In a European survey of young adults in 2011, it emerged that the prevalence of lifetime use 
of these drugs was 5% across Europe, but peaked at 16% in Ireland (European Commission, 
2011).  Over the period from 2009 to 2010, there was a massive increase in the number of 
headshops in Ireland peaking at 102 premises in May 2010, which is about 1 shop per 
45,000 people (Kelleher et al, 2011; Kavanagh & Power, 2014). There were increasing media 
reports of criminal, medical and mental health problems being associated with the 
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increased use of these NPS nationally and internationally (Kavanagh & Power, 2014). There 
were also reports in scientific papers about the harms associated with these drugs (El-
Higaya, Ahmed & Hallahan, 2011; Winstock et al, 2011; Every-Palmer, 2010). There was 
intense public and political debate about how Ireland should respond to the challenge 
posed by the surge in use of NPS (Ryall & Butler, 2011).  
Ultimately, the Irish government opted to proceed with a two-pronged legislative approach. 
Firstly, there was a legislative ban, adding over 100 substances to the Misuse of Drugs Act in 
May 2010 (Irish Statute Book, 2010a). This made possession, sale and supply of the named 
drugs a criminal offence. Then in August 2010, the Criminal Justice (Psychoactive 
Substances) Act was introduced (Irish Statute Book, 2010b). This Act was focused primarily 
at vendors of NPS. It states that ‘a person who sells a psychoactive substance knowing or 
being reckless as to whether that substance is being acquired or supplied for human 
consumption shall be guilty of an offence’. These two acts resulted in a dramatic decline in 
the number of headshops, initially to 48 shops in June 2010, and then falling to 7 shops in 
2011 (Kavanagh & Power, 2014). 
Much of the international literature discussing NPS points to the potential futility of simply 
banning all of these drugs (Meacher, 2013). A review conducted in Ireland suggested that 
the ban had been excessive and driven by "a moral panic" (Ryall & Butler, 2011). It is argued 
that new drugs, which are not named in legislation, will quickly emerge to replace any 
banned substances (Hammersly, 2010; Dargan et al, 2011). There is evidence that this did 
indeed occur in Ireland over the summer of 2010 (Kavanagh & Power, 2014). It is also 
argued that a ban will simply move the drugs from their quasi-legal but unregulated status 
to enter the criminal drug supply networks (Winstock, Mitcheson & Marsden, 2010). For 
these reasons, there have been increasing calls to explore regulation of this marketplace 
(Hughes & Winstock 2012). New Zealand has taken significant steps in this direction with 
the enactment of the Psychoactive Substances Act 2013 in July 2013 (Munro & Wilkins, 
2014). 
In countries which have implemented a ban, there is some evidence for an impact on 
reducing NPS use. There was a reduction in attendances linked to mephadrone use at 
emergency departments in the UK following their legislative ban (Wood, Greene, Dargan, 
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2013). Stogner et al (2013) reported a decline in use by young adults of Salvia divinorum 
following a legislative ban in Florida. An examination of phone calls to poison centres also 
indicated a dramatic fall in calls related to cathinones following the legislative ban in the 
USA (Loeffler & Craig, 2013). In New Zealand, use of BZP in a general population sample 
declined substantially following a ban of that drug (Wilkins & Sweetsur, 2013). The UNODC 
(2013) has argued that the overall range of legislative bans of mephadrone have been 
effective in reducing use and associated harms.  
Despite claims regarding the success of legislative bans, surveys of drug users report 
ongoing easy access to NPS and suggest that legislative bans had been ineffective at 
curtailing their use of these drugs (McElrath & O'Neill, 2011; Measham et al, 2011). A British 
study of club-goers indicated increased use of mephadrone in the year after the ban (Wood, 
Measham & Dargan, 2012). There have been no reports of the impact of the ban on 
populations attending addiction treatment or in adolescent populations. 
We decided that the legislative changes made in Ireland in 2010 represented an opportunity 
to conduct a natural experiment, to examine the ban’s impact on substance use among 
adolescents attending a specialist drug and alcohol treatment service. We hypothesised that 
(1) use of NPS would fall in this population after the legislative ban, (2) use of other 
substances would increase after the ban and (3) adolescents using NPS in the post-ban 
period would exhibit more problematic use of same. We also sought to identify patient 
characteristics associated with NPS use. 
 
7.4 Method 
7.4.1 Setting 
The Youth Drug & Alcohol (YoDA) service is a specialist drug and alcohol treatment service 
for adolescents aged under 18 years, in mixed urban and suburban setting, serving a 
catchment area in south-west Dublin. Approximately 100 patients attend per annum. It is 
funded by the Health Service Executive and treatment is provided at no financial cost to the 
patient. Referrals are accepted from families, professionals and from young people 
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themselves. Following referral, adolescents are offered an assessment appointment, usually 
within one week of referral. Parents, or those in a caring role, are also invited to attend. The 
assessment seeks to gain an understanding of the adolescent's substance use, psychological 
wellbeing, social functioning and developmental trajectory. It involves clinical interview with 
the adolescent, their parents and completion of some structured clinical instruments. As 
motivation is frequently poor in adolescents attending substance use treatment services, 
clinical staff prioritise patient engagement and building of a therapeutic alliance over data 
gathering (Tims et al, 2002). Assessment typically takes two separate appointments about 
one week apart. The treatment approach is tailored to the individual patient's needs and 
utilises motivational interviewing, cognitive therapy and family therapy. 
There were no changes to service delivery, referral criteria, staffing over the period 2009-
2011. There were no new services which opened or closed within our catchment area which 
might have resulted in alteration to the patient profile attending YoDA. 
Ethical approval was sought and obtained from the Research Ethics Committee of the 
National Drug Treatment Centre. 
 
7.4.2 Measures 
We utilised routinely gathered clinical information to examine the study hypotheses. All 
services which provide drug and alcohol treatment in Ireland are required to complete a 
form on all patients who complete assessment. This form is called the National Drug 
Treatment Report System (NDTRS) form (Bellerose, Carew & Lyons, 2011). In one section of 
this form, the clinician is required to enter the problem substance(s) which are currently 
causing difficulty for the patient. Between one and four substances, including alcohol but 
excluding tobacco, can be entered into the NDTRS form. The definition of "problem 
substance" is not operationalised. 
As part of the assessment process in YoDA the Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST) is utilised routinely. The ASSIST gathers information on life-time, as 
well as recent (i.e. past three month), use of substances. Additionally, it gathers information 
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on the problems associated with recent substance use. The ASSIST has been found to be a 
valid screening test for identifying psychoactive substance use in individuals who use a 
number of substances and have varying degrees of substance use (WHO ASSIST Working 
Group, 2002). It explores a range of substances during a structured clinician administered 
interview, and the interviewer is required to note use and non-use of each listed substance. 
For each substance ever used, questions are then asked about patterns of use and 
consequences relating to the three-month period prior to interview. This then generates a 
"risk score" for each substance ever used which ranges from 0 to 39. As the clinical team in 
YoDA noticed an increasing number of patients presenting with problematic use of NPS in 
early 2010, we opted to modify the ASSIST to include three additional drug categories, to 
reflect the range of NPS which were being used in Ireland. The three new categories were 
"Snortable Headshop drugs", "Smokable Headshop drugs", and "Headshop pills" (Kavanagh 
& Power, 2014). This amendment to the ASSIST was made on 14 Feb 2010. 
 
7.4.3 Participants 
We included consecutive patients who commenced assessment at YoDA during the time 
periods under examination in this study. Patients without a substance use disorder were 
excluded. Where an individual patient commenced assessment on more than one occasion, 
we included each separate episode of attendance. 
 
7.4.4 Statistics 
We consequently had two sources of information on use of NPS. Firstly, there was the 
NDTRS form which indicted current problematic use as identified by the clinician following 
the assessment. Secondly, we had the information from the ASSIST, albeit during a much 
shorter period of time in the pre-ban group (14 Feb 2010 to 10 May 2010). This provided 
self-reported use in the past three months and lifetime use for each category of NPS.  
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Assuming a baseline rate of problematic NPS use of 40% and a fall in use to 10%, we needed 
a sample of 38 people in each of the pre-ban and post-ban groups to have 80% power to 
detect such a change, with p value set at 0.05.  
In order to assess levels of use prior to the legislative ban, we opted to include all 
adolescents entering the service during the six month period prior to the ban, anticipating 
that this would include about 50 treatment episodes and the routinely gathered clinical 
information would be complete in about 80% (40) of these cases. Consequently, the pre-ban 
period under examination was 11 Nov 2009 to 10 May 2010.  
In order to assess use during the post-ban period we opted to include adolescents entering 
treatment during the same period, twelve months later, this being 11 Nov 2010 to 10 May 
2011. By using the same time period, we ensured that seasonal impacts (such as school 
holidays, Christmas holidays and St Patrick's day) were similar in the pre-ban and post-ban 
periods under examination. 
We decided a priori that the principal outcomes of interest were (1) use on any NPS and (2) 
problematic use of any NPS. We also planned to analyse secondary outcomes, examining 
changes in use of subcategories of NPS.  
In order to examine for a significant difference between rates of use pre and post ban, we 
conducted a chi square test, or Fisher Exact test as appropriate. In order to control for 
possible confounding, we planned to conduct two separate logistic regression analyses to 
identify covariates associated with problematic use of any NPS (from the NDTRS responses) 
and with recent use of any NPS (from the ASSIST responses). 
To examine variations in ASSIST risk scores before and after the ban we utilised the Mann 
Whittney U Test as scores are not normally distributed. Where a person reported use of 
more than one category of NPS, we utilised the category which generated the highest 
ASSIST score. 
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7.5 Results. 
7.5.1 Participant characteristics and Univariate analysis. 
There were 94 treatment episodes, by a total of 92 adolescents, included in the study, with 
50 assessments during the six months immediately prior to the legislation in May 2010, and 
44 assessments during the same six month period one year later. The characteristics of 
those adolescents are outlined in Table 7.1. Patients attending were generally white males 
living with their parents. The median age was 17 years (interquartile range [IQR] 15-17). 
Only 69% were engaged in education, training or employment. Parents were the main 
source of referral, followed by social workers, health professionals and the criminal justice 
system. There were significantly more females attending during the post-ban period. There 
were no other significant differences between the pre-ban and post-ban groups with regard 
to socio-demographic or referral characteristics. 
There were seven treatment episodes regarding whom there was no information on use or 
non-use of NPS from either the NDTRS form or from the ASSIST. All had very brief contact 
with the service attending for just one or two appointments. 
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Table 7.1. Characteristics of 94 treatment episodes attending an adolescent substance use 
treatment program, before and after NPS legislation. 
   Total Pre-ban Post-ban p   
   n (%) n (%) n (%)    
 Gender          
  Male 78 (83) 46 (92) 32 (73)    
  Female 16 (17) 4 (8) 12 (27) 0.01   
            
 Age - Mean (SD) 16.8 (1.2) 16.9 (1.2) 16.6 (1.2) 0.25   
            
 Living Situationa          
  Parent(s)/Family 83 (89) 45 (92) 38 (86)    
  Residential Care or 
Homeless 
10 (11) 4 (8) 6 (14) 0.39   
            
 Work/Educationa          
  Student 47 (52) 23 (47) 24 (57)    
  Vocational Training 12 (13) 8 (16) 4 (10)    
  Working 4 (4) 4 (8) 0 (0)    
  Not working or in 
education/training 
28 (31) 14 (29) 14 (33) 0.18   
            
 Ethnicitya          
  White Irish 83 (89) 45 (90) 38 (88)    
  Traveller 5 (5) 3 (6) 2 (5)    
  Other 5 (5) 2 (4) 3 (7) 0.80   
            
 Referral Sourcea          
  Parents 41 (45) 23 (47) 18 (42)    
  Social Work 19 (21) 7 (14) 12 (28)    
  Crim Justice 11 (12) 8 (16) 3 (7)    
  Other Health Professional 12 (13) 6 (12) 6 (14)    
  Self 3 (3) 1 (2) 2 (5)    
  School 6 (7) 4 (8) 2 (5) 0.44   
            
 Main Substance          
  Alcohol 20 (21) 8 (16) 12 (27)    
  Cannabis 60 (64) 33 (66) 27 (61)    
  Sedativesb 7 (7) 3 (6) 4 (9)    
  NPS 4 (4) 4 (8) 0 (0)    
  Heroin 2 (2) 1 (2) 1 (2)    
  Cocaine 1 (1) 1 (2) 0  (0) 0.29   
            
 Previous Treatment episode 14 (15) 7 (14) 7 (16) 0.80   
            
 NDTRS Form Completed 80 (85) 44 (88) 36 (82) 0.40   
            
 NPS Recorded on ASSIST c 48 (72) 17 (74) 31 (70) 0.77   
            
NS - Not statistically significant 
a
 Data missing in 1 to 3 cases. 
b 
Benzodiazepines/Z Drug 
c
 Specific questions on Novel Psychoactive Substances were added to ASSIST from 14/2/2010 
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Based upon NDTRS information, those attending prior to the ban were more likely to have 
problem alcohol use identified (Table 7.2). The Pre-ban assessments had a greater number 
of problem substances (Median =2, interquartile range [IQR] 1-3) compared to those 
assessed in the post ban period (Median =1, IQR1-2, p=0.005 [Mann Whitney U Test]). 
Adolescents attending in the pre-ban period were more likely to report recent use of 
amphetamines and cocaine. 
Although rates of lifetime use of NPS were very similar in the post-ban period compared to 
the pre-ban period, adolescents attending after the ban demonstrated significantly lower 
rates of recent use and problematic use of any NPS, of Snortable NPS and of Smokable NPS.  
Neither gender, referral source, educational status, recent or problematic use of alcohol, 
cannabis, cocaine nor amphetamines were significantly associated with problematic use of 
any NPS (based upon NDTRS Data). Those who reported recent (past 3 month) use of any 
NPS were more likely to also report recent cocaine use (83% vs 33%, p=0.003), recent use of 
amphetamine type drugs (82% vs 35%, p=0.007) and recent benzodiazepine use (69% vs 
34%, p=0.03). There was no significant association between recent NPS use and age, referral 
source, education situation, recent or problematic use of alcohol or cannabis. Males tended 
to be more likely to report recent use of NPS (54% vs 14%, p=0.06[Fishers test]). 
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Table 7.2. Substance use among adolescents entering treatment before and after a legislative ban 
on Novel Psychoactive Substances (NPS) 
   Total Pre-ban Post-ban p value   
  n (%) n (%) n (%)    
           
 Current problem substance use (n=80)        
  Alcohol 49 (61) 32 (73) 17 (47) 0.02   
  Cannabis 70 (87) 40 (91) 30 (83) 0.33a   
  Sedatives b 14 (17) 7 (16) 7 (19) 0.68   
  Ecstasy 4 (5) 3 (7) 1 (3) 0.62a   
  Heroin 3 (4) 1 (2) 2 (6) 0.58a   
  Cocaine 15 (19) 10 (23) 5 (14) 0.31   
  Any NPS 14 (17) 14 (32) 0 (0) <0.001   
  Snortable NPS 6 (7) 6 (14) 0 (0) 0.03a   
  Smokable NPS 7 (9) 7 (16) 0 (0) 0.01a   
  NPS oral pills 1 (1) 1 (2) 0 (0) 1.0a   
            
 Any use in past 3 months (n=48) c        
  Alcohol 42 (91) 15 (94) 27 (90) 1.0a   
  Cannabis  43 (93) 15 (94) 28 (93) 1.0a   
  Sedatives b 16 (36) 8 (50) 8 (28) 0.13   
  Amphetamine  11 (24) 7 (44) 4 (14) 0.03a   
  Opioid  0 (0) 0 (0) 0 (0) NA   
  Cocaine 12 (27) 9 (56) 3 (10) 0.002 a   
  Any NPS  22 (48) 14 (82) 8 (28) <0.001   
  Snortable NPS  12 (26) 8 (50) 4 (13) 0.01a   
  Smokable NPS 15 (33) 10 (62) 5 (17) 0.002   
  NPS oral pills 5 (11) 3 (20) 2 (7) 0.31a   
            
 Lifetime Use (n=47)          
  Any NPS  37 (79) 14 (82) 23 (77) 0.73a   
  Snortable NPS d  18 (41) 8 (50) 10 (36) 0.35   
  Smokable NPS e 31 (67) 11 (69) 20 (67) 0.89   
  NPS oral pills d 14 (32) 5 (33) 9 (31) 1.0a   
            
a
 Fishers Test 
b 
Benzodiazepines/Z Drug  
c
 Data missing in 2 or 3 cases for each drug category 
d
 Data missing in 3 cases 
e
 Data missing in 1 case 
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Among those reporting recent use of any NPS, the NPS ASSIST risk score was significantly 
greater in the pre-ban period (n=19, median 16 [IQR 4-31] vs 2 [IQR 2-6], Mann Whitney U 
test, p=0.02). 
Figure 7.1 presents changes in proportions of attendees presenting with problematic use of 
Snortable, Smokable and any NPS, from August 2009 to May 2011 inclusive. This includes 50 
patients assessed and on whom NDTRS forms were completed between 11 May 2010 and 
10 Nov 2010. This was during the intermediate period just after the Misuse of Drugs Act in 
May 2010 and during which the Criminal Justice (Psychoactive Substances) Act occurred. 
Patient presentations with problematic use of NPS peaked just after the initial legislative 
ban and then fell away rapidly. The fall in presentations linked to Smokable NPS occurred 
earlier than the fall in those associated with Snortable NPS. 
Figure 7.2 depicts the changes in the proportion of patients who were reporting use of NPS 
substances in the three months prior to assessment and includes patients assessed from 
February 2010 to May 2011. 
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Figure 7.1. Change in Problematic Use of NPS before and after legislative ban among adolescents 
entering drug and alcohol treatment (n=152). 
 
 
 
 
Figure 7.2 Change in use of NPS before and after legislative ban among adolescents entering drug 
and alcohol treatment (n=90). 
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7.5.2 Multivariate analysis 
It was not possible to conduct a multivariate analysis of covariates associated with current 
problematic use of any NPS with the time-period (i.e. pre-ban vs post-ban) included in the 
equation, as there was no case identified as having current problematic use of any NPS in 
the post-ban period. 
A multivariate analysis examining covariates associated with recent use (past 3 months) of 
any NPS was conducted to determine if the time period remained significantly associated 
with use. Following examination of the covariates associated with recent NPS use, a number 
of models were examined. The best fit involved a model which included time-period, gender 
and recent amphetamine use (Table 3). This confirmed that there was a significant 
reduction in use of any NPS in the post ban period (p=0.01). The 95% confidence intervals 
were very wide reflecting the small numbers involved. The model fit was very good, 
correctly predicting 82% of outcomes and the Nagelkerke R Square was 0.48. 
 
Table 7.3. Logistic regression analysis of patient characteristics associated with use of any NPS 
(n=45) 
   Odds Ratio 
[OR] 
(95% CI OR) p value 
 Period of attendance    
  Nov 2009-May 2010 7.4 (1.5-37) 0.01 
  Nov 20010-May 2011 1.0   
      
 Amphetamine use in past 3 months    
  No use 1.0   
  Some use 9.9 (1.0-98) 0.05 
      
 Gender    
  Female 1.0   
  Males 13.6 (0.6 - 334) 0.11 
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7.6 Discussion. 
We found substantial reductions in use of NPS among treatment attending adolescents 
within a year after a legislative ban on their use, supply and sale. The detected reduction in 
use among these adolescents in this study does mirror reductions in use of specific 
categories of NPS in other populations following similar bans in other settings (Wood, 
Greene, Dargan, 2013; Stogner et al, 2013; Loeffler & Craig, 2013; Wilkins & Sweetsur, 
2013). Reductions in use of cathinone and piperazine compounds have also been 
demonstrated in opiate dependent patients attending methadone maintenance treatment 
in Ireland during the year after the legislative ban (O'Byrne et al, 2013).  
The legislation has certainly not eliminated use of these drugs. There was evidence of 
ongoing use of all categories of NPS six to twelve months after the law was changed. A 
recent European survey confirmed ongoing use of NPS among 15-25 year olds in Ireland, 
with 9% reporting some use of NPS in the past year (European Commission, 2014). We had 
speculated that young people who persisted with use of these drugs following their 
prohibition would exhibit more problematic patterns of use compared to those accessing 
them during the pre-ban period when they were readily available in headshops. We found 
no evidence to support this hypothesis. Indeed we found that the ASSIST scores present in 
users of NPS after the ban were significantly lower than those before the ban, indicating less 
frequent and less problematic use.  
Why might a legislative ban have resulted in a reduction in the proportion of substance 
abusing teenagers who chose to use NPS and reduction in intensity of use among those who 
persisted with use? Our study cannot answer this question. Ninety-three per cent of the 
headshops closed in the year following the two new pieces of legislation. This appears to 
have had a massive impact of the nascent marketplace for these drugs in Ireland. Looking 
beyond NPS, we know that access and availability are key factors influencing patterns of use 
of other substances. Alcohol availability is a potent factor influencing alcohol use and harms 
(Babor et al, 2010). MacCoun & Reuter (2001) have argued that increased availability and 
commercialisation of cannabis in the Netherlands was associated with increased use of that 
drug among youth. While generally sceptical of the impact of supply-orientated policies, 
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Caulkins (2012) does acknowledge that such polices can be very efficient in certain types of 
drug markets. Therefore, our findings have face validity.  
It seems unlikely that concerns regarding criminal sanction acted as an important deterrent 
for use of NPS in this group. They did demonstrate ongoing use of a broad range of similarly 
illegal drugs after the legislative ban. The consequences of an adolescent being caught by 
police in Ireland with drugs for personal use are relatively benign, typically resulting in no 
more than a caution. Criminal prosecution is very rarely proceeded with in this age range for 
this type of offence.  
Simple drug policy measures can have unintended and adverse consequences (Greenfield & 
Paoli, 2012). We deliberately cast the net wide in terms of NPS in this study due to concerns 
that success at reducing use of a single drug such as mephadrone, might conceal increased 
use of other emerging and not yet illegal NPS (Dargan et al, 2011). We found a fall in rates of 
use of the broad group of NPS, as further new substances did indeed arrive into the drugs 
marketplace in Ireland following the legislation (Kavanagh & Power, 2014; O'Byrne et al, 
2013).  
We also examined the possibility that NPS may simply have temporarily displaced other 
more established illegal drugs such as cocaine, amphetamines and cannabis. Not only did 
we fail to find any evidence of increased use of these older drugs following the reduction in 
NPS use, we found that young people presenting for treatment in the post-ban period were 
less likely to be using cocaine and amphetamines. Polydrug use was more evident in the 
pre-ban period. While the reason for this is unclear it does not raise concerns regarding 
untoward effects of the legislation on patterns of use. Nevertheless, it is possible that the 
disruption which the legislation caused to patterns of drug use and to the drug marketplace 
may have generated other social or personal harms not examined in this study (Greenfield & 
Paoli, 2012). 
Although, there were just two principal outcomes, we conducted multiple additional 
statistical tests to examine secondary outcomes and to explore factors associated with NPS 
use. Despite this, we opted to make no adjustments for the multiple tests undertaken 
because they can result in a higher type II error rate, reduced power, and increased 
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likelihood of missing important findings (Rothman, 1990). The key sources of information 
(i.e. the NDTRS form and the ASSIST) were unavailable in 15-30% of cases raising the 
possibility of selection bias. There was also scope for clinical subjectivity with regard to 
determinations of "problem substance use" in the NDTRS form as this term is not 
operationalised. The findings may not generalise to other settings with a more established 
pattern of NPS use or with a different network of supply of NPS. Specifically, legislative bans 
targeted primarily at headshops such as those which occurred in Ireland may have little or 
no impact where the internet acts as the major supplier.  
Overall, the legislative measures undertaken in Ireland in response to escalating use of NPS 
coincided with reduced use of the broad category of NPS within this narrow but important 
group of high risk adolescents attending treatment services. While we watch with interest 
the outcome of attempts to regulate this marketplace, such as those in New Zealand, our 
findings do not provide a rationale for Ireland to alter its prohibitionist approach to NPS at 
this time. 
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8.1 Context of this chapter within overall Thesis 
Building upon the findings of the NPS study in chapter 8, this study seeks to determine if the 
changes observed in treatment attending adolescents at one treatment centre in Dublin 
generalise to young adults nationally. It characterises NPS users attending addiction 
treatment. It compares patterns of NPS use before and after the closure of the head shops. 
It uses JoinPoint trend analysis for the first time in the PhD. This permits exploration of the 
data on rates of NPS presentations over time to determine if that were any significant trend 
changes coinciding with either the arrival or departure of the head shops. It also examines 
for trend changes for presentations related to other drugs. 
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8.2 Abstract 
Introduction and Aims: New psychoactive substances (NPS) have hedonic effects which may 
lead to dependence. Headshops selling NPS increased in number in Ireland from late 2009. 
Legislation was enacted in May and August of 2010 which caused their closure. It is 
unknown whether such events impact the rate of NPS use disorders.   
Designs and Methods: We conducted a population based study using the Irish national 
database of episodes of addiction treatment between 2009 and 2012. We examined trends 
in the rate of NPS related treatment episodes among young adults. Joinpoint trend analysis 
software was used to identify significant changes in trend. 
Results: There were 31,284 episodes of addiction treatment commenced by adults aged 18 
to 34 years, of which 756 (2.4%) were NPS related. In 2012, the 12-month moving average 
rate had fallen 48% from its peak in 2010, from 9.0/100,00 to 4.7/100,000. Joinpoint 
analysis indicated that the rate of NPS related episodes increased by 218% (95% CI 86 to 
445, p=0.001) every four months until the first third of 2010. From that point, the rate 
declined by 9.8% (95% CI -14.1 to -5.4, p=0.001) per four-month period. There was no 
significant trend change in the rate of non-NPS related treatment episodes. 
Discussion and Conclusions: Over the two years after the enactment of prohibition-styled 
legislation targeting NPS and headshops, the rate of NPS related addiction treatment 
episodes among young adults declined progressively and substantially. We found no 
coinciding trend change in the rate of episodes linked to other drug groups.  
 
8.3 Introduction 
New psychoactive substances (NPS) have become a source of international concern in 
recent years.[1] These are new psychotropic drugs which are not controlled by previous 
1961 or 1971 UN conventions “but which may pose a public health threat comparable to 
that posed to substances listed in those conventions”.[2] They include cathinones, synthetic 
cannabinoids and substances with amphetamine and MDMA type effects, many of which 
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are piperazines or phenethylamines.[3,4] NPS have many of the same hedonic effects as 
more established drug classes and therefore have potential to cause dependence.[3,5-6]   
The marketplace for NPS has also been novel, posing challenges for legislators 
internationally.[2,7,8] While not scheduled as being illegal, NPS have been sold 
commercially in many jurisdictions.[9] In some countries the internet has constituted the 
major source of supply.[10,11] In countries such as Ireland, specialist shops, known as 
'headshops', opened to meet demand for these drugs.[9,12] A European survey of young 
adults in 2011 found that the lifetime prevalence of NPS use was 5% overall, but highest in 
Ireland at 16%.[9] Over the period from late 2009 to 2010, there was a substantial increase 
in the number of headshops in Ireland peaking at 102 premises in May 2010, approximately 
one shop per 45,000 people (see Figure S1 in online supplement).[12,13] Their presence 
quickly prompted public protests and demands for urgent political action.[14]  
In response, the Irish government opted to proceed with a two-pronged legislative 
approach. Firstly, there was a legislative ban, adding over 100 substances to the Misuse of 
Drugs Act in May 2010.[15] This made possession, sale and supply of the named drugs a 
criminal offence. Then in late August 2010, the Criminal Justice (Psychoactive Substances) 
Act was introduced.[16] This Act was focused primarily at vendors of NPS. It states that ‘a 
person who sells a psychoactive substance knowing or being reckless as to whether that 
substance is being acquired or supplied for human consumption shall be guilty of an 
offence’. These two Acts resulted in a dramatic decline in the number of headshops, initially 
to 48 shops in June 2010, and then falling to 10 shops by October 2010 (see Figure 8.1) .[13] 
Follow-up investigations by An Garda Síochána (Irish police) in late 2010 indicated that the 
remaining headshops were no longer selling NPS. Consequently, the eight-month period 
from January to August 2010 could be viewed as the Irish headshop era.
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Figure 8.1 Number of headshops in Ireland, May 2008 to May 2011. (Copy of Figure 2.17 in Chapter 2) 
 
Footnote to Figure 8.1 In mid-2008, An Garda Síochána (Irish police) were monitoring headshops due to concerns that some were selling Hawaiian Baby 
Woodrose seeds and Peyote cactus in contravention of the Misuse of Drugs Act, via Operation Flourine (See section 2.6.2.1 in Chapter 2). Monitoring of 
headshops then ceased on 17/10/2008. Due to concerns regarding widespread use of NPS, a second Garda operation commenced (Operation Kingfisher - 
See section 2.6.2.1 in Chapter 2) and a census of headshops was conducted on 30/03/2010, and intermittently over the following 14 months. From October 
2008 to March 2010 (dotted line) the number of headshops was not measured, although Garda reports suggest that the number of headshops began to 
increase substantially in late 2009.
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There is substantial contention internationally regarding the effectiveness of legislative 
bans. A review in Ireland suggested that the legislative response to NPS had been excessive 
and driven by "a moral panic".[14] There are international surveys of drug users which 
indicate ongoing easy access to and use of NPS following bans.[17,18] It has been argued 
that new drugs rapidly arrive to replace any specific banned substances.[10,19] There is 
evidence that this did indeed occur in Ireland over the summer of 2010, as drugs such as 
naphyrone and flourotropococaine went on sale in the remaining headshops.[13] This 
eventuality prompted the additional legislation in August. It is also possible that a ban just 
moves drugs from their quasi-legal status to enter criminal drug supply networks, with 
increased attendant risks or possibly diverts would-be NPS users towards other drugs.[20] 
There have been increasing calls to explore regulation of this marketplace.[21] New Zealand 
has taken initial steps in this direction with the enactment of the Psychoactive Substances 
Act in 2013.[2,7]  
In countries which have proceeded down the more traditional route of prohibition and 
legislative bans, such as those adopted by Ireland, there is some evidence of an impact on 
reducing NPS use. There was a reduction in attendances linked to mephedrone at 
emergency departments following a legislative ban in Britain.[22] There was a decline in use 
of Salvia divinorum after a legislative ban in Florida.[23] There was a dramatic fall in 
phonecalls regarding cathinones to a poison centre in USA following legislation.[24] In New 
Zealand, use of benzylpiperazine (BZP) in the general population declined substantially 
following its prohibition.[25] A study examining NPS use among adolescents entering 
addiction treatment in Dublin found reduced use one year after the legislative changes.[26]  
The emergence of headshops and the subsequent legislation provide an opportunity for a 
natural experiment.[8] We sought to examine whether the arrival and departure of the 
headshops coincided with changes in presentation of problem NPS use among adults 
attending addiction treatment services in Ireland. 
 
8.4 METHOD  
8.4.1 Setting  
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In Ireland, addiction treatment services are available across the country. There is a mixture 
of statutory, voluntary and private services. Most treatment is delivered on an outpatient 
basis. There are about 15,000 treatment episodes commenced annually, and almost half 
involve people entering treatment for the first time. Alcohol is the main problem drug in 
about half of episodes, while heroin and cannabis are the most common illegal drugs 
contributing to treatment episodes.[27] The proportion of primary heroin use disorders 
declined marginally 2007 to 2009, while treated cannabis use disorders increased over this 
period.[26] Most patients entering treatment for problem drug use present with 
problematic use of more than one drug.[27]  
The general population survey of 2010-11 found that past year prevalence of cannabis use 
was 10% among 15-34 year olds, and this was unchanged since the preceding survey in 
2006-07.[28] The past year prevalences of NPS, cocaine and amphetamines in this age range 
in 2010-11 were 7%, 3% and 1% respectively. Past year NPS use was only 1% among people 
aged over 34 years. Young males were three times more likely than young females to report 
past year NPS use. 
Ireland underwent significant social changes over the period 2009-2012, entering a 
recession following a period of sustained economic growth. The youth unemployment rate 
increased dramatically from 19% in January 2009 to 27% in January 2010, and increased by a 
further 2-3% over the following two years.  
 
8.4.2 Measures 
We utilised routinely gathered epidemiological information from the National Drug 
Treatment Report System (NDTRS). Services which provide addiction treatment in Ireland 
are expected to return information on each new treatment episode to the NDTRS,[27] with 
70% of services doing so. The therapist conducting the assessment writes the name of the 
main problem drug self-reported by the patient, and up to three additional problem drugs, 
onto the NDTRS form. The written text is then coded by staff at the NDTRS when entered 
into the database. Consequently, new drugs are captured once they begin presenting to 
treatment services. The definition of "problem drug” is not operationalised, although it is 
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generally understood to equate to dependence or harmful use as described in ICD-10. An 
episode of treatment, or case, was determined to be NPS-related if any NPS was identified 
as being a problem drug.  
The NDTRS form also captures information on socio-demographic and past treatment. There 
is no unique patient identifier. Consequently, the unit of analysis reported in this study is 
treatment episode. However, incidence was calculated from cases who had never previously 
been treated for a drug problem, as these constituted unique individuals. 
 
8.4.3 Population 
We examined all episodes of treatment recorded in the NDTRS over the period 2009 to 
2012.  We excluded episodes where the patient was aged under 18 years as this group have 
previously been examined.[25] In light of the general population survey indicating much 
higher rates of use among young adults, we focused upon cases aged 18-34 years for the 
trend analysis.[28]  
 
8.4.4 Statistics 
We opted to examine treatment attendances per four-month block of time, or third of each 
year. In view of the time points for the legislative changes, there were four full months 
(January to  April = 2010t1) in 2010 prior to the May legislation and a further four-month 
period (May to August = 2010t2) before the Psychoactive Substances Act at the end of 
August 2010. The NDTRS avoids reporting cell sizes of less than 5 people as patients may be 
identifiable. Analysis of treatment episodes in one or two month blocks would have resulted 
in frequent breach of this rule. 
In order to contrast proportions, such as the characteristics of NPS-related treatment 
episodes and episodes unrelated to NPS, we utilised odds ratios. We also report estimates 
of the 95% confidence intervals of the odds ratio. These are estimates of the confidence 
intervals as the episodes are not completely independent. An unknown proportion of 
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episodes, which we estimate to be about 15-25%, involve re-attendance by individuals on 
more than one occasion during the four year period. We also used odds ratios to describe 
changes in the prominence of NPS (i.e. main problem substance versus a secondary 
problem) within NPS-related treatment episodes over the four year period. 
We calculated the crude rate of all NPS-related treatment episodes among people aged 18-
34 years. We also calculated the incidence of NPS-related treatment episodes in this age 
range using cases who entered addiction treatment for the first time. The population at risk 
was obtained from the population estimates provided by the Central Statistics Office. To 
smooth out the effect of seasonal variation in treatment attendance, the graphs also report 
12 month moving averages, these being the average of the rates from the three preceding 
four-month blocks of time. As a comparator, we also measured the rate of addiction 
treatment episodes which were unrelated to NPS use. 
Finally, we used the Joinpoint Regression Program, version 4.3.1.0 (National Cancer 
Institute, Bethesda, Maryland, USA, http://surveilance.cancer.gov/joinpoint) to further 
examine trends in the rate of attendances. Joinpoint regression is a log-linear model which 
uses Poisson regression, creating a Monte Carlo permutation test to identify points where 
the trend line changes significantly in magnitude or direction.[29] The location of the 
joinpoints is data driven. It starts by fitting a straight line (i.e. zero joinpoints) and tests 
whether the addition of one or more joinpoints yields a statistically significant improvement 
in fit. The percentage change per third of each year (PCT) is calculated for each line segment 
between joinpoints, along with 95% confidence intervals. The minimum number of 
observations from a joinpoint to either end of the data and the minimum number of 
observations between two joinpoints were set at three and four respectively (default 
settings). Consequently, with 12 observations, we could detect a maximum of two 
joinpoints per analysis. We used the Joinpoint software to explore for possible joinpoints in 
the trends of both NPS and non-NPS-related addiction treatment episodes, examining the 
rates of all episodes and of cases never previously treated. We further examined the non-
NPS-related episodes by main problem drug to determine if there were any significant 
changes in trends of presentations linked to other drug classes (cannabis, cocaine, other 
stimulants [e.g. amphetamine, MDMA], sedatives and hypnotics [e.g. benzodiazepines, 
zopiclone], opioids and alcohol). 
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8.5 Results. 
There were 58,251 treatment episodes, with some evidence of seasonal variation (35.5% of 
episodes occurred in the first third of the year versus 30.4% in the final third). Overall, 849 
(1.46%) episodes involved problematic NPS use. Of these, a NPS was the main problem drug 
in 255 (30.0%) cases. In 2009, 36% (14/39) of the NPS related episodes involved a NPS as the 
main problem, and in 2010 this proportion was 39% (138/354).  This proportion fell to 27% 
(75/278) in 2011 and then to 16% (28/178) in 2012.  Compared to 2010, NPS-related 
treatment episodes in 2011 and 2012 were less likely to involve a NPS as the primary drug 
with odds ratios of 0.6 (95% CI 0.4 to 0.8) and 0.3 (95% CI 0.2 to 0.5) respectively.  
The profiles of the NPS group and non-NPS group are provided in Table 8.1. Those episodes 
involving problem use of NPS were more likely to involve males and cases under 35 years of 
age. The median age of the NPS group was 25.0 years compared to 35.6 years in the non-
NPS group. The route of NPS use was 62.4% intranasal, 18.8% smoked, 13.6% oral and 5.2% 
injected. Further information on the subgroups of NPS, and how these changed over time, is 
provided in Table 8.2. 
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Table 8.1. Socio-demographic characteristics of all adult treatment episodes involving an NPS as 
problem drug compared to those which were unrelated to any NPS, 2009 to 2012 
 NPS  Non-NPS Odds 
ratio 
(OR) 
95% CI of 
OR^  (N = 849)  (N = 57402) 
 N %  N %  
Gender        
Male  631 74.3%  39105 68.3% 1.3 (1.1-1.6) 
Female 218 25.7%  18180 31.7% 1.0  
        
Age        
18 to 34 years 756 89.0%  30528 53.2% 7.2 (5.7-8.9) 
35 years and older 93 11.0%  26874 46.8% 1.0  
        
Living with whom?        
Alone 124 14.6%  12007 20.9% 0.4 (0.3-0.5) 
Parents/family 462 54.4%  19055 33.2% 1.0  
Friends 28 3.3%  1642 2.9% 0.7 (0.5-1.0) 
With partner  94 11.0%  14529 25.3% 0.3 (0.2-0.3) 
Alone with children 36 4.2%  3578 6.2% 0.4 (0.3-0.6) 
Other/not known 105 12.4%  6591 11.5% 0.7 (0.5-0.8) 
        
Accommodation        
Stable accommodation 721 84.9%  49691 86.6% 1.0  
Institution* 54 6.4%  1423 2.5% 2.6 (1.9-3.5) 
Homeless 32 3.8%  3542 6.2% 0.6 (0.4-0.9) 
Other unstable accommodation 27 3.2%  1884 3.3% 1.0 (0.7-1.5) 
Not known 15 1.8%  862 1.5% 1.2 (0.7-2.0) 
        
Employment        
In employment, education or training 236 27.8%  13133 22.9% 1.2 (1.0-1.4) 
Not in employment, education or training 565 66.5%  37717 65.7% 1.0  
Retired/ unable to work/disability 33 3.9%  3945 6.9% 0.6 (0.4-0.8) 
Other/not known 15 1.8%  2607 4.5% 0.4 (0.2-0.7) 
        
Source of referral        
Self 266 31.3%  22796 39.7% 1.0  
Family/friends 127 15.0%  5780 10.1% 1.9 (1.5-2.3) 
Other drug treatment centre 85 10.0%  5347 9.3% 1.4 (1.1-1.7) 
Mental health professional 91 10.7%  3426 6.0% 2.3 (1.8-2.9) 
Criminal justice system 83 9.8%  4385 7.6% 1.6 (1.3-2.1) 
Other health care professional/facility 72 8.5%  9318 16.2% 0.7 (0.5-0.9) 
Social services 73 8.6%  3373 5.9% 1.8 (1.4-2.4) 
Other/not known 52 6.1%  2977 5.2% 1.5 (1.1-2.0) 
        
Year of Treatment         
2009 39 4.6  13576 23.7 0.1 (0.1-0.2) 
2010 354 41.7  14301 24.9 1.0  
2011 278 32.7  14966 26.1 0.7 (0.6-0.9) 
2012 178 21.0  14559 25.4 0.5 (0.4-0.6) 
        
Main Problem        
Alcohol 173 20.4%  31206 54.4% 1.0  
Any drug other than alcohol 676 79.6%  26196 45.6% 4.6 (3.9-5.5) 
^ The 95% confidence intervals for odds ratios should be viewed as estimates, as reliable calculations of these 
confidence intervals requires episodes to be fully independent. We estimate that 15-25% of people re-
attended addiction treatment during this four year period, so this rule of independence is breached. 
* Institution includes prison, halfway house, residential centre
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Table 8.2. Sub-type of NPS identified as problem substances by adults attending addiction treatment services, contrasting the period when headshops were 
selling NPS with the period after Headshops ceased their sale. 
Category of NPS Total  Jan 2009 to 
Aug 2010  
 Sept 2010 to 
Dec 2012 
Odds 
ratio 
(OR) 
95% CI of ORa 
    (N = 320)  (N = 554) 
  N %  N %  N %  
            
NPS Stimulant Powdersb 530 61%  134 42%  396 71% 1.0  
NPS Cannabis-like substancesc 114 13%  74 23%  40 7% 0.2 (0.1-0.3) 
NPS Stimulant Party Pillsd 31 4%  20 6%  11 2% 0.2 (0.1-0.4) 
NPS Hallucinogenic Substancese <5 0%  <5 1%  0 0% NA  
Other Specified NPS 27 3%  15 5%  12 2% 0.3 (0.1-0.6) 
Unspecified NPS 168 19%  73 23%  95 17% 0.4 (0.3-0.6) 
           
NPS is the Primary drug Problem           
 NPS Stimulant Powders 156 61%  49 40%  107 80% 1.0  
 NPS Cannabis-like substances 45 18%  34 28%  11 8% 0.2 (0.1-0.3) 
 Other NPS 27 11%  19 16%  8 6% 0.2 (0.1-0.5) 
 Unspecified NPS 27 11%  20 16%  7 5% 0.2 (0.1-0.4) 
            
NPS is the Secondary drug Problem           
 NPS Stimulant Powders 374 60%  85 43%  289 69% 1.0  
 NPS Cannabis-like substances 69 11%  40 20%  29 7% 0.2 (0.1-0.4) 
 Other NPS 35 6%  20 10%  15 4% 0.2 (0.1-0.5) 
 Unspecified NPS 141 23%  53 27%  88 21% 0.5 (0.3-0.8) 
            
NPS Stimulant Powders           
 Primary Substance Problem 156 29%  49 37%  107 27% 1.0  
 Secondary Substance Problem 374 71%  85 63%  289 73% 1.6 (1.0-2.4) 
            
NPS Cannabis-like substances           
 Primary Substance Problem 45 39%  34 46%  11 28% 1.0  
 Secondary Substance Problem 69 61%  40 54%  29 73% 2.2 (0.9-5.6) 
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Unspecified NPS           
 Primary Substance Problem 27 16%  20 27%  7 7% 1.0  
 Secondary Substance Problem 141 84%  53 73%  88 93% 4.7 (1.8-13.3) 
            
a
 The 95% confidence intervals for odds ratios should be viewed as estimates, as reliable calculations of these confidence intervals requires episodes to be fully independent. 
We estimate that 15-25% of people re-attended addiction treatment during this four year period, so this rule of independence is breached. 
b 
mephedrone, butylone, MDVP, flephedrone, methylone, “Snow”,”snowblow”, “bath salts”, “Bubble”. “Hurricane Charlie”, “Vanilla sky”, “Whack”, “Wildcat” or Unspecified 
NPS Stimulant powder. 
c
 “smoke”, “spice”, “Bonsai”, “Pulse”, “King B”, Unspecified NPS Cannabis-like Substance.  
d
 “Rocket Fuel”, “Speed Freak”, “Exotic Super”, Unspecified NPS Stimulant Party 
e
 Salvia, NPS Hallucinogenic Substances 
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There were 31,284 episodes of addiction treatment commenced by adults aged 18 to 34 years 
during this period, of which 756 (2.4%) were NPS-related. Figure 8.2 demonstrates the crude rates of 
NPS-related treatment episodes among these young adults. The rate rises rapidly, peaking in 2010t2 
and then falls progressively after that point.  During the headshop era from January to August 2010, 
4.2% (n=236) of all addiction treatment episodes in this age range involved problematic NPS use. In 
2012, the 12-month moving average rate had fallen 48% from its peak in 2010, from 9.0/100,000 to 
4.7/100,000. In contrast, the rate of non-NPS-related treatment episodes was relatively stable.  
 
Figure 8.3 demonstrates the changes in incidence of NPS-related treatment episodes among 18-34 
year-olds. These were cases who had never sought drug treatment previously. Incidence peaked in 
2010t1 at 6.0 cases/100,000 and fell steadily after that point. By end of 2012, the 12-month moving 
average had fallen by 66% from its peak in 2010 of 4.9/100,000 to 1.7/100,000. 
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Figure 8.2 Rate of addiction treatment episodes among people aged 18-34 years-old, from 2009-2012, comparing episodes related to NPS to those related 
to all other substances 
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Figure 8.3 Incidence of new addiction treatment cases among people aged 18-34 years-old, from 2009-2012, comparing cases related to NPS to those 
related to all other substances 
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Table 8.3 and Figure 8.4 to 8.9 provide the results of the joinpoint analyses. This indicates 
that the trend in the rate of total NPS-related episodes and in the incidence of new NPS 
cases changed in 2010t1. These rates were each rising substantially and significantly up to 
that period. Beyond that point, the rates declined progressively and significantly. No 
joinpoints were detected when the rates of non-NPS related episodes were examined, and 
the overall trend in rates across the period examined did not differ from zero.  
The examination of all non-NPS related episodes by main problem drug indicted no 
significant change in trend (i.e. no joinpoint identified) for cannabis, cocaine, other 
stimulants, alcohol or opioids. There was a significant but steady decrease in the rate of 
cocaine-related episodes over the study period while the rates of cannabis and of sedatives 
and hypnotics related episodes increased steadily and significantly. Importantly, there was 
no change in these trends during these 4 years. There was a significant change in trend of 
presentations linked to sedatives and hypnotics among those who had never previously 
sought drug treatment. This occurred in 2012t1, when the trend of rising incidence 
reversed.  
The examination of subcategories of NPS within NPS related treatment episodes (Table 8.2), 
indicates that NPS Stimulant Powders accounted for an increased proportion of NPS related 
cases after August 2010, while the proportion of NPS Cannabis-like substances declined. 
Among those presenting with problematic use of NPS Stimulant Powders, the proportion for 
whom this was a primary problem declined after August 2010. 
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Table 8.3. Trends in crude rates of addiction treatment episodes per third of a year, among people aged 18-34 years between 2009 and 2012. 
 Period PCT*  (95% CI PCT) Joinpoint (95% CI of 
Joinpoint) 
Period PCT (95% CI PCT) 
         
All Treatment Episodes         
 NPS 2009t1 to 2010t1 218 (86 to 445) 2010t1 (2009t3 – 2010t2) 2010t1 to 2012t3 -9.8 (-14.1 to -5.4) 
 Non-NPS 2009t1 to 2012t3 1.1 (-0.5 to 2.8)      
 Main Problem Drug among 
non-NPS episodes 
        
  Cocaine 2009t1 to 2012t3 -3.5 (-6.2 to -0.7)      
  Cannabis 2009t1 to 2012t3 5.1 (2.7 to 7.5)      
  Other stimulants 2009t1 to 2012t3 -0.9 (-3.7 to 1.9)      
  Sedatives & Hypnotics 2009t1 to 2012t3 12.5 (7.7 to 17.5)      
  Alcohol 2009t1 to 2012t3 0.9 (-0.7 to 2.6)      
  Opioids 2009t1 to 2012t3 -0.6 (-2.6 to 1.5)      
           
Incident Cases  (never treated previously)        
 NPS 2009t1 to 2010t1 310 (83-820) 2010t1 (2009t3 – 2010t2) 2010t1 to 2012t3 -15.7 (-21.1 to -6.1) 
 Non-NPS 2009t1 to 2012t3 0.0 (-1.4 to 1.4)      
 Main Problem Drug among 
non-NPS episodes 
        
  Cocaine 2009t1 to 2012t3 -4.8 (-7.1 to -2.4)      
  Cannabis 2009t1 to 2012t3 4.1 (1.6 to 6.7)      
  Other stimulants 2009t1 to 2012t3 -2.3 (-5.6 to 1.1)      
  Sedatives & Hypnotics 2009t1 to 2012t1 16.4 (10.2 to 23.0) 2012t1 (2011t3 – 2012t1) 2012t1 to 2012t3 -20.8 (-52.2 to 31.3) 
  Alcohol 2009t1 to 2012t3 -0.5 (-2.1 to 1.0)      
  Opioids 2009t1 to 2012t3 -2.4 (-4.7 to -0.2)      
           
* PCT = Estimated per cent change per third of a year from best fitting Joinpoint model  
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Figure 8.4 Joinpoint regression analysis of all non-NPS related episodes of addiction treatment 
Rates per third of year and fitted joinpoint regression lines of trends for addiction treatment episodes among people aged 18-34years, from 
first third of 2009 (‘09t1) to final third of 2012 (‘12t3) 
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Figure 8.5 Joinpoint regression analysis of all new cases of addiction treatment unrelated to NPS – Rate of incident cases. 
Rates per third of year and fitted joinpoint regression lines of trends for addiction treatment episodes among people aged 18-34years, from 
first third of 2009 (‘09t1) to final third of 2012 (‘12t3) 
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Figure 8.6 Joinpoint regression analysis of all NPS related episodes of addiction treatment 
Rates per third of year and fitted joinpoint regression lines of trends for addiction treatment episodes among people aged 18-34years, from 
first third of 2009 (‘09t1) to final third of 2012 (‘12t3) 
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Figure 8.7 Joinpoint regression analysis of all new NPS related cases attending for a first ever episode of addiction treatment – NPS incidence. 
Rates per third of year and fitted joinpoint regression lines of trends for addiction treatment episodes among people aged 18-34years, from 
first third of 2009 (‘09t1) to final third of 2012 (‘12t3) 
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Figure 8.8 Joinpoint regression analysis of rate of presentations where cannabis was main drug among episodes unrelated to NPS.  
Rates per third of year and fitted joinpoint regression lines of trends for addiction treatment episodes among people aged 18-34years, from 
first third of 2009 (‘09t1) to final third of 2012 (‘12t3) 
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Figure 8.9 Joinpoint regression analysis of rate of presentations where cocaine was main drug among episodes unrelated to NPS.  
Rates per third of year and fitted joinpoint regression lines of trends for addiction treatment episodes among people aged 18-34years, from 
first third of 2009 (‘09t1) to final third of 2012 (‘12t3) 
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8.6 Discussion 
We found that NPS-related episodes of addiction treatment in Ireland increased from 
a very low base in 2009 to peak in early 2010, when headshops were also at their 
peak. During this headshop era, from January to August 2010, one in every 24 
episodes of addiction treatment among young adults involved problematic NPS use. 
This adds to the evidence that NPS can indeed cause substance use disorders and do 
generate treatment demand. [30]. Although NPS were relatively new to the drugs 
marketplace in Ireland, they rapidly gained a substantial foothold among young 
people, being second only in popularity to cannabis.[28] If it was easy access via an 
extensive network of headshops which was contributing to the their popularity, it 
seems possible that the rate of treatment attending NPS related substance use 
disorders would have climbed higher in time.  
The rate of attendance did not simply plateau following the headshop closures. It 
declined progressively by almost 50% over the two years after the termination of legal 
sale of NPS, and declined more acutely among young people who had never sought 
drug addiction treatment previously. The onset of the decline in NPS-related cases 
coincided with legislative changes which targeted NPS and which resulted in mass 
closure of headshops.  
While a NPS was the main problem drug in 39% of NPS related attendances in 2010, 
this proportion fell to 16% in 2012. This indicates that problematic NPS use did 
continue to feature in treatment episodes following the headshop closures, but it was 
more likely to be a peripheral problem in those later cases. This mirrors the findings 
previously reported for adolescents attending addiction treatment.[26] 
The examination of data on episodes of drug treatment which were unrelated to NPS 
indicates that the changes in trend of NPS episodes were not reflective of some 
general change in treatment seeking or treatment availability during the study period. 
We found no evidence of any adverse effect of the headshop closures on addiction 
treatment episodes linked to other specific substances. However, given the relatively 
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low rate of NPS related episodes compared to rates associated with other drugs, we 
think it unlikely that this analysis would have the ability to detect a substantial move 
of would-be NPS users to other drug categories. 
 
Strengths of this study include the use of a national dataset involving a large number 
of treatment episodes and the ability to simultaneously explore for changes in non-
NPS related treatment episodes. Limitations include the fact that there was no unique 
patient identifier, so an episode of treatment attendance is used as the unit of analysis 
and no adjustment could be made for possible multiple attendances by the same 
person. A separate analysis was conducted, however, for cases on their first treatment 
episode, these therefore being unique individuals. The patterns to emerge from that 
subset were similar to the full sample. Coverage of the NDTRS is over 70% of services 
but it is not possible to fully ascertain what effect or bias the exclusion of the data of 
the non-participating services may have had on the results.  However there were no 
NPS-specific services in Ireland at the time and service participation did not alter over 
the study period. Treatment services have finite capacity. Consequently, if there had 
been any dramatic increase in demand for overall addiction treatment it would be 
unlikely to produce an immediate increase in treatment episodes of similar 
magnitude.  
The previous Irish study of this issue involved a small sample, was specific to 
adolescents, confined to just one treatment site in one city and examined change over 
only a one year period.[26] That study found a very substantial fall in NPS-related 
cases following the headshop closures and found a decline in problem severity where 
NPS use did persist.  This study indicates that these changes generalise to adults aged 
18-34 years across the country and importantly, that they were sustained over a two 
year period at least. While the impact of legislation on the entire group of NPS has not 
been examined in other countries, there are many other examples of declines in use 
and harms following legislative bans of specific NPS.[22-25] For legal drugs such as 
alcohol and tobacco, it is generally accepted that curtailing availability is an effective 
strategy to reduce harm.[31,32]  Recent Australian research indicates that many young 
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people interpret legal sale as an indication of safety and report increased willingness 
to use NPS in that scenario. [33] 
Our findings are consistent with a hypothesis that the legislation and consequent 
closure of the headshops contributed to a reduction in NPS-related substance use 
disorders in Ireland. However, there are alternative possible explanations for the 
observations and the study design does not exclude the possibility that the observed 
change is simply a coincidence. It has been suggested that criminalization of drug use 
may cause people with dependence to be reluctant to access treatment.[34] Secondly, 
the substantial adverse publicity which NPS generated in Ireland during 2010 may 
have contributed to a peak in referrals, more vigilant screening for NPS use disorders 
among people accessing treatment and also to a preventative impact upon 
subsequent use in the general population. Patterns of drug use tend to fluctuate over 
time, whether legislative changes occur or not.[35] Escalating youth unemployment, 
which occurred over the period of this study, is an example of a contextual factor 
which can contribute to increases in drug problems.[36] Such societal changes 
complicate interpretation of our findings. If the decline in NPS-related presentations 
was indeed related to the closure of the headshops, this impact may not generalise to 
other countries where supply of NPS is primarily via the internet.  
While the addition of many NPS to the Misuse of Drugs Act in May 2010 was 
associated with closure of many headshops, it was the Criminal Justice (Psychoactive 
Substances) Act which effectively ended the sale of NPS by headshops. This Act was 
innovative and controversial[8]. It sought to catch all current and future NPS, it 
aspired to end the ‘cat and mouse game’ being played out between legislators and the 
chemists designing NPS. Other countries in Europe have enacted similar legislation in 
recent years.[2,8] While legislation in New Zealand indicates a willingness in principal 
to regulate sale and supply of NPS, implementing this in practice has proven complex 
and the current regime appears to have resulted in de facto prohibition. [2,8] 
Whatever their legislative response, we hope that other countries will evaluate the 
impact of legislative changes on NPS related harms, as drawing general conclusions 
from the experience of individual countries has proving both divisive and problematic. 
[37]  
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The substantial and progressive decline in addiction treatment episodes linked to NPS 
in the two years after the enactment of legislation which targeted NPS and the 
headshops selling them is a very positive development from a public health 
perspective. While policy responses based on prohibition type principals appear to 
have fallen out of favour globally in the past decade, the experience of Ireland’s 
response to NPS suggest that such polices remain a legitimate component of society’s 
response to this complex and ever-changing challenge.  
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9.1 Context of this chapter within overall Thesis 
This final study builds upon the two previous studies in Chapters 7 & 8, to examine another 
aspect of potential NPS related harm. It returns to the harm examined in the OST study in 
chapter 6, this being mental health. Like the study in the previous chapter, this study makes 
use of a national database and focuses again on young adults. Given the evidence that NPS 
certainly have the potential to precipitate and exacerbate acute mental health problems, this 
study seeks to determine if there was any detected change in the trend of drug related 
psychiatric admissions in Ireland coinciding with the arrival and departure of head shops.  
 
9.2 Abstract  
Background: New psychoactive substance (NPS) use can cause or exacerbate acute 
psychiatric disorders. These may result in drug related psychiatric admissions (DRPA). 
In Ireland, there was a rapid expansion in the number of head shops selling NPS in 
early 2010. Young adults, especially young males, demonstrated high rates of NPS use. 
Government responded to public protests regarding the head shops by enacting 
legislation in May and August 2010 to end this trade. We sought to determine if 
changes in head shop activity coincided with changes in the rate of DRPA. 
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Methods: The national database on psychiatric admissions was examined. Eighteen to 
34 year-olds admitted from 2008-2012 were included. There is no method of 
identifying NPS related DRPA specifically. The head shop era was taken as January to 
August 2010 inclusive. We compared the monthly rate of DRPA during this period to 
the same months in each of the other years. Joinpoint regression analysis was also 
utilised to examine for the presence of changes in trend of DRPA. 
Results: There were 3670 DRPA over this 60-month period, 12% of all admissions. The 
median monthly rate/100,000 of DRPA was 6.1 in 2010 during the head shop era and 
this was significantly higher than the rates in 2008 (4.8, p=0.003), 2009 (5.0, p=0.005) 
and 2012 (5.0, p=0.003). The rate was 5.7 (p=0.065) in 2011. Joinpoint regression 
identified a significant downward trend change which occurred in July 2010 (95% CI 
Feb 2010 to April 2011). Young males aged 18 to 24 years showed evidence of greatest 
change in DRPA, a trend of rising admissions changing to one of declining admissions 
in May 2010 (95% CI Feb 2010 to October 2010). After May 2010, the model estimated 
a decline in DRPA of 1.4% per month (95% CI 0.7 to 3.7% decline) among those young 
males. 
Conclusions: The expansion of a network of head shops selling NPS coincided with an 
increase in the overall rate of DRPA. The cessation of NPS sale by head shops 
coincided with a reversal in this upward trend. Causality cannot be determined. The 
changes in DRPA were most evident in very young men. 
 
9.3  Introduction  
New psychoactive substances (NPS) are a source of international concern, being 
associated with a range of addiction, medical and mental health problems.[1,2] The 
arrival of NPS, and the head shops selling them, has prompted substantial debate 
among policy makers.[3-6] Some countries have enacted novel legislative approaches 
in the hope of reducing NPS-related harms across the population.[1] Ireland passed 
the Criminal Justice (Psychoactive Substances) Act in August 2010 in response to 
widespread public protest at the vast number of head shops selling NPS which had 
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opened across the country in the preceding months.[7] This legislation successfully 
targeted the high-street businesses selling NPS. It provoked considerable criticism 
from experts in the fields of sociology and drugs policy.[3] Some predicted that 
prohibition styled legislative responses would increase harms.[8]  
There is some data from Ireland indicating that addiction treatment episodes related 
to NPS use escalated very rapidly in the first months of 2010 and then declined in the 
two years after the closure of head shops.[9,10] NPS such as synthetic cannabinoids 
and cathinones appear to have a particular propensity to provoke or exacerbate 
psychiatric symptoms and this may result in hospitalization.[1,11-13] Lally et al 
conducted a survey of adults attending mental health services in Ireland when the 
head shops were at their peak level of activity and found that 24% of inpatients 
reported use of NPS in the past year, rates of use being highest in young males.[14] 
If the expansion and subsequent abrupt closure of head shops was genuinely 
associated with changes in NPS use and related harms, it is possible that this may have 
manifested itself in changes to acute psychiatric presentations linked to NPS. If these 
events were sufficiently numerous, it seems possible that they may have had a 
detectible impact on the overall rate of drug related psychiatric admissions (DRPA). In 
this study, we sought to examine this possibility by exploring rates of DRPA in Ireland 
prior to, during and after the era of widespread head shop expansion.  
 
9.4 Method  
9.4.1 Setting & Context 
In Ireland the usual route to mental health services is by referral from primary care or 
the emergency department and most patients are treated on an outpatient basis. 
There are about 20,000 psychiatric inpatient admissions per annum, with 90% of these 
being voluntary. The decision to admit is largely based upon clinical severity and this is 
determined by doctors trained in psychiatry. Around 2010, there was a significant 
increase in the number of psychiatric beds available for people aged under 18 years 
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and there have been determined efforts to avoid admitting children into adult 
psychiatric hospitals. 
In recent decades Irish mental health services have altered their approach to addiction 
related presentations. In the latter part of the 20th century, alcohol dependence was a 
frequent reason for admission into psychiatric hospitals in Ireland, accounting for 
about 20% of all admissions.[15] At that time, a person could be involuntarily detained 
and treated in a psychiatric hospital for the treatment of addiction. In 2006, Ireland’s 
mental health policy document, ‘A Vision for Change’, stated that "the major 
responsibility for care of people with addiction lies outside the mental health system". 
That same year, a revised Mental Health Act was implemented and this removed 
addiction as a reason for involuntary admission (i.e. ‘sectioning’ a patient). The rate of 
alcohol related psychiatric admissions declined by two-thirds from 1990 to 
2006.[16,17]  
Ireland underwent significant social changes over the period 2008-2012, the economy 
entering into a recession after a decade of sustained growth. Youth unemployment 
increased rapidly and a pattern of immigration quickly turned into a period of 
emigration. The youth unemployment rate increased dramatically from 10% in January 
2008 to 27% in January 2010, and then peaked at 31% in January 2012, before falling 
back slightly to 28% in January 2013.  
The Irish general population survey of 2010-11 found that past year prevalence of 
cannabis use was 10% among 15-34 year olds, and this was unchanged since the 2006-
07 survey. [18] The past year prevalence of NPS, cocaine and amphetamines in this 
age range were 7%, 3% and 1% respectively. Past year NPS use was only 1% in people 
aged over 34 years. Young males were three times more likely than young females to 
have used NPS in the past year. 
9.4.2 Head shops 
Over the period from 2009 to 2010, there was a substantial increase in the number of 
head shops in Ireland peaking at 102 premises in May 2010, which is about one shop 
per 45,000 people.[7,10,19] This constituted a five-fold increase in the number of 
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head shops in existence in 2008. In response to public protests surrounding these new 
businesses which began selling a wide range of NPS in late 2009, the Irish government 
opted to proceed with a two-pronged legislative approach. Firstly, there was a 
legislative ban, adding over 100 substances to the pre-existing Misuse of Drugs Act in 
May 2010.[20] This made possession, sale and supply of the named drugs a criminal 
offence. While this Act coincided with closure of many head shops, it seems likely that 
it contributed to the prompt arrival of non-banned substances such as naphyrone and 
flourotropococaine which were then implicated in further DRPA.[7,21] This 
phenomenon of head shops simply switching from a banned drug to a drug not yet 
banned has been seen in many countries.[22]  
In the hope of ending this game of ‘cat and mouse’, the controversial Criminal Justice 
(Psychoactive Substances) Act was enacted in late August 2010.[23] This Act was 
focused primarily at vendors of NPS. It states that ‘a person who sells a psychoactive 
substance knowing or being reckless as to whether that substance is being acquired or 
supplied for human consumption shall be guilty of an offence’.  
These two Acts resulted in a dramatic decline in the number of head shops, initially to 
48 shops in June 2010, and then falling to 10 shops by October 2010.[10] Undercover 
investigations by the Irish police force indicated that those few shops which remained 
open after September 2010 were no longer selling NPS. Based upon the changes in the 
known number of head shops and the evidence that NPS related addiction treatment 
episodes escalated greatly at the start of 2010, we view the months from January 
2010 to August 2010 as the ‘head shop era’ in Ireland.[9,10] 
 
9.4.3 Measures  
Basic clinical information on all admissions is completed by the treating team 
following a psychiatric admission. At discharge the clinical team determine the 
primary diagnosis, and any additional diagnoses, which led to the admission. Diagnosis 
is determined using ICD-10 criteria. These data, along with demographic information, 
are sent to Ireland’s Health Research Board (HRB) for entry into the National 
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Psychiatric In-Patient Reporting System (NPIRS) database.  For the purposes of this 
study, hospitalisations were defined as being a drug-related psychiatric admission 
(DRPA) if either the primary or any secondary discharge diagnosis was in the F11 to 
F19 ICD-10 diagnostic categories.  
Every psychiatric inpatient unit in the Republic Of Ireland participates in NPIRS. There 
were no changes to NPIRS during the study period. An audit of the NPIRS database 
took place in 2012. This audit returned an accuracy rate for the data of 97.8% (2.2% 
discrepancy rate) with the majority of fields exceeding a 99% accuracy rate. All fields 
were within acceptable levels of completeness. Both the accuracy and completeness 
rate were within the benchmark set for the audit of 95% (5% discrepancy rate). 
 
9.4.4 Participants. Inclusion and exclusion criteria 
We examined all psychiatric admissions of people aged between 18 years and 34 years 
inclusive in the Republic of Ireland over the five years from 2008 to 2012. We excluded 
people under the age of 18 years in view of the policy changes regarding psychiatric 
admissions among this age range over the period in question. We opted to focus upon 
adults under 35 years of age as it was this age range which demonstrated the highest 
rates of NPS use in both general population and mental health service user 
studies.[14,18] Therefore, if the arrival and departure of the head shops resulted in 
changes in psychiatric events linked to NPS use, it was in this age range that change 
should be most evident. There is no unique patient identifier in Ireland. Therefore, the 
unit of analysis was episode of admission, not individual patient. Ethical approval was 
provided by the research ethics committee of the National Drug Treatment Centre. 
For data protection reasons, cell values of less than 5 episodes are not reported.  
 
9.4.5 Statistics 
In order to contrast proportions, such as the characteristics of DRPA and admissions 
unrelated to drug use, we utilised the chi square test. We also reported odds ratios 
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and estimates of the 95% confidence intervals of the odds ratio to indicate the 
direction and magnitude of differences. These are estimates of the confidence 
intervals as the episodes are not completely independent. An unknown proportion of 
episodes involve re-admission of some individuals on more than one occasion during 
the five year period.  
We calculated the crude rate of admissions per month among people aged 18-34 
years. Rates are reported per 100,000. The population at risk was obtained from the 
population estimates provided by the Central Statistics Office. In view of the age and 
gender differences in NPS use in the general population samples and in NPS related 
addiction treatment episodes, we examined the rates by gender and age group (18-24 
years and 25-34 years).[10,18] 
In order to contrast DRPA during the head shop era with the period before and after 
the head shops, we focused upon the months January to August inclusive in each year 
to ensure seasonal factors would not confound the results. We used the Mann 
Whitney U test to compare the monthly rates of DRPA during this period of 2010 
against those of the other four years. 
Finally, we used the Joinpoint Regression Program, version 4.3.1.0 (National Cancer 
Institute, Bethesda, Maryland, USA, http://surveilance.cancer.gov/joinpoint) to 
further examine trends in the rate of admissions. Joinpoint regression is a log-linear 
model which uses Poisson regression, creating a Monte Carlo permutation test to 
identify points where the trend line changes significantly in magnitude or 
direction.[24] Although initially developed for use in examining changes in cancer 
trends, it has been widely used to examine trends in rates of other disorders, including 
psychiatric conditions.[25,26] The location of the joinpoints is data driven. Analysis 
starts by fitting a straight line (i.e. zero joinpoints) and tests whether the addition of 
one or more joinpoints yields a statistically significant improvement in fit. The 
estimated percentage change per month (PCM) is calculated for each best fitting line 
segment between joinpoints, along with 95% confidence intervals of the PCM. The 
minimum number of observations from a joinpoint to either end of the data and the 
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minimum number of observations between two joinpoints were set at three and four 
respectively (these being the default settings).  
 
9.5 Results. 
9.5.1 Characteristics of DRPA 
There were 30647 psychiatric admissions of young adults over the course of this study, 
and 12.0% of these were DRPA. The characteristics of these admissions are outlined in 
Table 9.1, along with a comparison between DRPA and the non-drug related 
admissions. Admission for drug related reasons was associated with male gender, 
younger age, unstable accommodation, being single or divorced and less skilled work. 
DRPA were more likely to be voluntary, a first admission and in a public hospital. In 
2010, 13.6% of all admissions were DRPA and this was a significantly greater 
proportion than that observed in any other individual year. 
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Table 9.1 Characteristics of 30647 admissions to psychiatric hospitals from 2008-2012 by 
people aged 18-34 years, by drug related admission. 
  Total Drug Related Non-Drug Related ORa 95% CI 
OR 
p 
value   N (%) N (%) N (%)  
           
Total 30647 (100) 3670 (12.0) 26977 (88.0)    
           
Gender          
 Male 17152 (56.0) 2799 (76.3) 14353 (53.2) 2.8 (2.6-3.1) <0.001 
 Female 13495 (44.0) 871 (23.7) 12624 (46.8) 1.0   
Age          
 Under 25years 10568 (34.5) 1546 (42.1) 9022 (33.4) 1.4 (1.3-1.5) <0.001 
 25-34 years 20079 (65.5) 2124 (57.9) 17955 (66.6) 1.0   
           
Accommodation          
 No Fixed Abode 453 (1.5) 121 (3.3) 332 (1.2) 2.7 (2.2-3.4) <0.001 
 Has accommodation 30194 (98.5) 3549 (96.7) 26645 (98.8) 1.0   
           
Marital Status          
 Married 2425 (7.9) 137 (3.7) 2288 (8.5) 1.0   
 Single 26177 (85.4) 3320 (90.5) 22857 (84.7) 2.4 (2.0-2.9) <0.001 
 Widowed 36 (0.1) <5 (0.1) 34 (0.1) 1.0  0.98 
 Divorced 117 (0.4) 12 (0.3) 105 (0.4) 1.9 (1.0-3.7) 0.04 
 Unspecified 1892 (6.2) 199 (5.4) 1693 (6.3)    
           
Socio-Economic Group          
 Professional, 
Employer 3212 (10.5) 171 (4.7) 3041 (11.3) 
1.0   
 Agricultural sector 321 (1.0) 11 (0.3) 310 (1.1) 0.6 (0.3-1.2) 0.14 
 Non-Manual 4481 (14.6) 358 (9.8) 4123 (15.3) 1.5 (1.3-1.9) <0.001 
 Skilled/semi-skilled 4080 (13.3) 573 (15.6) 3507 (13.0) 2.9 (2.4-3.5) <0.001 
 unskilled 1934 (6.3) 284 (7.7) 1650 (6.1) 3.1 (2.5-3.7) <0.001 
 unspecified 16619 (54.2) 2273 (61.9) 14346 (53.2)    
           
Voluntary Admission          
 Voluntary 27731 (90.5) 3400 (92.6) 24331 (90.2) 1.0   
 Involuntary 
(‘sectioned’) 2916 (9.5) 270 (7.4) 2646 (9.8) 
0.7 (0.6-0.8) <0.001 
           
Previous admission          
 First Admission 11681 (38.1) 1533 (41.8) 10148 (37.6) 1.2 (1.1-1.3) <0.001 
 Readmission 18966 (61.9) 2137 (58.2) 16829 (62.4) 1.0   
           
Hospital Type          
 Public hospitals 25726 (83.9) 3256 (88.7) 22470 (83.3) 1.6 (1.4-1.8) <0.001 
 Private hospitals 4921 (16.1) 414 (11.3) 4507 (16.7) 1.0   
           
Admission Year          
 2008    6,524  (21.3) 669 (18.2) 5,855  (21.7) 0.7 (0.6-0.8) <0.001 
 2009 6268 (20.5) 713 (19.4) 5555 (20.6) 0.8 (0.7-0.9) <0.001 
 2010 6316 (20.6) 857 (23.4) 5459 (20.2) 1.0   
 2011 5927 (19.3) 729 (19.9) 5198 (19.3) 0.9 (0.8-1.0) 0.04 
 2012 5612 (18.3) 702 (19.1) 4910 (18.2) 0.9 (0.8-1.0) 0.04 
           
a 
OR = Odds ratio 
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Table 9.2 outlines the drugs involved in the DRPA. The most common drug category 
was F19 which indicates multiple drugs or drugs other than the typical substance 
groups. The most frequently encountered specific drug category contributing to DRPA 
was cannabinoids (F12). While the exact type of psychiatric disorder was unspecified 
in 44.4% of cases, the most common types specified were acute intoxication, 
psychotic disorder and dependence.  
 
Table 9.2 Characteristics of 3670 drug related psychiatric admissions among 18-34yo, 2008-12 
   Number (%)  
      
 Type of Drug Related Admission    
  1o Diagnosis is F11-19 2875 (78.3)  
  2o diagnosis, but not 1o diagnosis,  is F11-19 795 (21.7)  
      
 Specific Primary Drug related diagnosis    
  F11 - Opioids 227 (7.9)  
  F12 - Cannabinoids 368 (12.8)  
  F13 - Sedatives 72 (2.5)  
  F14 - Cocaine 46 (1.6)  
  F15 - Other stimulants 30 (1.0)  
  F16 - Hallucinogens 19 (0.7)  
  F17 - Tobacco <5 (0.0)  
  F18 - Volatile Substances 6 (0.2)  
  F19 - Multiple drug use or Other drugs 2106 (73.3)  
      
 Primary Drug related disorder type    
  F1x - clinical condition not specified 1277 (44.4)  
  F1x.0 - Acute intoxication 444 (15.4)  
  F1x.1 - harmful use 209 (7.3)  
  F1x.2 - Dependence 402 (14.0)  
  F1x.3 - Withdrawal state 36 (1.3)  
  F1x.4 - Withdrawal state with delirium 10 (0.3)  
  F1x.5 - Psychotic Disorder 443 (15.4)  
  F1x.6 - Amnesic syndrome 8 (0.3)  
  F1x.7 - Residual psychotic disorder 9 (0.3)  
  F1x.8 - Other mental disorder 28 (1.0)  
  F1x.9 - unspecified mental disorder 9 (0.3)  
      
 Non-drug related primary diagnosis for admissions with drug 
related secondary diagnosis   
 
  F10 : Alcohol related disorders 210 (26.4)  
  F20-29 : Schizophrenia, schizotypal, delusional disorders  184 (23.1)  
  F30-39 : Mood (affective) disorder 219 (27.5)  
  F40-49 : Neurotic, stress-related & somatoform disorders 55 (6.9)  
  F60-69 : Disorders of adult personality and behaviour 113 (14.2)  
  F00-09, 50-59, 70-99 : Other disorders 14 (1.8)  
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9.5.2 Comparison between the head shop era and other years 
Table 9.3 contrasts the crude monthly rates of DRPA over the eight month head shop 
era with the same months in the other four individual years. It indicates that the rates 
of admission in 2010 were significantly higher than in 2008, 2009 and 2012. The actual 
crude rates of DRPA per 100,000 during this eight month period for each of the years 
from 2008 to 2012 are 38.2, 40.1, 48.4, 44.2 and 41.9 respectively. The increase from 
2008 to 2010 was 27% and the decrease from 2010 to 2012 was 13%. 
 
Table 9.3. Rates of drug related psychiatric admissions per month among 18-34 year olds, 
comparing the head shop era of January to August 2010 with the same period in other years. 
  Year Monthly rate/100,000  Comparison with 2010   
   Median (IQR)  p value  
        
  2008 4.8  (3.9 to 5.7)  0.003  
  2009 5.0 (4.4 to 5.6)  0.005  
  2010 6.1 (5.6 to 6.6)  N/A  
  2011 5.7 (4.9 to 6.0)  0.065  
  2012 5.0 (4.9 to 5.8)  0.003  
        
        
 
9.5.3 Joinpoint trend analysis  
Table 9.4 and Figures 9.1 to 9.3 present the results of the Joinpoint trend analysis. This 
analysis found no evidence of a trend change in the rate of all psychiatric admissions 
in this age range and the overall trend was not significantly different from zero (Figure 
9.1, p=0.25). For DRPA, the best fitting joinpoint model indicated a trend change in 
July 2010 (Figure 2). Over the 30 months prior to this, the rate of DRPA was increasing 
significantly by 1.0% per month (p=0.002). Then in July 2010, this trend of increasing 
DRPA turned downwards. The downward slope after July 2010 was not significantly 
different from zero (p=0.14). Analysis of the female subgroups and the older male 
subgroup revealed no significant trend changes (i.e. zero joinpoints). Analysis of the 
young adult males revealed two trend changes, the first occurring in January 2010 
when there was a substantial increase in the rate of DRPA (Figure 9.3). This was then 
followed four months later by a downward turn in the rate in May 2010 until the end 
of the study period. This decline of 1.4% per month after May 2010 was significantly 
different from zero (p<0.001).    
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Table 9.4. Trends in crude rates of psychiatric admissions per month among people aged 18-34 years between 2008 and 2012. 
 Period PCM
a
 (95% CI 
PCM)
b
 
First 
Joinpoint 
(95% CI of 
Joinpoint) 
Period 2 PCM (95% CI 
PCM) 
Second 
Joinpoint 
(95% CI of 
Joinpoint) 
Period 3 PCM (95% CI 
PCM) 
              
All admissions Jan 08 to 
Dec 12 
 
-0.1 (-0.2, 
0.0) 
          
 DRPA
 c
 Jan 08 to 
Jul 10 
1.0 (0.4,  
1.6) 
Jul 10 (Feb 10, 
Apr 11) 
Jul 10 to 
Dec 12 
-0.5 (-1.1, 
0.2) 
     
               
 DRPA              
  18-24 yo 
Males  
 
Jan 08 to 
Jan 10 
0.8 (-0.5, 
2.1) 
Jan 10 (Nov 08, 
Apr 10) 
Jan 10 to 
May 10 
12.8 (-15.6, 
50.8) 
May 10 (Feb 10, 
Oct 10) 
May 10 
to Dec 12 
-1.4 (-0.7, -
3.7) 
  18-24 yo 
Females  
 
Jan 08 to 
Dec 12 
0.4 (-0.3, 
1.0) 
          
  25-34 yo 
Males  
 
Jan 08 to 
Dec 12 
0.0 (-0.3, 
0.3) 
          
  25-34 yo 
Females  
Jan 08 to 
Dec 12 
0.3 (-0.3, 
0.8) 
          
                
a
 PCM = Estimated per cent change per month for this segment from the best fitting Joinpoint model  
b
 CI = confidence interval 
c
 DRPA = Drug related psychiatric admission 
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Figure 9.1. Monthly rate of psychiatric admissions for all diagnoses among 18 to 34 year olds, and trend line from the joinpoint analysis indicating the best fitting 
model. 
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Figure 9.2. Monthly rate of DRPA among 18 to 34 year olds, and trend line from the joinpoint analysis indicating the best fitting model. 
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Figure 9.3. Monthly rate of DRPA among 18 to 24 year old males, and trend line from the joinpoint analysis indicating the best fitting model. 
199 
 
9.6 Discussion. 
9.6.1 Changes in DRPA 
We found that the rate of DRPA was significantly higher in 2010 during the head shop 
era than it was over the same months in the years before the major head shop 
expansion and also significantly higher than in 2012. The joinpoint trend analysis 
indicates that the pattern of escalating DRPA reversed and the best estimate of the 
turning point is July 2010, two months after the initial legislation beginning the head 
shop closures. These changes cannot be explained by alterations in the rate of overall 
psychiatric admissions among young adults in Ireland over the period 2008 to 2012 as 
these were static. 
The most enthusiastic users of NPS in Ireland in 2010 were young males, who reported 
a rate of past year NPS use of 9.7%. This was approaching that of cannabis and vastly 
exceeded that of other ‘traditional’ drugs such as cocaine or ecstasy.[18] The study of 
Irish mental health service users also found the highest rates of NPS use among young 
males.[14] It was this subgroup of the population which also showed the most change 
in DRPA over this study period. The onset of the head shop era in January 2010 
coincided with a dramatic increase in the rate of such admissions. The trend then 
reversed early in the summer of 2010, the best fitting joinpoint being May 2010, which 
coincides with the month in which the head shops began closing following the changes 
to the Misuse of Drugs Act. These changes in DRPA closely mirror the observed 
changes in NPS related addiction treatment episodes in Ireland which peaked in the 
first third of 2010 and then fell progressively by 48% over the following two years.[10] 
NPS related addiction treatment episodes also declined in adolescents.[9] The general 
population survey of 2014-15 also confirms that NPS use among young males reduced 
greatly, with past year use falling by four-fifths to 1.9%.[27,28] These changes along 
with those reported in this study are all pointing in the one direction. 
 
9.6.2 Critics of prohibition styled policy towards NPS 
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In a review of stakeholders’ views in Ireland following the Government action on NPS, 
it was concluded that the legislative changes were driven by a “moral panic” and 
constituted “a clear victory for traditional ‘war on drugs’ values”.[3] Our finding of 
increased DRPA, along with the previous findings confirming high rates of NPS use by 
Irish psychiatric inpatients and increased NPS related addiction episodes, adds support 
to the view that Government action was preceded by evidence of real harms. This 
suggests that the early criticisms were probably excessive and premature.  
The frequent role of NPS in psychiatric admissions has been described both in Ireland 
and elsewhere in the intervening years.[13,21]  The study by Lally et al of mental 
health service users coincided with the peak in head shop activity. One third of the 
patients reporting NPS use denied use of illegal drugs.[14] Most of those who did 
report past use of illegal drugs indicated that NPS use was now supplemented on top 
of that use which continued unchanged. Both findings suggest that the arrival of NPS 
was adding to the overall burden of drug use and not simply displacing use of 
traditional drugs.  
The UK has recently proceeded with its own version of the Psychoactive Substances 
Act, along with some other European countries.[1,6] In contrast to the UK, the 
equivalent Irish legislation was enacted with little or no warning and minimal 
consultation. In common with the Irish Act, the UK legislation has been greeted with 
criticisms from drug policy experts.[5,6] 
Included among the criticisms, there were predictions that closure of the head shops 
would result simply in an immediate and effective migration of the NPS market to 
drug dealers and to the internet, with possible increased attendant risks.[8] Although 
there was clearly some movement of supply towards the black market, the evidence 
from this or other Irish studies does not support the pessimistic view that problems 
would persist unchanged or possibly deteriorate.[9,10,28] Following the head shop 
closures, the increasing rate of DRPA abruptly halted and began to decline. The simple 
comparison of the overall monthly rates indicates that they were significantly lower in 
2012 compared to 2010, reverting back towards the rates seen in 2008 when the few 
existing head shops were not selling NPS. In the demographic group with the highest 
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rate of DRPA, young males, this decline was sustained and significant based upon the 
joinpoint analysis.  
 
9.6.3 Impact of legislative bans elsewhere 
In other countries which have proceeded down the route of legislative bans, there is a 
growing body of evidence for an impact on reducing NPS use and related harms. Of 
greatest specific relevance to our study, it was found in New Zealand that emergency 
psychiatric presentations linked to use of synthetic cannabinoids declined by 42% 
following legislation and there was also a sustained decline in general hospital 
admissions related to these drugs.[29,30] Also in New Zealand, use of BZP in a general 
population sample declined substantially following a ban of that drug.[31] In Scotland, 
a temporary class drug order on ethylphenidate was effective in reducing infections 
among people who inject drugs.[32] There was a reduction in attendances linked to 
mephedrone at emergency departments in the UK following the ban of that drug.[33] 
Stogner et al reported a decline in use by young adults of Salvia divinorum following a 
legislative ban in Florida.[34] Our findings appear to be the first which suggest a more 
general impact across a broad health related measure, as opposed to the drug specific 
changes highlighted here. 
 
9.6.4 Impact on services 
In spite of the policy changes on management of addiction issues by Irish mental 
health services in the years immediately preceding this study, DRPA continued to 
account for one in every eight admissions in this age range. This was the primary 
diagnosis in 78% of such admissions. Therefore changes to DRPA are not simply of 
academic interest. They impact substantially on the workload of adult mental health 
services.[13] DRPA were more likely to involve younger males, mirroring the higher 
prevalence of drug use in that demographic.[18] The analysis sheds very little light on 
the type of drugs involved in these admissions, most being coded as F19, indicating 
polydrug use or use of an individual substance which fell outside the specific 
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substance categories noted in ICD-10. Polydrug use is common among youth drug 
users in particular.[9, 35] 
We know from data on addiction treatment episodes, mental health services and from 
drug user surveys that the most widely used NPS during this period in Ireland were 
synthetic cannabinoids and cathinone type substances.[9,10,14,19] Depending on the 
knowledge of both patient and doctor, a presentation linked to NPS could have been 
coded as F12, F15, F16 or F19. Consequently it was not possible to explore changes in 
NPS related psychiatric admissions specifically. Future iterations of the ICD diagnostic 
system may need to consider increasing the number of substances specified with a 
unique code to permit easier examination of trends relating to individual drugs or drug 
classes.  
There is some evidence to indicate that NPS have a greater propensity to cause 
adverse psychiatric symptoms when compared to the more established drugs which 
they mimic such as cannabis or amphetamines,[11,12,28] Common mental health 
symptoms in people who use NPS include anxiety, paranoia and occasionally, 
psychosis.[2,14,21,28] 
 
9.6.5 Strengths and limitations 
Our inability to examine NPS related psychiatric admissions specifically could be 
viewed as a weakness of this study. However, from a public health perspective, the 
impact of the arrival and departure of the head shops on all DRPA is of most interest in 
any case. Simple drug policy measures can have unintended and adverse 
consequences.[36] In theory, increased NPS use may have diverted young people 
away from more psychotogenic substances. Similarly, reductions in NPS use due to 
curtailed access following head shop closures could theoretically cause users to return 
to other traditional but more dangerous substances. Consequently, we view the 
examination of the entire group of DRPA to be a feature which adds to the importance 
of these findings. 
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Overall, this study reveals a strong temporal relationship between the timing of the 
expansion and extinction of the sale of NPS by head shops with increases and then 
decreases in DRPA. This does not confirm causality. It is possible that some other 
unmeasured factor contributed to changes in DRPA. If the trends in DRPA are indeed 
related to NPS, there are factors other than legislation and head shop availability that 
may have lead to a decline in use. Patterns of drug use tend to wax and wane over 
time.[37] There was widespread media coverage of adverse effects of NPS use and 
health service education campaigns on this topic.[3] These may also have lead to 
reduced use and harms. It is also possible that the media attention around NPS at this 
time caused psychiatrists to be more likely to attribute psychiatric symptoms to drug 
use during this period. Although both pieces of legislation in Ireland occurred with 
minimal advance warning, it is possible that they caused short term changes in retailer 
or purchaser behaviour resulting in acute increases in sales and related harms.  Ideally 
in epidemiological studies, one hopes that they occur over a period of social stability. 
This was not the case in Ireland which entered a major recession during these years. 
Rising youth unemployment may certainly have contributed to increased DRPA.[37] 
However, it cannot explain the downward turn in DRPA seen after 2010, as youth 
unemployment remained above those 2010 levels over the next two years. 
Use of a national database with complete coverage of all psychiatric inpatient units 
constitutes a strength of this study. The absence of a unique patient identifier in 
Ireland represents a weakness. An unknown number of admissions comprised 
readmissions by the same individual during the five year study period. Data is not 
systematically gathered on outpatient attendances at mental health services in 
Ireland. Consequently, this study is confined to the small minority of patients with 
drug related psychiatric disorders who were admitted. This fact reduced our power to 
detect significant changes in such disorders.  
 
9.6.6 Conclusions 
Our findings indicate that the situation regarding DRPA in Ireland was on a trajectory 
of deterioration prior to Government action on head shops. While accepting the 
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important caveat that correlation does not prove causation, we found that this trend 
came to an abrupt halt around the time which the head shops ceased sale of NPS. The 
rate of admissions declined over the following two years as opposed to simply 
stabilising. Taken together with the other evidence on reduced NPS use in the general 
population, reduced NPS addiction treatment episodes, our findings on DRPA lend 
weight to the view that the steps taken in Ireland to address NPS were associated with 
a positive public health impact.  
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10.1 Context of this chapter within the overall Thesis. 
This brief chapter brings together the key findings of the preceding three chapters 
which examined different aspects of harms related to NPS. The letter was prompted 
by a review paper by Reuter & Pardo, published in the highly regarded journal 
Addiction, and entitled “Can NPS be regulated effectively? An assessment of the 
British Psychoactive Substances Bill”. When reporting on the international evidence, 
this review stated:- 
Governments around the world have attempted various solutions to the NPS 
problem, with depressing results. 
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Although it acknowledged that Ireland was the “pioneer” of the type of “blanket 
prohibition” being contemplated by Britain, it reported that there was no systematic 
evaluation of its impact in Ireland. I felt that the NPS related studies included in this 
thesis could address that reported gap in the literature and challenge the view that 
the results of government action were “depressing”.  
 
10.2 Research letter 
The recent review paper on new psychoactive substances (NPS) by Reuter & Pardo 
(2017), and the subsequent commentaries, outline the multiple and complex policy 
challenges posed by this phenomenon [1]. They critique the Psychoactive Substances 
Bill , recently enacted in the UK. They are sceptical that it will have any real impact on 
demand, use and harms. They note that Ireland was the first country to proceed with 
this type of legislation, enacting the Criminal Justice (Psychoactive Substances) Act in 
late August 2010. This Act was focused primarily at vendors of NPS. It states that ‘a 
person who sells a psychoactive substance knowing or being reckless as to whether 
that substance is being acquired or supplied for human consumption shall be guilty of 
an offence’. The vast majority of the head shops in Ireland closed within weeks of its 
arrival, and the remaining head shops ceased sale of NPS. The number of head shops 
in Ireland had already dropped from their peak of May 2010, following the addition of 
over 100 NPS to the pre-existing Misuse of Drugs Act in that month. 
What is the evidence from Ireland on NPS use and harms following those 
developments? Firstly, there is now good evidence of a decline in population use of 
NPS. The National Drug Prevalence Survey occurs every 4 years. By good fortune, it 
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occurred in 2010/11, so questions on past year use overlapped with that period of 
time when head shops were active and widespread [2]. Past year use of NPS among 
15-24year olds was 9.7% and among 25-34 year olds, it was 4.6%. The survey was 
repeated in 2014/15 and the corresponding prevalence rates were 1.9% and 1.3%, 
indicating a very dramatic decline [3].  
There is also evidence of declines in NPS-related substance use disorders presenting to 
addiction treatment services. A small study at one clinic for adolescents in Dublin 
found that one in three presentations involved problematic use of NPS in early 2010 
while the head shops were open [4]. There were no cases of problematic NPS use 
during the same period one year later. The proportion of clients reporting any NPS use 
in the preceding 3 month period dropped from 82% to 28%. 
Among young adults, aged 18 to 34 years, attending addiction treatment in Ireland, 
there was also a substantial change in NPS-related presentations over this period [5]. 
They rose very steeply from early 2009 to the first third of 2010. The closure of the 
head shops coincided with the onset of a significant and steady decline in NPS related 
addiction treatment episodes over the following two years. The 12 month moving 
average rate of NPS related presentations fell by 48% from 2010 to 2012.  
The expansion of the network of head shops selling NPS coincided with an increase in 
the overall rate of drug related psychiatric admissions (DRPA) in Ireland. The cessation 
of NPS sale by head shops coincided with a reversal in this upward trend. The changes 
in DRPA were most evident in young men aged 18-24 years, these being the 
demographic with the highest prevalence of NPS use based upon the population 
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surveys mentioned above. After May 2010, the model estimated a progressive decline 
in DRPA of 1.4% per month among those young males over the following 30 months. 
Figure 10.1 seeks to collate of the findings regarding these actual and potential NPS 
related harms, and gives an indication of how they relate to the number of head shops 
and the specific legislative actions. 
Unfortunately, most of the international discussion about the experience of Ireland 
following the NPS inspired legislation has suggested that it was largely ineffective. The 
reality appears to be very different. Any suggestion that the NPS landscape was 
unchanged in Ireland following the closure of head shops seems entirely contradicted 
by the data above. Obviously causality cannot be attributed, but the pessimism seems 
misplaced. Ongoing monitoring will be required to see if the observed reductions 
during these first 2-3 years persist into the future. It would also be premature to read 
too much into the experiences of a single country. However, informed debate will 
hopefully be assisted by dissemination of accurate information. 
 
 
10.3 Author contributions 
BPS was the sole author of this letter. 
212 
 
213 
 
 
References 
1. Reuter, P., & Pardo, B. (2017). Can new psychoactive substances be regulated 
effectively? An assessment of the British Psychoactive Substances Bill. Addiction 
2017; 112: 25-31. 
2. NACD. Drug Use in Ireland and Northern Ireland 2010/2011: First Results from the 
Drug Prevalence Survey. Dublin: National Advisory Committee on Drugs 2011. 
Available at: 
http://www.nacda.ie/images/stories/docs/publicationa/drug_use_ireland.pdf 
(accessed 8 March 2017) (archived by WebCite® at  
http://www.webcitation.org/6ooQXDwMx ) 
3. NACDA. Prevalence of drug use and gambling in Ireland and drug use in Northern 
Ireland. Dublin; November 2016. National Advisory Committee on Drugs & Alcohol. 
Available at:  
http://www.nacda.ie/images/stories/docs/publicationa/2016druggamble.pdf  
(accessed  8 March 2017) ((archived by WebCite® at  
http://www.webcitation.org/6ooQhvwTQ ) 
4. Smyth B.P., James P., Cullen W., Darker C.  "So prohibition can work?" Changes in 
use of novel psychoactive substances among adolescents attending a drug and alcohol 
treatment service following a legislative ban. Int J Drugs Pol 2015; 26: 887-889. 
5. Smyth B.P., Lyons S., Cullen W.  Decline in new psychoactive substance use 
disorders following legislation targeting headshops: evidence from national addiction 
treatment data. Drug Alc Rev 2017, in press. DOI: 10.1111/dar.12527 
214 
 
Chapter 11 
Discussion & Conclusions 
11.1 Objectives 
This thesis sought to examine strategies which strive to tackle a range of harms that 
can arise for youth who use psychoactive substances. It explored the impact of 
treatment on individuals with substance use disorders, seeking to determine if there 
were reductions in substance use and improvements in mental health. Secondly, it 
sought to identify evidence which might point towards a positive public health impact 
across the wider youth population arising from prohibition styled legislative actions. 
To do this, data on episodes of addiction treatment and psychiatric hospitalizations 
among youth were interrogated.  
 
11.2 Key findings from each chapter. 
11.2.1 Study 1: Outcome for adolescents abusing alcohol and cannabis following 
outpatient treatment 
This study is the first study to report outcome of an outpatient adolescent addiction 
treatment service in Ireland. It confirms that abstinence at three months is indeed 
elusive. It emerged that only 11% of those with a cannabis use disorder and 11% of 
those with an alcohol use disorder were abstinent for the full month of follow-up. This 
is at the lower end of the range reported in international studies.(3, 147-152) This 
relatively low rate of abstinence could be used to build a case for a move back 
towards more explicitly abstinence focused treatments.  
However, another key finding of this study was the very poor motivation evident 
among adolescents with substance use disorders. Problem recognition was 
determined to be low or very low in the majority (68-97%) of adolescents with risky 
use of all substances apart from the small number of heroin users. Other studies have 
highlighted poor motivation among adolescents in particular.(153, 154) It is likely to 
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prove challenging to persuade such a group of poorly motivated adolescents to 
embrace a goal of abstinence.(3) Demanding that they do so, could result in a 
substantial increase in unplanned treatment exits and could thereby result in 
increased use and increased harms.(155)  
Many of the National Institute of Drug Abuse (NIDA) recommended and evidence 
based treatment approaches in adolescent addiction, including ACRA, CBT and 
Motivational enhancement therapy, avoid any demand for abstinence.(156) 
The study examined the proportion of adolescents who achieved a reliable reduction 
in their alcohol and cannabis use.(157, 158) Although this methodology has been used 
to explore treatment outcome in adults, there are very few studies which have used 
this approach in adolescent addiction.(159) It emerged that 36% of the high risk 
cannabis users achieved a reliable reduction in use, although only 14% of the high risk 
drinkers did so.  
We also found that high risk drinkers were significantly less motivated than high risk 
users of illegal drugs. It seems possible that this poorer motivation among drinkers 
may have contributed to their poorer outcomes.(160, 161) Given the wider focus of 
this thesis on legislation it is interesting to note that motivation to change use of the 
legal drug was less than that to change use of the illegal drug. 
By measuring the size of change, this study can be useful is estimating change for use 
in power calculations if clinical trials are conducted with similar patient groups in 
similar settings in the future. 
 
11.2.2 Study 2: Opioid substitution treatment and heroin dependent adolescents: 
Reductions in heroin use and treatment retention over twelve months 
This study found that 21% of patients were abstinent from heroin in their third month 
of treatment. This rate of abstinence is almost double that achieved for cannabis or 
alcohol in the previous study. Importantly, the proportion of patients who 
demonstrated abstinence from heroin increased substantially and significantly after 
216 
 
12 months of treatment. This finding of clinically and statistically significant 
improvement in outcome over time poses a challenge to the view articulated in the 
report on adolescent addiction treatment by the Department of Health & Children 
which advised that OST “should only be considered as a short term solution”.(75)  
It is not really possible to accurately compare the rates of abstinence achieved in this 
study with those of other studies of OST in adolescents as most other studies fail to 
report on use during treatment and those which do used different methodology 
involving very infrequent drug testing.(93)  
The study failed to find evidence of a significant reduction in use of other drugs. 
However, there was no evidence of an increase either, this being suggested as a 
possibility in the DARP study.(89) 
 
11.2.3 Study 3: Changes in psychological well-being among heroin-dependent 
adolescents during psychologically supported opiate substitution treatment. 
This is the first ever study to report upon changes in mental health symptoms among 
heroin dependent adolescents in receipt of OST over a three-month period. We found 
evidence of significant improvement in the domains of depression, anxiety and anger. 
This is an encouraging finding. While it mirrors the findings from adult studies of 
OST,(67, 162) it is noteworthy that the only Irish study to examine this issue among 
adults failed to find a significant improvement in mental health during OST.(163)  
Although only conducted as a post hoc analysis, it was interesting to note that the 
improvement is depressive symptoms was significantly greater in those who ceased 
heroin use at follow-up. This again highlights the inter-relationship between drug use 
and mental health, although it doesn’t point towards a direction of causality.(164) 
 
11.2.4 Study 4: Changes in use of novel psychoactive substances among adolescents 
attending a drug and alcohol treatment service following a legislative ban. 
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This study confirmed that NPS can indeed cause substance use disorders in 
adolescents and that these increased rapidly during the period of head shop 
expansion, being an issue for 34% of adolescents attending the service in the months 
prior to the initial legislative action. There was a significant decline in NPS substance 
use disorders and in self-reported NPS use one year later, at which point all of the 
head shops had either closed or ceased selling NPS. However, there was still some NPS 
use which confirms that there was some migration of use into the black market.(165) 
In the few cases where use persisted in the black market era, this was associated with 
significantly less problems than occurred among users during the head shop era. 
 
11.2.5 Study 5: Decline in new psychoactive substance use disorders following 
legislation targeting headshops: evidence from national addiction treatment data. 
Building on the findings of the previous study, this study confirmed that NPS use 
disorders were also evident in the young adult age range across Ireland using a 
national dataset. NPS related presentation increased very rapidly during the period of 
head shop expansion, peaked in the first four months of 2010 and then the trend 
changed significantly. The rate of NPS presentations fell progressively over the 
following two years, albeit not as dramatically as that observed among the 
adolescents in study 4. Where cases involving a NPS use disorder did present after the 
closure of the head shops, it was less likely to be the primary disorder. This mirrors the 
finding in the study of adolescents (study 4) which found reduced harm associated 
with NPS use in the post head shop era. As such it challenges the dire predictions of 
the opponents to the legislative bans.(102, 166-168) 
 
11.2.6 Study 6: Legislation targeting head shops selling new psychoactive substances 
and changes in drug related psychiatric admissions: A national database study 
The presence and variety of mental health difficulties among adolescents with 
substance use disorders was highlighted in studies 1 and 3, these findings mirroring 
those seen across the world.(7, 164, 169, 170) 
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Having found evidence of changes in NPS related addiction episodes coinciding with 
the expansion and contraction of the head shop network, this study was ambitious in 
examining for changes in a much broader public health impact. It utilised a national 
database of all drug related psychiatric admissions (DRPA) among young adults. It 
emerged that there was a trend change in DRPA and the best estimate for the timing 
of this change was July 2010. When we looked at young males, the group known to be 
the heaviest users on NPS in Irish general populations surveys, it emerged that the 
best fitting join point model had two trend changes.(40) There was an increase in 
DRPA in January 2010 and the upward trend turned downwards in May 2010.  
While this study could confirm that the changes in DRPA coincided with changes in 
NPS availability through head shops, it could not confirm that NPS caused or even 
contributed to the observed change. However, a study by Lally et al of patients 
attending adult mental health services during the head shop era in Ireland did confirm 
that NPS use featured very prominently amongst the drug use by patients at that 
time.(171) Research from elsewhere has also highlighted the contribution of NPS to 
mental health difficulties among inpatients.(116, 130, 172) One of these studies in the 
UK found that NPS use was reported by 22% of psychiatric admissions, especially in 
those of young males.(155) The NPS use was deemed to have contributed to the 
admission in most cases. 
 
11.3 Methodological issues which emerged  
Statistical analysis was hampered by small sample sizes in the treatment studies and 
small number of events per unit of time in the NPS trend studies.(144) The small 
samples were due to the finite number of heroin dependent adolescents in Dublin, 
and the rate of entry into studies declined progressively as the incidence of adolescent 
heroin dependence dropped progressively. Although two of the NPS trend studies 
made use of national datasets, trend changes would have been easier to detect if the 
population was 50 million, such as in the UK, instead of just 5 million in Ireland. In 
order to ensure adequate number of event per time period, we had to widen the unit 
of time to four months in study 5 as opposed to just one month.(145) This 
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consequently reduces the ability to specify the exact point at which a trend changed. 
The timing of the trend changes in the Joinpoint analysis constitute estimates in all 
cases, and the 95% confidence intervals are quite wide, this again being a function of 
the relatively small number of events per unit of time. 
Joinpoint appears to be a very interesting and useful tool for exploring trend changes 
in time series type data.(146) It probably has utility for examining trend changes in a 
range of national databases across health and other sectors, not just NDTRS & 
NPIRS.(173-175)  
All studies received ethical approval from research ethics committees.  (Appendix 2 
collates the information on ethics approval for all of the studies.) The study which 
posed the most ethical challenges was the treatment study examining outcome of 
alcohol and cannabis use disorders. These challenges arose primarily due to the 
follow-up components of that study design. It is necessary to obtain consent to follow 
people up after their treatment. Complications with consent are typical of research 
focusing on adolescents.(176) Although there is legislation to indicate that people 
aged 16 and over can consent to medical treatment on their own behalf in Ireland, this 
has not been confirmed by case law. In view of this uncertainty, we only accepted 
adolescents into that study where we obtained consent from both the adolescent and 
a parent (or legal guardian). This then posed a limitation on our ability to recruit into 
the study adolescents who are in voluntary care of social services, and had minimal 
ongoing parental contact.  
 
11.4 Interconnections between the studies 
Polysubstance use was evident across the studies examining both treatment outcome 
and NPS related harms. Many researchers having identified this as a particular 
challenge among younger drug users.(177) There was some evidence of variation in 
treatment outcome across substances. Others have noted that reductions in use of 
the main drug can be associated with increases in use of other substances.(178, 179)  
Previous researchers have noted that treatment outcomes for substances such as 
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cannabis and alcohol tends to be poorer that that for other substances.(3) We found 
that motivation to address alcohol problems was poorer that that to address illegal 
drugs and that meaningful reductions in alcohol use appear harder to achieve than 
reductions in cannabis use. While not designed as a head to head comparison, the 
heroin dependent adolescents were at least as likely to be abstinent from that drug 
after three months (21%) as the adolescents with alcohol (11%) or cannabis (11%) use 
disorders treated in the YoDA service. Within the treated heroin dependent group, 
reductions in use of other substances were not evident.  
The studies in this thesis highlight the many and varied intersections between mental 
health and substance use. We added to the substantial literature which indicates that 
very many youth who access addiction treatment have histories of mental health 
difficulties and/or evidence of current mental health problems.(7, 8, 142, 170, 180) 
We found evidence that addiction treatment delivers improvements in psychological 
wellbeing, with the first ever study to examine impact of OST on mental health in 
adolescents. Finally, we found evidence that polices which are focused on reducing 
easy access to drugs may have an impact upon levels of drug related psychiatric 
disorders in the community. Others have demonstrated that policy measures targeting 
alcohol and drugs can have an impact upon mental health outcomes, suicide in 
particular.(181, 182)  
Although the legislative changes targeting head shops and NPS were quite generic, 
both studies examining changes in NPS use among people attending addiction 
treatment generate information which pointed towards a lesser or delayed impact on 
cathinone type NPS relative to that observed upon the synthetic cannabinoids. It is 
unclear why this might have occurred but it suggests that cathinone type NPS were 
less impacted by the closure of the head shops, if it was indeed the closure of the 
head shops which explains the overall changes.  
 
11.5 Overall weaknesses and strengths of the studies. 
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Five of the six studies focused upon people who attend for addiction treatment. As 
described in section 2.4.3, about 10% who use a drug will become dependent upon it 
and only 10% of those will seek treatment in any given year.(2, 6, 44, 62, 183) 
Consequently, treatment attenders constitute only the tip of the iceberg in terms of 
drug use across the population.(3, 156) They are nevertheless a very important 
subgroup and likely to include the individuals at greatest risk of harm.(121) 
Section 2.3 highlighted the fact that patterns of substance use do change over time. 
While society strives to influence those changes, they often occur with minimal 
explanation.(37) The trend changes detected in these studies may constitute this type 
of random fluctuation. However, the facts that we were able to examine time periods 
shorter than one year and that the location of change across studies appeared to 
coincide quite closely with changes in head shop activity, add weight to the argument 
that they may be causally related.  
In the two studies which examined addiction treatment outcome (Studies 1 & 2), 
there was minimal success in identifying either patient or treatment characteristics 
associated with better outcome, even with the exploratory analysis and decision not 
to adjust for multiple statistical testing.(143) This may be in part down to the 
limitations of sample size discussed above in section 11.3. However, many other 
studies have struggled to identify patient characteristics associated with better 
outcome.(98, 184)  
The two studies of OST were confined to analysing data obtained during treatment. 
Ideally it would have been useful to interview people who had left treatment 
regarding their drug use and mental health. However, consent was not obtained to 
follow people up in that manner. 
 
11.6 Implications for practice and policy 
Polysubstance use must be assessed and efforts made to address it. In doing so, it will 
be important to be mindful of possibility of quite variable motivation by the individual 
to address use of separate substances.(177, 185, 186) 
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Mental health competencies seem essential for staff working in services providing 
treatment to adolescents with substance use disorders.(7, 8) The ongoing separation 
of addiction treatment services from mental health services in Ireland would appear to 
warrant review.(187) If it is to persist, there is a need for excellent inter agency 
collaboration between youth addiction treatment services and youth mental health 
services.(188, 189) 
National polices focused upon improvements in mental health should include 
measures which address substance use, in view of the evidence suggesting an impact 
of the latter upon the former.(181)  
While adolescents, parents, policy makers, politicians and treatment providers may all 
have a preference for the duration of OST to be as short as possible, enforcing a time 
limit on OST for heroin dependent adolescents appears unreasonable.(79, 96) 
Given the evidence from these studies that expansion of the network of head shops 
coincided with increased NPS use disorders and increased DRPA, and their departure 
saw these trends reverse, it would appear reasonable that Ireland maintain its 
intolerant attitude towards sale of NPS by head shops. This position is also largely 
supported by the findings from the literature review in section 2.6.2.3, and a very 
recently published review of this literature by Meader, Mdege & McCambridge.(190) 
The Criminal Justice (Psychoactive Substances ) Act was novel and has faced some 
legitimate scrutiny.(82, 83, 107) However, it has withstood the test of the courtroom, 
with a couple of successful prosecutions and more importantly there has been no 
return to widespread availability of NPS in head shops.(109) The legislation has also 
received the ultimate form of flattery in that it has been imitated in a number of other 
jurisdictions.(83) 
While it probably should not need to be said, it seems clear that no policy can 
completely eliminate all substance use and every related harm.(10, 20) Complete 
cessation of use and all harms across the entire population has certainly not been a 
goal of drugs policy in Ireland in recent decades.(22, 191, 192) The UNODC declared a 
goal of “a drug free world” as recently as the 1990s and argued that legislative bans 
could assist in delivering that state of perfection.(10, 193) Declaring unachievable 
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targets brings into disrepute the effective measures employed to reduce use and 
associated harms once those impossible goals are not delivered upon.(10, 20, 24) 
 
11.7 Implications for future research. 
Cannabis policy is hotly debated currently, both in Ireland and internationally.(19, 194-
199) While only a tentative finding, the variability in motivation and possibility of 
poorer outcome for alcohol use disorders warrants further exploration. If this relates 
to its legal status and widespread availability and use of alcohol across society, then 
this raises the possibility of adverse and untoward consequences for society if 
cannabis use is normalised and policy is liberalized.(119) The literature on NPS 
suggests that their legal status influenced decision making regarding their use.(117) As 
society moves towards a more benign view of cannabis and there is increasing 
discourse of that drug as a possible medicine and candidate for regulated sale, like 
alcohol, it seems likely that people will view use as increasingly normal and less risky. 
Such views regarding drugs tend to be associated with increased use.(6, 36, 200, 201) 
Cannabis use is on an upward trajectory in Ireland in recent years among both 
adolescents and young adults (see Figures 2.7 & 2.8).(39, 41) Study 5 produced an 
incidental finding that the rate of treated cannabis use disorders (CUD) among youth 
in Ireland rose significantly during the period 2009 to 2012. It will be important to 
monitor changing rates of use, changing incidence of CUD and the potential impact on 
treatment outcome for that subset of users who develop a CUD.(196, 202-204)  
Studies 4 & 5 both found evidence that cathinone type drugs seemed to persist more 
effectively after the closure of the head shops, relative to other NPS subclasses. There 
is certainly some ongoing concern regarding use of these drugs by specific populations 
of drug users, especially people who inject drugs.(205, 206) There may be 
opportunities to interrogate the NDTRS dataset to better characterise those who have 
persisted with cathinone use in the post-head shop era. A better understanding of 
that patient group may permit development of a targeted response to reduce harm. 
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The NACD general population surveys may also provide opportunities to characterise 
NPS users. Given the fact that the 2010/11 survey overlapped with the head shop era, 
there may be an opportunity to determine if there have been changes to the profile of 
NPS user during the commercialised sale of NPS via head shops versus the NPS user in 
the 2014/15 survey.(40, 41)  
Finally there are other potential measures of independent imperfection which could 
be interrogated to see if there is further evidence of increased harms while the head 
shops expanded and reduction in harms after the shops were closed.(23) Specifically, 
the Hospital In-Patient Enquiry (HIPE) system could be examined to see if there were 
trend changes in drug related medical admissions over this period. It may be possible 
to utilise data from An Garda Siochana (e.g. the Police Using Leading Systems 
Effectively database) to determine if drug related incidents of public disorder changed.  
 
11.8 Is harm reduction treatment appropriate for youth with SUDs? 
The archetypical harm reduction treatment is OST. It remains controversial among 
adults in spite of the fact that it has more evidence that almost any other treatment in 
addiction.(5, 12, 14, 22, 68, 207, 208) However, the evidence for OST in adolescents 
has been weak and this has added to the caution in its utilization in this age range.(17, 
96, 99) Heroin dependence generally commences in early adulthood not adolescence, 
and consequently cases are relatively rare.(209)  There appears to be a circular 
problem with lack of evidence driving clinician wariness and clinician wariness making 
it more difficult to generate evidence.(18) 
The studies of OST in this thesis point towards respectable and incremental reductions 
in heroin use and towards improvements in mental health among the adolescents 
who persist with this treatment. Consequently, the thesis adds weight to the 
argument in favour of this harm reducing treatment.(18, 79, 92) 
A previous examination of a residential abstinence based treatment in Ireland 
demonstrated that that vast majority of patients relapsed to heroin use within months 
of discharge, with younger patients being particularly likely to relapse.(184, 210) 
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Previous studies on OST in adolescents in Dublin also highlighted frequent relapse 
after detoxification.(211) Relapse following detoxification is particularly hazardous as 
it brings with it an increased risk of fatal accidental overdose.(212) 
It seems appropriate that both treatments, OST and abstinence based, be available to 
patients and to clinicians.(207) It would appear unreasonable to demand that patients 
pursue either path. If the addiction treatment guidelines for adolescents are being 
reviewed by the Department of Health & Children, the findings of this thesis suggest 
the removal of the recommendation that OST “be viewed as only a short term 
solution”.(75) 
 
11.9 Is prohibition an acceptable strategy for reduction of population based harm 
among youth? 
As mentioned in Chapter 1, Donald Campbell suggested a quasi-experimental 
approach to policy evaluation by using ‘multiple measures of independent 
imperfection’.(23) In this thesis, three imperfect but independent measures were 
examined. All point towards emerging and escalating harm while the head shops were 
openly selling NPS and expanding across Ireland. All point towards a reversal of this 
trend around the time when the head shops closed. While no single study provides 
proof, taken together they do appear to constitute an important body of evidence that 
the legislative measures may well have had a substantial positive impact in Ireland. 
This view is further bolstered by the evidence which emerged from the latest iteration 
of the NACDA general population survey which happen to be repeated during the 
course of this PhD. It found that past year use of NPS among 15-24year olds was 1.9% 
in 2014/15, having been 9.7% in 2010/11.(41) Finally it is also consistent with quite a 
substantial body of research indicating reduced NPS use and/or harms following 
legislative restrictions in other jurisdictions.(130, 133, 135, 213, 214) These were 
summarised in section 2.6.2.3. 
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While this thesis only examined this one aspect of the prohibition styled legislation in 
Ireland, it does lend support to this approach and does not build a case for moving 
away from this approach within Ireland.  
While there have been many reviews of drug policy in recent years which have 
examined novel, and generally liberal, approaches to policy, there is one country 
which has been largely ignored by these reviews.(4, 80, 82) In the 1990s, teenagers in 
Iceland demonstrated very concerning levels of drunkenness, higher than almost any 
other country in Europe.(39) Drug use was lower than the EU average at that time. 
Nevertheless, they implemented a comprehensive and multifaceted sweep of 
measures focused primarily on alcohol use. These included an increase in the legal 
drinking age to 20 years and legal restrictions on the ability of children to be out at 
night unaccompanied. Alcohol taxes are very high, advertising and sponsorship are 
banned and off-sales alcohol can only be purchased in state owned off licenses.(122) 
In sum, these were very conservative measures. They have delivered remarkable 
results with teenage drunkenness now being one of the lowest in Europe and rates of 
past month cannabis use falling also (See Figure 2.7 in Chapter 2).(215-217)  
A recent international review of evidence based measures to reduce harms associated 
with adolescent substance use concluded that enforcement of laws was effective.(11) 
While New Zealand was hailed as the standard bearer for those countries seeking to 
contemplate a more liberal approach to drug use via its Psychoactive Substances Act, 
a recent review of this initiative has highlighted its many pitfalls.(218) It has proved 
largely unworkable and has highlighted the need for substantial ongoing law 
enforcement and extensive regulatory structures and resources.   
 
11.10 Can harm reduction and prohibition co-exist? 
Returning to the quandary presented in Figure 2.14, can liberal treatment approaches 
such as harm reduction interventions like OST appropriately co-exist with conservative 
and ‘out of fashion’ approaches to prevention such as prohibition? 
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It may well be the case that this apparent paradox in superficially contradictory 
policies is far from unique. Without delving into another topic in any great detail, 
efforts to tackle injury from road traffic collisions involves the exact same apparent 
contradictions. The WHO’s “World report on road traffic injury prevention” advises a 
number of actions. (219)These include “Setting and securing compliance with key road 
safety rules” (i.e. legal requirements to adhere to low risk driving, assertive monitoring 
of driver behaviour and administration of punishments to those who fail to do so). The 
report simultaneously recommends “Delivering post-crash care”. This involves prompt 
arrival of trained medical personnel to the crash site and high quality care in the 
emergency department, irrespective of the possible contribution of driver behaviour 
to their own injuries. In other words, treatment of individuals who experience harm 
should be responsive, high quality and non-judgemental. At the same time, the wider 
population of drivers should be assertively monitored. Those who drive in a high risk 
manner should be identified and punished, and potentially lose the right to drive 
altogether if they repeatedly drive in an unsafe manner.  
The Drugs & Public Policy Group have stated:- 
The drug policy debate is dominated in many countries by false dichotomies 
which can mislead policy maker about the range of legitimate options and 
their expected impact. Law enforcement and health services approaches each 
contribute to the other’s mission.(5)   
The studies presented here suggest that current treatment approaches deliver 
meaningful reductions in harm for individuals with substance dependence. At the 
same time, prohibition styled legislative responses appear to deliver reductions in 
harm at the population level. The weight of evidence in this thesis indicates that, just 
like the efforts to reduce morbidity caused by road traffic collisions, the policy 
approach to reducing harm related to drug use across society should simultaneously 
include a liberal approach to treatment for those few individuals who experience 
significant harm (i.e. develop addiction) and a conservative and intolerant approach to 
drug use at the broader population level. 
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Appendix 1. Additional information on contributions to research papers. 
In section 7 of each of the chapters reporting a research paper, (i.e. Chapters 4 to 9 
inclusive), there is a section on Author Contributions. This describes the input 
provided by the co-authors. 
In addition to that support into the various studies, there was also important input by 
a number of individuals into some of these research papers. This occurred particularly 
in the area of statistical methodology. These contributions are described below. 
 
Outcome for adolescents abusing alcohol and cannabis following outpatient 
treatment: how many 'reliably improve'? (Chapter 4) 
Professor Joe Barry provided advice on the research questions and on the study 
methodology. He provided guidance on strategies to ensure better recruitment and 
retention of research participants.  
 
Opiate substitution treatment and heroin dependent adolescents: Reductions in heroin 
use and treatment retention (Chapter 5) 
Professor Alan Kelly and Dr Ailish Hannigan provided advice on statistical 
methodology for this study. Dr Conor McDonald also assisted with the statistical 
analysis. 
 
Changes in psychological wellbeing among heroin dependent adolescents during 
psychologically supported opiate substitution treatment (Chapter 6) 
Dr Ailish Hannigan was consulted regarding statistical methodology for this study. 
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"So prohibition can work?" Changes in use of novel psychoactive substances among 
adolescents attending a drug and alcohol treatment service following a legislative ban 
(Chapter 7) 
Dr Ailish Hannigan was advised on the statistical methodology for this study. 
 
Decline in new psychoactive substance use disorders following legislation targeting 
headshops: Evidence from national addiction treatment data (Chapter 8) 
Advice and guidance on statistical methods for this study was obtained from Dr Ailish 
Hannigan, Dr Conor McDonald and Dr Jason Ferris. 
 
Legislation targeting head shops selling new psychoactive substances and changes in 
drug related psychiatric admissions: A national database study (Chapter 9) 
Advice and guidance on statistical methods for this study was obtained from Dr Jason 
Ferris. In addition to this, Dr Ailish Hannigan and Dr Conor McDonald both assisted 
with the statistical analysis. 
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Contact Information for 
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Secretary 
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2 Opioid substitution treatment and heroin dependent 
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substances and changes in drug related psychiatric 
admissions: A national database study 
 
National Drug Treatment Centre Board 
Research Ethics Committee 
Mr Seamus Noone 
Vice-Chairman 
NDTC REC 
30/31 Pearse St 
Dublin 2 
 
Phone: 01-6488600 
 
 
 
